Page last updated: 2024-12-05

gossypol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Gossypol: A dimeric sesquiterpene found in cottonseed (GOSSYPIUM). The (-) isomer is active as a male contraceptive (CONTRACEPTIVE AGENTS, MALE) whereas toxic symptoms are associated with the (+) isomer. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3503
CHEMBL ID51483
SCHEMBL ID3939
MeSH IDM0009556

Synonyms (244)

Synonym
AC-20251
HMS3268O22
c30h30o8
BRD-K19295594-015-02-8
BRD-K19295594-001-06-9
[2,8'-dicarboxaldehyde, 1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-5,5'-bis(1- methylethyl)-
nsc-624336
smr000058386
MLS000028490
at 101
KBIO1_000173
DIVK1C_006698
DIVK1C_000173
NCI60_004391
NCI60_001588
NCIMECH_000271
1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)-2,2'-binaphthalene-8,8'-dicarbaldehyde
(2,2'-binaphthalene)-8,8'-dicarboxaldehyde, 1,1',6,6',7,7'-hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-
brn 1917878
(2,2'-binaphthalene)-8,8'-dicarboxaldehyde, 1,1',6,6',7,7'-hexahyd
(2,2'-binaphthalene)-8,8'-dicarboxaldehyde, 1,1',6,6',7,7'-hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-, (+)-
ccris 2689
(2,2'-binaphthalene)-8,8'-dicarboxaldehyde, 1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)-, (-)-
8-formyl-1,6,7-trihydroxy-5-isopropyl-3-methyl-2,2'-bisnaphthalene
ai3-22957
nsc 56817
(+-)-gossypol
racemic-gossypol
nsc 624336
8-formyl-1,7-trihydroxy-5-isopropyl-3-methyl-2,2'-bisnaphthalene
[2,8'-dicarboxaldehyde, 1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)-
nsc-56817
(2,8'-dicarboxaldehyde, 1,1',6,6'7,7'-hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-
[2,8'-dicarboxaldehyde, 1,1',6,6',7,7'-hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-
SPECTRUM_000359
SPECTRUM_001521
SPECTRUM4_001931
SPECTRUM5_000693
PRESTWICK_1031
NCGC00025331-01
NCGC00016423-01
tocris-1964
cas-303-45-7
PRESTWICK3_000677
IDI1_000173
PRESTWICK2_000677
BPBIO1_000851
SMP2_000170
SPECTRUM5_001035
BSPBIO_003191
(-)-1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)[2,2'-binaphthalene]-8,8'-dicarboxaldehyde
7-(8-formyl-1,6,7-trihydroxy-5-isopropyl-3-methyl-2-naphthyl)-2,3,8-trihydroxy-4-isopropyl-6-methyl-naphthalene-1-carbaldehyde
(-)-2,2'-bis(1,6,7-trihydroxy-3-methyl-5-isopropyl-8-aldehydonaphthalene)
tash 1
(+)-gossypol
[2,2'-binaphthalene]-8,8'-dicarboxaldehyde, 1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)-
(-)-gossypol
pogosin
(+)1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)[2,2'-binaphthalene]-8,8'-dicarboxaldehyde
UPCMLD-DP103:001
AB00052921
303-45-7
gossypol
C07667
1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)[2,2'-binaphthalene]-8,8'-dicarboxaldehyde
NSC56817 ,
2,2'-bis(1,6,7-trihydroxy-3-methyl-5-isopropyl-8-aldehydonaphthalene)
(+/-)-gossypol
nsc624336
7-(8-formyl-1,6,7-trihydroxy-3-methyl-5-(methylethyl)(2-naphthyl))-2,3,8-trihydroxy-6-methyl-4-(methylethyl)naphthalenecarbaldehyde
(+/-)-gossypol from cotton seeds, >=95% (hplc)
UPCMLD-DP103
UPCMLD-DP103:002
NCGC00025331-06
NCGC00025331-07
NCGC00025331-03
NCGC00025331-02
KBIO2_000839
KBIO2_007137
KBIO3_002691
KBIO2_003407
KBIOGR_001451
KBIO2_004569
KBIO1_001642
KBIOGR_002303
KBIOSS_002001
KBIO3_002024
KBIO2_005975
KBIO2_002001
KBIOSS_000839
SPBIO_002694
SPECTRUM2_001472
SPBIO_001423
PRESTWICK0_000677
SPECPLUS_000602
SPBIO_001687
SPECTRUM3_001516
SPECTRUM3_001102
NINDS_000173
SPECTRUM2_001624
PRESTWICK1_000677
SPECTRUM4_000846
SPECTRUM1504019
BSPBIO_002804
nsc-726190
(r)-gossypol
90141-22-3
(r)-(-)-gossypol
[2,8'-dicarboxaldehyde, 1,1',6,6',7,7'- hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)-, (2r)-
nsc726190
nsc728875
nsc-728875
BSPBIO_000773
cid_3503
gossypol, 4
7-[8-formyl-1,6,7-trihydroxy-3-methyl-5-(propan-2-yl)naphthalen-2-yl]-2,3,8-trihydroxy-6-methyl-4-(propan-2-yl)naphthalene-1-carbaldehyde
NCGC00025331-04
bdbm23223
chembl51483 ,
gossypol sodium salt
gossypol, (-)-isomer
gossypol, (+)-isomer
dipotassium salt, gossypol
(2,2'-binaphthalene)-8,8'-dicarboxaldehyde, 1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)-
gossypol, (+-)-isomer
sodium salt, gossypol
gossypol dipotassium salt
LMPR0103330002
NCGC00016423-09
no fertil
bl-193
AKOS002140475
HMS1570G15
7-(8-formyl-1,6,7-trihydroxy-3-methyl-5-propan-2-ylnaphthalen-2-yl)-2,3,8-trihydroxy-6-methyl-4-propan-2-ylnaphthalene-1-carbaldehyde
NCGC00016423-03
1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-5,5'-di(propan-2-yl)-2,2'-binaphthalene-8,8'-dicarbaldehyde
STK063457
HMS3262J15
HMS2097G15
unii-kav15b369o
bl 193
hsdb 7872
kav15b369o ,
unii-8dy2x8lxw4
gissypol, (r)-
gossypol, (r)-
8dy2x8lxw4 ,
nsc 726190
ST065835
7-[8-formyl-1,6,7-trihydroxy-3-methyl-5-(methylethyl)(2-naphthyl)]-2,3,8-trihy droxy-6-methyl-4-(methylethyl)naphthalenecarbaldehyde
A820340
BCP9000332
dtxsid5023110 ,
tox21_110434
dtxcid803110
CCG-35400
NCGC00016423-10
NCGC00016423-04
NCGC00016423-07
NCGC00016423-05
NCGC00016423-02
NCGC00016423-08
NCGC00016423-06
gossypol, (s)-
xna7dr63cq ,
4-08-00-03754 (beilstein handbook reference)
unii-xna7dr63cq
20300-26-9
HY-15464
CS-0966
BCP0726000183
FT-0631917
NCGC00016423-14
LP00847
S6852
gtpl4204
HY-13407
SCHEMBL3939
NCGC00016423-15
tox21_110434_1
QBKSWRVVCFFDOT-UHFFFAOYSA-N
tox21_500847
NCGC00261532-01
1,1',6,6',7,7'-hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-[2,2'-binaphthalene]-8,8'-dicarbaldehyde
cid_227456
acetic acid;7-(8-formyl-1,6,7-trihydroxy-5-isopropyl-3-methyl-2-naphthyl)-2,3,8-trihydroxy-4-isopropyl-6-methyl-naphthalene-1-carbaldehyde
bdbm46555
acetic acid;7-(8-formyl-1,6,7-trihydroxy-3-methyl-5-propan-2-yl-2-naphthalenyl)-2,3,8-trihydroxy-6-methyl-4-propan-2-yl-1-naphthalenecarboxaldehyde
ethanoic acid;7-[8-methanoyl-3-methyl-1,6,7-tris(oxidanyl)-5-propan-2-yl-naphthalen-2-yl]-6-methyl-2,3,8-tris(oxidanyl)-4-propan-2-yl-naphthalene-1-carbaldehyde
(s)-(+)-gossypol
1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)-[2,2'-binaphthalene]-8,8'-dicarboxaldehyde
(-)-1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)-[2,2'-binaphthalene]-8,8'-dicarboxaldehyde
[2,2'-binaphthalene]-8,8'-dicarboxaldehyde,1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)-, (2r)-
AC-34521
pogosin; at101
HB0304
2,2'-bi[8-formyl-1,6,7-trihydroxy-5-isopropyl-3-methylnaphthalene]
AC-30274
mfcd00017352
EX-A068
SR-01000597521-5
SR-01000597521-1
SR-01000597521-6
sr-01000597521
HMS3651C18
thespesin
( inverted exclamation marka)-gossypol from cotton seeds
gossypol from cotton seeds
J-017920
A15004
SW197103-2
DB13044
NCGC00016423-34
NCGC00016423-17
NCGC00016423-12
BCP03607
Q411882
1,1',6,6',7,7'-hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl[2,2'-binaphthalene]-8,8'-dicarbaldehyde
(+/-)-gossypol from cotton seeds
303-45-7 (free)
HMS3677L10
(s)-gossypol
HMS3413L10
BRD-K19295594-001-10-1
1,1',6,6',7,7'-hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-2,2'-binaphthyl-8,8'-dicarbaldehyde
SB17342
HMS3868F13
SDCCGSBI-0051726.P004
AT25344
ssypol
AS-55885
BP-25397
(2,2'-binaphthalene)-8,8'-dicarboxaldehyde, 1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)-, (s)-
gossypol s-form [mi]
(2,2'-binaphthalene)-8,8'-dicarboxaldehyde, 1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)-, (2s)-
gossypol, (+)-
gossypol, r-
r-(-)-gossypol
(r)-2,2'-bis(8-formyl-1,6,7-trihydroxy-5-isopropyl-3-methylnaphthalene)
gossypol r-form [mi]
gossypol [mart.]
gossypol [mi]
gossypol [vandf]
go3 ,

Research Excerpts

Overview

Gossypol is an inhibitor of eukaryotic cells with an undetermined mode of action. It is a toxic sesquiterpene dimer produced by cotton plants which deters herbivory by insects and vertebrates.

ExcerptReferenceRelevance
"Gossypol is an inhibitor of eukaryotic cells with an undetermined mode of action. "( Yeast Chemogenomic Profiling Reveals Iron Chelation To Be the Principle Cell Inhibitory Mode of Action of Gossypol.
Hoepfner, D; Jaeg, T; Prescott, TAK, 2018
)
2.14
"Gossypol is a toxic sesquiterpene dimer produced by cotton plants which deters herbivory by insects and vertebrates. "( Consumption of gossypol increases fatty acid-amino acid conjugates in the cotton pests Helicoverpa armigera and Heliothis virescens.
Heckel, DG; Joußen, N; Kai, M; Krempl, C; Reichelt, M; Vogel, H, 2021
)
2.42
"Gossypol is a yellow natural polyphenolic compound extracted from the seeds, leaves, stems, and flower buds of the cotton plant. "( Gossypol exposure induces mitochondrial dysfunction and oxidative stress during mouse oocyte in vitro maturation.
Ahmad, MJ; Chen, YW; Ding, ZM; Duan, ZQ; Huo, LJ; Liang, AX; Liu, M; Wang, YS; Xiong, JJ; Yang, CX; Yang, SJ, 2021
)
3.51
"Gossypol is a unique secondary metabolite and sesquiterpene in cotton, which is mainly synthesized in the root system of cotton and exhibits many biological activities. "( Transcriptome analysis reveals the effect of grafting on gossypol biosynthesis and gland formation in cotton.
Teng, T; Yang, T; Ye, K; Zhao, D; Zhao, Y, 2023
)
2.6
"Gossypol is a binaphthyl compound made by cotton plants."( Dirigent gene editing of gossypol enantiomers for toxicity-depleted cotton seeds.
Chen, FY; Chen, XY; Chen, ZW; Fang, X; Guo, XX; Huang, JF; Huang, JQ; Li, JX; Lin, JL; Liu, NJ; Martin, C; Wang, LJ; Wu, WK; Xu, B, 2023
)
1.93
"Gossypol is a complex plant polyphenol reported to be cytotoxic and anti-inflammatory, but little is known about its effect on gene expression in macrophages. "( Plant Polyphenol Gossypol Induced Cell Death and Its Association with Gene Expression in Mouse Macrophages.
Cao, H; Sethumadhavan, K, 2023
)
2.69
"Gossypol is a polyphenol from the cotton plant with anti-inflammatory and anti-oxidation activities and can also function as a histone deacetylase (HDAC) inhibitor. "( Gossypol improves myocardial dysfunction caused by sepsis by regulating histone acetylation.
Lv, X; Shi, X; Xiao, D, 2023
)
3.8
"Gossypol is a polyphenolic compound, commonly found in cotton seeds, that impairs male reproduction."( Gestational and lactational exposure to gossypol alters the testis transcriptome.
Amorín, R; Corrêa, PS; Ieda, EH; Jimenez, CR; Liu, L; Louvandini, H; McManus, CM; Peñagaricano, F; Tsai, SM, 2020
)
1.55
"Gossypol is a specific secondary metabolite in Gossypium species. "( Cotton roots are the major source of gossypol biosynthesis and accumulation.
Chen, J; Li, C; Mei, L; Xie, Q; Yu, JZ; Zhao, T; Zhu, S, 2020
)
2.27
"Gossypol is a natural polyphenol presently considered as a promising biological phytochemical with a range of activities including anticancer. "( Lytic and sublytic effects of gossypol on red blood cells and thymocytes.
Chorieva, NM; Fayziev, DD; Gafurov, MB; Khamidova, OJ; Kurbannazarova, RS; Merzlyak, PG; Sabirov, RZ; Toshtemirova, GA; Tsiferova, NA; Ziyaev, KL, 2021
)
2.35
"Gossypol is a natural polyphenolic compound with anti-inflammation, anti-oxidant, and anticancer activities."( Gossypol Reduces Metastasis and Epithelial-Mesenchymal Transition by Targeting Protease in Human Cervical Cancer.
Chen, PN; Chu, SC; Hsieh, YS; Huang, SC; Kao, SH; Lin, MS, 2021
)
2.79
"Free gossypol is a toxic compound which naturally occurs in cottonseed and its derivates, affecting animal and possibly human health. "( Evaluation of ozone technology as an alternative for degradation of free gossypol in cottonseed meal: a prospective study.
Abdalla, AL; Augusto, PED; Calori-Domingues, MA; Romero, AC, 2021
)
1.37
"Gossypol is an axially chiral natural polyphenol classically extracted from the Malavaceae family. "( Development of SECheM Concept for Isolation and Chemical Modification of Gossypol Directly from Cienfuegosia digitata.
Aliyenne, A; Boumediana, AI; Daïch, A; Lawson, AM; Lepitre, T; Othman, M; Ould Elemine, B; Ould Hadou, A; Sidi Boune, MV, 2017
)
2.13
"Gossypol is a polyphenolic, yellowish compound derived from cottonseed extract. "( Gossypol induces cell death by activating apoptosis and autophagy in HT-29 cells.
Li, LY; Li, PH; Lu, MD; Sun, WJ; Wang, FH; You, T; Zheng, ZQ, 2017
)
3.34
"Gossypol acts as a Bcl-2 inhibitor that induces apoptosis in apoptosis-competent cells."( A novel role of the mitochondrial permeability transition pore in (-)-gossypol-induced mitochondrial dysfunction.
Hamann, A; Kögel, D; Meyer, N; Osiewacz, HD; Warnsmann, V, 2018
)
1.44
"Gossypol is a yellow polyphenol isolated from cotton seeds. "( Gossypol inhibits 5α-reductase 1 and 3α-hydroxysteroid dehydrogenase: Its possible use for the treatment of prostate cancer.
Cao, S; Ge, F; Ge, RS; Li, X; Wang, G; Wang, Y; Zhu, Q, 2019
)
3.4
"Gossypol is a polyphonic toxic compound that is present in cotton plants. "( Effect of a functional recombinant cytochrome P450 enzyme of Helicoverpa armigera on gossypol metabolism co-expressed with NADPH-cytochrome P450 reductase in Pichia pastoris.
Chen, C; Ge, W; Liang, J; Ma, X; Nie, CX; Pi, W; Wang, Y; Zhang, WJ; Zhang, Y, 2019
)
2.18
"Gossypol, which is a natural polyphenolic aldehyde isolated from the seeds of the cotton plant, has been shown to exert antitumoral activity in leukemia and lymphoma and in breast, head and neck, colon and prostate cancers."( In vivo and in vitro inhibition of osteosarcoma growth by the pan Bcl-2 inhibitor AT-101.
Bei, R; Benvenuto, M; Cerbelli, B; Ciuffa, S; Fazi, S; Izzi, V; Lucarelli, E; Masuelli, L; Mattera, R; Modesti, A; Potenza, V; Tresoldi, I; Zago, E, 2020
)
1.28
"Gossypol is a highly reactive compound present in cotton (Gossypium spp.). "( Effectiveness of albumin-conjugated gossypol as an immunogen to prevent gossypol-associated acute hepatotoxicity in rats.
Fonseca, NB; Gadelha, IC; Oloris, SC; Soto-Blanco, B, 2013
)
2.11
"Gossypol is a naturally occurring polyphenolic compound extracted from cotton plants. "( Induction of apoptosis and antitumor effects of a small molecule inhibitor of Bcl-2 and Bcl-xl, gossypol acetate, in multiple myeloma in vitro and in vivo.
Lin, J; Wu, Y; Yang, D; Zhao, Y, 2013
)
2.05
"Gossypol is a kind of yellow polyphenolic compounds extracted from root stem and seed of the cotton plant. "( Gossypol suppresses mouse T lymphocytes via inhibition of NFκB, NFAT and AP-1 pathways.
Guan, S; Huang, G; Li, G; Lu, J; Song, B; Tong, C; Wang, Z; Xiong, Y; Zhang, S, 2013
)
3.28
"Gossypol is a polyphenolic compound that has attracted attention because of its biological effects."( Therapeutic potential of gossypol: an overview.
Goliaei, B; Keshmiri-Neghab, H, 2014
)
1.43
"Gossypol is a putative BH3 mimetic proposed to inhibit BCL2 and BCLXL based on cell-free assays. "( Gossypol increases expression of the pro-apoptotic BH3-only protein NOXA through a novel mechanism involving phospholipase A2, cytoplasmic calcium, and endoplasmic reticulum stress.
Danilov, AV; Eastman, A; Soderquist, RS, 2014
)
3.29
"Gossypol is a Bcl-2 homology 3 (BH3)-mimetic agent and is able to bind to the BH3 domain of B-cell lymphoma 2 (Bcl-2) family members."( Identification of a novel potential antitumor activity of gossypol as an APE1/Ref-1 inhibitor.
Cheng, Y; Li, M; Li, Z; Qian, C; Ren, T; Sui, J; Wang, D; Zhang, L; Zhou, L, 2014
)
1.37
"Gossypol is a phenolic compound produced by pigment glands in cotton stems, leaves, seeds, and flower buds (Gossypium spp.). "( Gossypol toxicity from cottonseed products.
Fonseca, NB; Gadelha, IC; Melo, MM; Oloris, SC; Soto-Blanco, B, 2014
)
3.29
"Gossypol is a phenolic aldehyde extracted from plants and is known to be an antitumor agent to induce cancer cell apoptosis. "( Proteomic analysis of gossypol induces necrosis in multiple myeloma cells.
Liu, C; Tang, H; Tian, E; Wang, Q; Xu, R, 2014
)
2.16
"Gossypol (Gos) is a natural polyphenolic compound extracted from cotton plants, and has been shown to possess anti-neoplastic activity against various tumors."( Gossypol induces apoptosis in multiple myeloma cells by inhibition of interleukin-6 signaling and Bcl-2/Mcl-1 pathway.
Ikeda, Y; Kizaki, M; Nakajima, H; Nakazato, T; Okamoto, S; Sadahira, K; Sagawa, M; Uchida, H, 2014
)
2.57
"Gossypol is a polyphenolic extract of cottonseeds."( Gossypol sensitizes the antitumor activity of 5-FU through down-regulation of thymidylate synthase in human colon carcinoma cells.
Cao, Y; Feng, W; Hou, K; Liu, Y; Qu, J; Qu, X; Xu, L; Yang, D, 2015
)
2.58
"Gossypol is a chemical present in the seeds of cotton plants (Gossypium sp.) that reduces fertility in farm animals. "( Mechanisms involved in reproductive damage caused by gossypol in rats and protective effects of vitamin E.
Bizerra, PF; Guelfi, M; Medeiros, HC; Mingatto, FE; Santana, AT; Tavares, MA, 2015
)
2.11
"Gossypol is a part of the cotton plant's defense system against pathogens and herbivorous insects. "( Synthesis and antiviral, insecticidal, and fungicidal activities of gossypol derivatives containing alkylimine, oxime or hydrazine moiety.
Li, L; Li, Y; Li, Z; Liu, Y; Wang, K; Wang, Q, 2016
)
2.11
"Gossypol is a defense compound in cotton plants for protection against pests and pathogens. "( Dirigent Proteins from Cotton (Gossypium sp.) for the Atropselective Synthesis of Gossypol.
Effenberger, I; Klaiber, I; Li, L; Liu, Y; Pfannstiel, J; Schaller, A; Wang, Q; Zhang, B, 2015
)
2.09
"Gossypol is a chemical isolated from cotton seeds. "( Gossypol enantiomers potently inhibit human placental 3β-hydroxysteroid dehydrogenase 1 and aromatase activities.
Dong, Y; Ge, RS; Guan, H; Huang, P; Li, L; Li, X; Lian, Q; Mao, B; Su, Y, 2016
)
3.32
"Gossypol is an important allelochemical produced by the subepidermal glands of some cotton varieties and important for their ability to respond to changing biotic stress by exhibiting antibiosis against some cotton pests. "( Rhizobacteria activates (+)-δ-cadinene synthase genes and induces systemic resistance in cotton against beet armyworm (Spodoptera exigua).
Fadamiro, H; Kloepper, JW; Song, Y; Zebelo, S, 2016
)
1.88
"Gossypol, is a polyphenolic compound naturally occurring in cotton seed, was originally identified as a male contraceptive but it has several proposed clinical applications. "( The genotoxic effects of anti-cancer drug gossypol on human lymphocytes and its mitigation by melatonin.
Narechania, MB; Rao, MV, 2016
)
2.14
"Gossypol is a polyphenolic secondary metabolite produced by cotton plants, which is toxic to many organisms. "( Gossypol toxicity and detoxification in Helicoverpa armigera and Heliothis virescens.
Boland, W; Heckel, DG; Heidel-Fischer, HM; Jiménez-Alemán, GH; Joußen, N; Krempl, C; Menezes, RC; Reichelt, M; Vogel, H, 2016
)
3.32
"Gossypol is known to be a polyphenolic compound toxic to animals. "( Dietary gossypol suppressed postprandial TOR signaling and elevated ER stress pathways in turbot (Scophthalmus maximus L.).
Bian, F; He, G; Jiang, H; Mai, K; Man, M; Xu, W; Zhou, H, 2017
)
2.33
"Free gossypol (Fig. 1) is a toxic phenolic compound which becomes detoxified in ruminants by binding to milk proteins, but gossypol is still an active inhibitor of tumour growth in the excreted milk."( Long-term clinical remission of a patient with chronic lymphocytic leukemia using alternative treatment option: cottonseed oil (gossypol).
Politzer, WM, 2008
)
1.01
"Apogossypolone (ApoG2) is a semi-synthesized derivative of gossypol. "( Apogossypolone, a nonpeptidic small molecule inhibitor targeting Bcl-2 family proteins, effectively inhibits growth of diffuse large cell lymphoma cells in vitro and in vivo.
Aboukameel, A; Al-Katib, A; Arnold, AA; Banerjee, S; Chen, J; Lin, Y; Ling, X; Mohammad, RM; Nikolovska-Coleska, Z; Sun, Y; Wang, S; Wu, J; Yang, D, 2008
)
1.59
"Gossypol is a polyphenolic compound originally isolated from cottonseed that has long been used successfully as a contraceptive drug for males. "( Gossypol suppresses telomerase activity in human leukemia cells via regulating hTERT.
Choi, YH; Kim, GY; Kim, MO; Kim, ND; Lee, HG; Moon, DO, 2008
)
3.23
"Gossypol is a constituent of the lysigenous foliar glands of cotton plants and is also found in glands in cottonseed. "( Effect of racemic, (+)- and (-)-gossypol on survival and development of Heliothis virescens larvae.
Dowd, MK; Duke, SE; López, JD; Puckhaber, LS; Stipanovic, RD, 2008
)
2.07
"Gossypol is a polyphenol isolated from the seed, roots and stem of cotton plant (Gossypium sp.) It has been associated with adverse effects on female reproduction, but recently also shown having promising effects against several malignancies. "( Gossypol, a polyphenolic aldehyde from cotton plant, interferes with swine granulosa cell function.
Baioni, L; Basini, G; Bussolati, S; Grasselli, F, 2009
)
3.24
"Gossypol is a natural disesquiterpene that blocks the activity of the mammalian facilitative hexose transporter GLUT1. "( Endofacial competitive inhibition of the glucose transporter 1 activity by gossypol.
Cárcamo, JG; Castro, M; Concha, II; Ojeda, L; Ojeda, P; Ortega, M; Pérez, A; Rauch, MC; Reyes, AM; Rivas, CI; Sánchez, C; Valenzuela, X; Vera, JC, 2009
)
2.03
"apogossypolone (ApoG2) is a novel derivate of gossypol. "( ApoG2 induces cell cycle arrest of nasopharyngeal carcinoma cells by suppressing the c-Myc signaling pathway.
Hu, ZY; Sun, J; Yang, D; Zeng, YX; Zhu, XF, 2009
)
0.97
"Gossypol is a natural polyphenolic compound extracted from cotton plant (Gossypium species) which has shown potent inhibitory effect on cell growth of many types of cancers. "( Enhancement of taxane-induced cytotoxicity and apoptosis by gossypol in human breast cancer cell line MCF-7.
Atmaca, H; Karabulut, B; Karaca, B; Sanli, UA; Uslu, R; Uzunoglu, S,
)
1.82
"Apogossypolone (ApoG2) is an analogue of (-)-gossypol, exhibiting binding activity with Ki values of 35 nmol/L for Bcl-2 and 25 nmol/L for Mcl-1."( Preclinical studies of apogossypolone, a novel pan inhibitor of bcl-2 and mcl-1, synergistically potentiates cytotoxic effect of gemcitabine in pancreatic cancer cells.
Aboukameel, A; Banerjee, S; Chen, J; Choi, M; Mohammad, M; Mohammad, RM; Sarkar, FH; Wang, Z; Yang, D, 2010
)
1.17
"Apogossypolone, which functions as a potent pan-Bcl-2 family inhibitor, seems therapeutically promising for future translational studies including the treatment of pancreatic cancer."( Preclinical studies of apogossypolone, a novel pan inhibitor of bcl-2 and mcl-1, synergistically potentiates cytotoxic effect of gemcitabine in pancreatic cancer cells.
Aboukameel, A; Banerjee, S; Chen, J; Choi, M; Mohammad, M; Mohammad, RM; Sarkar, FH; Wang, Z; Yang, D, 2010
)
1.28
"Gossypol is an attractive therapeutic anti-tumor agent as an apoptosis inducer and is being evaluated in preclinical tests. "( Gossypol inhibits phosphorylation of Bcl-2 in human leukemia HL-60 cells.
Hu, JQ; Huang, LH; Jiang, J; Li, GM; Li, YH; Liu, XS; Tao, WQ; Xie, PY, 2010
)
3.25
"Gossypol is a yellowish polyphenolic compound originally from cotton plant, which has been shown to exert a potential for anti-cancer and anti-inflammatory effects. "( Gossypol decreases tumor necrosis factor-α-induced intercellular adhesion molecule-1 expression via suppression of NF-κB activity.
Choi, YH; Kim, GY; Kim, WJ; Moon, DO; Moon, SK, 2011
)
3.25
"Gossypol is a dimeric sesquiterpenoid first identified in cottonseed, but found in various tissues in the cotton plant including the seed. "( Hemigossypol, a constituent in developing glanded cottonseed (Gossypium hirsutum).
Bell, AA; Liu, J; Puckhaber, LS; Stipanovic, RD; Wagner, TA, 2012
)
2.38
"Gossypol is a polyphenolic aldehyde extracted from cotton plants."( Amino acid derivatives of the (-) enantiomer of gossypol are effective fusion inhibitors of human immunodeficiency virus type 1.
An, T; Chen, G; Guo, D; Li, J; Li, L; Ouyang, W; Pan, W; Tien, P; Wu, S; Yang, J, 2012
)
1.36
"Gossypol is a polyphenolic aldehyde that is produced in the cotton plant. "( Apogossypolone, derivative of gossypol, mobilizes endogenous copper in human peripheral lymphocytes leading to oxidative DNA breakage.
Ahmad, A; Hadi, SM; Khan, HY; Ullah, MF; Wu, D; Zubair, H, 2012
)
2.44
"Gossypol is a toxic compound that occurs as a mixture of enantiomers in cotton plant tissues including seed and flower petals. "( Capillary electrophoresis to quantitate gossypol enantiomers in cotton flower petals and seed.
Akhunov, A; Golubenko, Z; Namazov, S; Pshenichnov, E; Stipanovic, RD; Vshivkov, S, 2012
)
2.09
"Gossypol (GP) is a potent antifertility agent contained in cottonseed and other parts of cotton plants. "( Effects of gossypol on O2 consumption and CO2 production in human prostate cancer cells.
Chang, HL; Czekajewski, J; Ghosh, PK; Jiang, J; Kulp, SK; Lin, YC; Liu, S; Sugimoto, Y,
)
1.96
"Gossypol is a bifunctional agent, capable of cross-linking amino acid side chains, and its action on brush-border enzymes may be due to this mechanism."( Inactivation of intestinal brush-border enzymes by gossypol.
Baram, N; Cogan, U; Mokady, S, 1987
)
1.15
"Gossypol is a male contraceptive derived from cotton seeds."( Telomerase inhibitors in anticancer therapy: gossypol as a potential telomerase inhibitor.
Mego, M, 2002
)
1.3
"Gossypol is a natural defense compound in the plant that protects it against pests and diseases, but can have antinutritional quality effects when consumed by dairy cattle."( Increasing dietary levels of cracked pima cottonseed increase plasma gossypol but do not influence productive performance of lactating Holstein cows.
DePeters, EJ; Pareas, JW; Prieto, JG; Robinson, PH; Santos, JE; Taylor, SJ, 2003
)
1.27
"Gossypol was found to be a stimulator of heme oxygenase activity in the liver and kidney to varying degrees."( Modulatory influence of tin-protoporphyrin on gossypol-induced alterations of heme oxygenase activity in male Wistar rats.
Aneja, R; Chandra, R; Dass, SK,
)
1.11
"Gossypol is a natural toxicant present in cottonseeds, and is hepatotoxic to animals and human. "( Effect of gossypol on intracellular Ca2+ regulation in human hepatoma cells.
Chen, WC; Cheng, HH; Cheng, JS; Jan, CR; Liu, CP; Lo, YK; Yeh, JH, 2003
)
2.16
"Gossypol was found to be a potent stimulator of heme oxygenase (HMOX) activity in rat liver and kidney to varying degrees."( Effect of gossypol in association with chromium protoporphyrin on heme metabolic enzymes.
Aneja, R; Chandra, R; Dass, SK; Prakash, S, 2004
)
1.45
"Gossypol is a component present in cottonseeds and has been demonstrated to be an effective contraceptive drug in preventing spermatogenesis in mammalian species. "( Involvement of reactive oxygen species-independent mitochondrial pathway in gossypol-induced apoptosis.
Fujii, M; Hou, DX; Imamura, I; Ose, T; Takeshita, T; Tanigawa, S; Tong, X; Uto, T, 2004
)
2
"Gossypol is a di-sesquiterpene natural-product in the form of a functionalised binaphthyl and is isolated from cotton plants. "( Mapping the binding site for gossypol-like inhibitors of Plasmodium falciparum lactate dehydrogenase.
Brady, RL; Cameron, A; Conners, R; Croft, SL; Easton, A; Read, J; Schambach, F; Sessions, RB; Vivas, L, 2005
)
2.06
"Gossypol is an allelochemical that occurs naturally throughout the cotton plant as an enantiomeric mixture. "( Ratios of (+)- and (-)-gossypol in leaves, stems, and roots of selected accessions of Gossypium hirsutum var. marie galante (Watt) Hutchinson.
Bell, AA; Puckhaber, LS; Stipanovic, RD, 2006
)
2.09
"Gossypol is a sesquiterpene that occurs naturally in seed and other parts of the cotton plant. "( Effect of racemic and (+)- and (-)-gossypol on the survival and development of Helicoverpa zea larvae.
Dowd, MK; Duke, SE; Lopez, JD; Puckhaber, LS; Stipanovic, RD, 2006
)
2.05
"Gossypol is a natural polyphenolic compound isolated from cottonseed and has antiproliferative activity in a variety of cancer cell lines."( (-)Gossypol and its combination with imatinib induce apoptosis in human chronic myeloid leukemic cells.
Chen, X; Fu, J; Li, H; Li, J; Li, Y; Liu, H; Liu, Y; Meng, Y, 2007
)
1.68
"Gossypol is a yellowish phenolic compound ocurring naturally in certain species of cotton plants of the family Malvaciae, mostly in the seeds and root bark."( Gossypol: a potential antifertility agent for males.
Qian, SZ; Wang, ZG, 1984
)
2.33
"Gossypol acetic acid is a polyphenolic compound present in the seed of cotton plants. "( Effect of the antifertility agent, gossypol acetic acid, on the metabolism and testosterone secretion of isolated rat interstitial cells in vitro.
Homonnai, ZT; Paz, GF, 1984
)
1.99
"Gossypol is a competitive inhibitor of NADH, Ki = 30 microM (Km = 17 microM), and NAD+, Ki = 6 microM (Km = 130 microM), and noncompetitive for pyruvate, Ki = 220 microM (Km = 224 microM), and lactate, Ki = 52 microM (Km = 5.6 mM)."( Kinetics of gossypol inhibition of bovine lactate dehydrogenase X.
Olgiati, KL; Toscano, WA, 1983
)
1.37
"Gossypol is a yellow substance which occurs in various parts of the cotton plant; its chemical structure is naphthol phenol."( Clinical study of gossypol as a male contraceptive.
Liu, GZ,
)
1.09
"Gossypol is a phenolic compound isolated from the seeds, stems, and roots of the cotton plant. "( Gossypol as an oral contraceptive for men.
, 1980
)
3.15
"Gossypol is a polyphenolic aldehyde occurring naturally in cottonseed that produces antisteroidogenic activity in vivo, has been extensively investigated as a male contraceptive agent, and has demonstrated anticancer activity. "( Antiproliferative activity of gossypol and gossypolone on human breast cancer cells.
Brueggemeier, RW; Chang, CJ; Gilbert, NE; Lin, YC; O'Reilly, JE, 1995
)
2.02
"Gossypol was found to be a noncompetitive inhibitor of arylsulfatase with a Ki of 120 microM."( Inhibition of rabbit sperm acrosomal enzymes by gossypol.
Shi, QX; Srivastava, PN; Yuan, YY, 1995
)
1.27
"Gossypol is a lipid soluble polyphenolic compound isolated from cotton seed oil which has been previously shown to have antiproliferative activity in vitro against a variety of human solid tumor cell lines. "( In vitro and in vivo cytotoxicity of gossypol against central nervous system tumor cell lines.
Coyle, T; Levante, S; Shetler, M; Winfield, J, 1994
)
2
"Gossypol (GP) is a natural polyphenolic compound that possesses antifertility and antisteroidogenic activities in both males and females. "( Gossypol inhibits human chorionic gonadotropin-stimulated testosterone production by cultured canine testicular interstitial cells.
Chang, W; Kulp, S; Lin, YC; Mushtaq, M, 1996
)
3.18
"Gossypol (GOS) is a polyphenolic compound derived mainly from cottonseed oil, which has been found to have anti-fertility effects in males. "( The inhibitory effects of gossypol on human sperm motility characteristics: possible modes of reversibility of those effects.
Zarmakoupis-Zavos, PN; Zavos, PM, 1996
)
2.04
"Gossypol is an antisteroidogenic compound naturally found in cottonseed. "( Gossypol induces spermidine/spermine N1-acetyltransferase in canine prostate epithelial cells.
Canatan, H; Chang, WY; Kulp, SK; Lin, YC; Shidaifat, F; Sugimoto, Y, 1997
)
3.18
"Gossypol is an antinutritional polyphenolic pigment found in cottonseed."( Use of expander cottonseed meal in broiler diets formulated on a digestible amino acid basis.
Bailey, CA; Calhoun, MC; Gamboa, DA; Haq, AU; Kuhlmann, SW, 2001
)
1.03
"Gossypol is an antifertilizing agent in males and females. "( Gossypol and gossypolone enantiomers in tissues of rainbow trout fed low and high levels of dietary cottonseed meal.
Dabrowski, K; Lee, KJ, 2002
)
3.2
"Gossypol is a polyphenol isolated from the seed, roots, and stem of the cotton plant (Gossypium sp.). "( Gossypol: a contraceptive for men.
Coutinho, EM, 2002
)
3.2
"Gossypol is a naturally occurring toxin with potent antifertility action in both males and females. "( Transfer of 3H-gossypol to neonatal rats via milk of nursing dams.
Chang, CJ; Hu, YF; Kulp, SK; Lin, YC; Moh, PP, 1992
)
2.08
"Gossypol is a toxic factor indigenous to the cotton plant genus Gossypium. "( Effects of gossypol and cottonseed products on reproduction of mammals.
Chase, CC; Randel, RD; Wyse, SJ, 1992
)
2.12
"Gossypol is a potent antifertility agent contained in seeds and other parts of cotton plants. "( Characteristics of covalent gossypol binding to microsomal proteins.
Brueggemeier, RW; Darby, MV; Li, PK; Lin, YC; Moh, PP, 1992
)
2.02
"Gossypol is an antifertility agent which inhibits steroidogenesis in both sexes. "( Binding of 3H-gossypol in organelles of cultured bovine luteal cells.
Brueggemeier, RW; Gu, Y; Lin, YC; Rikihisa, Y, 1992
)
2.09
"Gossypol is a Chinese cottonseed derivative, which, taken orally, inhibits spermatogenesis in men."( Contraception--a look forward, Part II: Mifepristone and gossypol.
Woolley, RJ,
)
1.1
"Gossypol is a polyphenolic dialdehyde, occurring in 2 racemic isomers with different biological activities."( Effects of gossypol on the motility of mammalian sperm.
Porat, O, 1990
)
1.29
"Gossypol is an orally active male anti-fertility agent that has been used in China by more than 10,000 men."( Inactivation of human immunodeficiency virus in vitro by gossypol.
Armstrong, D; Baron, PA; Gold, JW; Polsky, B; Segal, SJ; Ueno, H, 1989
)
1.14
"Gossypol is an orally active male contraceptive with cardio-depressant side effects. "( Modification of the positive inotropic effects of catecholamines, cardiac glycosides and Ca2+ by the orally active male contraceptive, gossypol, in isolated guinea-pig heart.
Akera, T; Ng, YC; Ye, YX, 1989
)
1.92
"Gossypol is a naturally occurring yellow substance in cotton plant that has male reproductive toxicity both in humans and some experimental animal species. "( Interspecies comparison of pharmacokinetic profile and bioavailability of (+/-)-gossypol in male Fischer-344 rats and male B6C3F mice.
Abou-Donia, MB; Obih, P; Othman, MA, 1989
)
1.95
"Gossypol proved to be a potent inhibitor of the angiotensin converting enzyme (ACE) detectable in high concentrations in seminal plasma."( Effect of ace-inhibitors, calmodulin antagonists, acetylcholine receptor blocking, and alpha receptor blocking agents on motility of human sperm.
Krassnigg, F; Placzek, R; Schill, WB, 1988
)
1
"Gossypol was found to be an effective male contraceptive. "( Effects of K salt or a potassium blocker on gossypol-related hypokalemia.
Cao, JA; Ch'iu-Hinton, K; Li, BY; Liu, GZ; Zhu, CX, 1988
)
1.98
"Gossypol is a unique compound since it alone, but not any of its derivatives, has in vivo as well as in vitro antifertility activity."( Anti-fertility and other actions of gossypol analogues.
Corin, RE; Haspel, HC; Hoffer, AP; Huang, JT; Ren, YF; Sonenberg, M; Su, TL; Watanabe, KA, 1988
)
1.17
"Gossypol is a polyphenolic pigment, which is employed as a male antifertility drug. "( Binding of gossypol to purified tubulin and inhibition of its assembly into microtubules.
Andreu, JM; Medrano, FJ, 1986
)
2.1
"Gossypol proved to be a powerful inhibitor of the six enzymes studied."( In vitro inhibition by gossypol of oxidoreductases from human tissues.
Blanco, A; Burgos, C; Gerez de Burgos, NM; Rovai, LE, 1986
)
1.3
"Gossypol is a yellow phenolic compound which reversibly inhibits spermatogenesis making it one of the few effective male antifertility drugs. "( Ribonucleotide reductase: an intracellular target for the male antifertility agent, gossypol.
Chan, AK; Creasey, DC; McClarty, GA; Wright, JA, 1985
)
1.94
"Gossypol is a cumulative toxin; the amount of free gossypol fed was approximately 5.4 to 5.7 mg/kg/day for an unknown duration."( Heart failure caused by gossypol poisoning in two dogs.
Gompf, RE; Legendre, AM; Patton, CS; Walker, MA, 1985
)
1.3

Effects

Gossypol has an in vitro antiamebic effect, which is 11,39, and 980 times more potent than emetime, metronidazole and diiodohydroxyquinolein on five Entamoeba histolytica axenic strains.

Gossypol has been shown to have an anti-HCC effect, but the underlying mechanism requires further study. It has anti-cancer effects by dual-targeting MDM2 and VEGF in human breast cancer.

ExcerptReferenceRelevance
"Gossypol has an antibiotic effect on Aphis gossypii, and as the concentrations of gossypol were increased in the present study, the mortality of cotton aphids increased from 4 to 28%."( Cytochrome P450 CYP6DA2 regulated by cap 'n'collar isoform C (CncC) is associated with gossypol tolerance in Aphis gossypii Glover.
Bi, R; Gao, X; Pan, Y; Peng, T; Shang, Q; Xi, J; Xin, X; Yang, C; Yang, S; Zhang, L, 2016
)
1.38
"Gossypol has an in vitro antiamebic effect, which is 11,39, and 980 times more potent than emetime, metronidazole and diiodohydroxyquinolein, respectively, on five Entamoeba histolytica axenic strains. "( Further studies on the in vitro activity of gossypol as antiamebic agent.
González-Garza, MT; Mata-Cárdenas, BD; Matlin, SA; Said-Fernández, S, 1992
)
1.99
"Gossypol has gained considerable research interest due to its attractive biological activities, especially antitumor and antivirus."( Structure, properties of gossypol and its derivatives-from physiological activities to drug discovery and drug design.
Liu, Y; Wang, L; Zhang, Y; Zhao, L, 2022
)
1.75
"Gossypol has been reported to exhibit antitumor effects against several human cancers. "( Bioinformatics Analysis of the Signaling Pathways and Genes of Gossypol Induce Death of Nasopharyngeal Carcinoma Cells.
Ge, J; Gong, Z; He, Y; Huang, W; Jiang, X; Li, P; Mo, Y; Wang, J; Xiong, W; Yu, J; Zeng, Z; Zhu, K, 2021
)
2.3
"Gossypol has been shown to have an anti-HCC effect, but the underlying mechanism requires further study."( Dual effects of gossypol on human hepatocellular carcinoma via endoplasmic reticulum stress and autophagy.
Cao, Y; Chen, W; Ji, A; Jiang, C; Qiang, G; Wang, Z; Wu, J; Zhang, G, 2019
)
1.58
"Gossypol has been reported to have anti-inflammatory properties. "( Protective effect of gossypol on lipopolysaccharide-induced acute lung injury in mice.
Cao, Y; Fu, Y; Li, F; Liang, D; Liu, Z; Song, X; Yang, Z; Zhang, N; Zhang, W; Zhang, X; Zhou, E, 2013
)
2.15
"Gossypol has served as a lead compound for developing more efficient BH3 mimetics such as ABT-737 and its orally available structural analog ABT-263 (Navitoclax)."( Polyphenols as mitochondria-targeted anticancer drugs.
Fichna, J; Gorlach, S; Lewandowska, U, 2015
)
1.14
"Gossypol has an antibiotic effect on Aphis gossypii, and as the concentrations of gossypol were increased in the present study, the mortality of cotton aphids increased from 4 to 28%."( Cytochrome P450 CYP6DA2 regulated by cap 'n'collar isoform C (CncC) is associated with gossypol tolerance in Aphis gossypii Glover.
Bi, R; Gao, X; Pan, Y; Peng, T; Shang, Q; Xi, J; Xin, X; Yang, C; Yang, S; Zhang, L, 2016
)
1.38
"Gossypol has anti-proliferative effects on cancer cell lines."( The genotoxic effects of anti-cancer drug gossypol on human lymphocytes and its mitigation by melatonin.
Narechania, MB; Rao, MV, 2016
)
1.42
"Gossypol has anti-cancer effects by dual-targeting MDM2 and VEGF in human breast cancer. "( Gossypol has anti-cancer effects by dual-targeting MDM2 and VEGF in human breast cancer.
Li, J; Su, T; Wang, J; Xiong, J; Yang, Q; Zhou, S, 2017
)
3.34
"Gossypol has recently been identified as a potential anticancer agent. "( A liposomal delivery vehicle for the anticancer agent gossypol.
Lee, RJ; Li, H; Lin, YC; Lu, Y; Wu, J; Ye, W; Yu, B; Zhai, G; Zhao, X,
)
1.82
"Gossypol has been proven to be a very effective male contraceptive. "( The (+)- and (-)-gossypols potently inhibit human and rat 11beta-hydroxysteroid dehydrogenase type 2.
Cai, H; Chen, BB; Ge, RS; Gu, DY; Hardy, DO; Hu, GX; Lian, QQ; Lin, H; Su, Y; Zhou, HY, 2009
)
2.14
"Gossypol has been reported to have a potent anticancer activity in many types of cancer."( Apogossypolone, a novel inhibitor of antiapoptotic Bcl-2 family proteins, induces autophagy of PC-3 and LNCaP prostate cancer cells in vitro.
An, QX; Chen, R; Hu, XB; Huang, XF; Mu, SJ; Wu, DC; Xia, AJ; Yang, SM; Yi, J; Zhan, YH; Zhang, XQ, 2010
)
1.7
"Gossypol has been reported as a potential inhibitor of cell proliferation in various types of cancers, such as prostate cancer, breast cancer, leukemia, and lung cancer."( Involvement of Smac, p53, and caspase pathways in induction of apoptosis by gossypol in human retinoblastoma cells.
Hsiao, WT; Jow, GM; Lee, YJ; Tien, LT; Tsai, MD, 2012
)
1.33
"Gossypol has also been an effective drug for treatment of gynecological diseases, such as menopause functional bleeding, uterine tumor, and endometrial symptoms."( [Gossypol and its related compounds as contraceptive drugs and drugs for gynecological diseases].
Wu, GP, 1988
)
1.81
"Gossypol has been applied during clinical experiments throughout China and the results of its applications have been quite satisfactory. "( [Methods of extraction and purification of gossypol].
Yuan, JR, 1984
)
1.97
"Gossypol has been shown to impair sperm production in male ruminants. "( Reversibility of the reproductive toxicity of gossypol in peripubertal bulls.
Ehrhart, EJ; Faulkner, DB; Firkins, LD; Hassan, ME; Ott, RS; Schaeffer, DJ; Smith, GW, 2004
)
2.02
"Gossypol has wide antineoplastic effects in vitro, but its effects on human lung cancer have not been explored. "( Upregulation of Fas/Fas ligand-mediated apoptosis by gossypol in an immortalized human alveolar lung cancer cell line.
Chang, JS; Chiang, LC; Hsu, YL; Kuo, PL; Lin, CC, 2004
)
2.02
"Gossypol has received significant attention as a result of its potential therapeutic application as a male antifertility agent. "( Investigations on gossypol: past and present developments.
Anderson, RJ; Dodou, K; Groundwater, PW; Small, DA, 2005
)
2.1
"Gossypol has little effect on the activities of the total spermatozoal ATPase, the spermatozoal flagellar ATPase, and the mitochondrial fragment ATPase."( Effect of gossypol on boar spermatozoal adenosine triphosphate metabolism.
Lee, CS; Tso, MY; Tso, WW, 1982
)
1.39
"Gossypol has deleterious effects directly on TR-ST cells originating from a rat testicular tumor. "( Direct effect of gossypol on TR-ST cells: perturbation of rhodamine 123 accumulation in mitochondria.
Bellvé, AR; Chen, LB; Tanphaichitr, N, 1984
)
2.05
"Gossypol has been used as oral contraceptive for man in People's Republic of China. "( Gossypol as oral contraceptive for male: trial case report.
Hoshiai, H; Mori, R; Nagaike, F; Suzuki, M; Tsuiki, A; Uehara, S, 1982
)
3.15
"Gossypol has been reported to be much less effective as a male contraceptive in the rabbit than in man."( Effects of gossypol acetic acid on the activity of LDH-C4 from human and rabbit spermatozoa.
Eliasson, R; Virji, N, 1983
)
1.28
"Gossypol has been shown to be an effective oral male contraceptive. "( Cottonseed oil as a vaginal contraceptive.
Lee, CS; Tso, WW, 1982
)
1.71
"Gossypol has been shown to inhibit steroidogenesis in the canine prostate and may inhibit canine prostate growth."( Gossypol induces spermidine/spermine N1-acetyltransferase in canine prostate epithelial cells.
Canatan, H; Chang, WY; Kulp, SK; Lin, YC; Shidaifat, F; Sugimoto, Y, 1997
)
2.46
"Gossypol has demonstrated in vitro effects on cell cycle regulation and anti-tumor activity against mammary carcinoma cell lines. "( Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial.
Bacotti, D; Bloch, R; Borgen, P; Gollub, M; Hudis, C; Ligueros, M; Moasser, MM; Norton, L; Reidenberg, MM; Seidman, AD; Sklarin, N; Sonenberg, M; Van Poznak, C; Van Zee, K; Yao, TJ, 2001
)
2.27
"Gossypol has an in vitro antiamebic effect, which is 11,39, and 980 times more potent than emetime, metronidazole and diiodohydroxyquinolein, respectively, on five Entamoeba histolytica axenic strains. "( Further studies on the in vitro activity of gossypol as antiamebic agent.
González-Garza, MT; Mata-Cárdenas, BD; Matlin, SA; Said-Fernández, S, 1992
)
1.99
"Gossypol, a drug which has been shown to be an inhibitor of kinase C activity in mouse mammary tissues, is shown to abolish several of the actions of prolactin in cultured mouse mammary gland explants. "( Effect of kinase C inhibitor, gossypol, on the actions of prolactin in cultured mouse mammary tissues.
Etindi, RN; Rillema, JA, 1987
)
2
"Gossypol has been shown to inhibit steroidogenesis in leydig cells. "( Inhibition by gossypol of cyclic AMP production in mouse Leydig cells.
Donaldson, A; Jeffcoate, SL; O'Shaughnessy, PJ; Pearce, S; Sufi, SB, 1986
)
2.07
"Gossypol has potential for widespread use as a male oral antifertility agent in humans since it appears to be highly efficacious, with reversible spermatostatic effects and minimal side effects. "( Variable sister-chromatid exchange response in human lymphocytes exposed in vitro to gossypol acetic acid.
Best, RG; McKenzie, WH, 1988
)
1.94
"Gossypol acetic acid has been shown to have the effect of increasing the SCE frequencies in the spermatogonial cells of mice. "( Gossypol acetate-induced SCEs in spermatogonia and bone marrow cells of mice: dose-response relationships.
Tan, YB; Wang, RL; Zhang, ZS, 1988
)
3.16
"(-)-Gossypol has been isolated from cottonseed of G. "( Isolation of (-)-gossypol from natural plant.
Lin, XD; Zhou, RH, 1988
)
1.17
"Gossypol has been resolved into its pure optical isomers by conversion into the Schiff's base derivative of (+)-phenylalanine methyl ester, normal or reverse phase chromatography and hydrolysis. "( Large-scale resolution of gossypol enantiomers for biological evaluation.
Belenguer, A; Brookes, AN; Matlin, SA; Tyson, RG; Zhou, RH, 1988
)
2.02
"Gossypol has no detectable effect on the concentration of TNBP in RS."( The effects of gossypol on nuclear protein in rat testes. I. Reduction in the content of basic proteins in the spermiogenic cells.
Fei, RR; Teng, CS, 1988
)
1.35
"(+)-Gossypol has neither antifertility effect nor toxicity at the dosage of 30 mg/kg orally for 14 days in male rats, but slight damage was found in the germinal epithelium of the testis in animals dosed for 4 weeks. "( Effect of (-)- and (+)-gossypol on fertility in male rats.
Guan, MH; Lei, HP; Wang, NG; Zhou, LF, 1987
)
1.14
"Gossypol has been under clinical trial in China for years and shown to be effective in 99.9% of over 10,000 men tested with no or mild side effects."( Clastogenicity of a male contraceptive, gossypol, in mammalian cell cultures with and without the metabolic activation by S9 mix.
Liang, JC; Ye, WS, 1985
)
1.26

Actions

Gossypol acetate can inhibit the growth of Raji cells and induce their apoptosis. GossypOL did not inhibit ovulation in the rat at dosages up to 80 mg/kg/day but did cause 90% inhibition of pregnancy in mice treated with 80mg/kg-a-day during the first two weeks of pregnancy.

ExcerptReferenceRelevance
"Gossypol displays anticancer behavior and anti-fertility in males. "( Mutual anti-oxidative effect of gossypol acetic acid and gossypol-iron complex on hepatic lipid peroxidation in male rats.
Bader El-Dein, MM; El-Shahawy, IN; El-Sharaky, AS; Fawzy, RA; Wahby, MM, 2009
)
2.08
"Gossypol acetate can inhibit the growth of Raji cells and induce their apoptosis. "( [Effect of gossypol acetate on proliferation and apoptosis in Raji lymphoblastoid cell line].
Cheng, W; Li, YM; Yang, DJ; Zhao, YQ, 2009
)
2.19
"Gossypol was shown to inhibit TNF-α-induced ICAM-1 expression and U937 cell adhesion to MDA-MB-231 and MCF-7 cells."( Gossypol decreases tumor necrosis factor-α-induced intercellular adhesion molecule-1 expression via suppression of NF-κB activity.
Choi, YH; Kim, GY; Kim, WJ; Moon, DO; Moon, SK, 2011
)
2.53
"The gossypol mediated an increase of heme oxygenase activity, elevated bilirubin levels leading to hyperbilirubinemia."( Modulatory influence of tin-protoporphyrin on gossypol-induced alterations of heme oxygenase activity in male Wistar rats.
Aneja, R; Chandra, R; Dass, SK,
)
0.87
"Gossypol did not increase chromosome aberrations in the treated cells."( Effect of gossypol on DNA synthesis and cell cycle progression of mammalian cells in vitro.
Rao, PN; Wang, Y, 1984
)
1.39
"Gossypol did not inhibit ovulation in the rat at dosages up to 80 mg/kg/day but did cause 90% inhibition of pregnancy in mice treated with 80 mg/kg/day during the first two weeks of pregnancy."( Antifertility and endocrine activities of gossypol in rodents.
Hahn, DW; Homm, R; Johnson, AN; Probst, A; Rusticus, C, 1981
)
1.25
"(-)-gossypol was found to inhibit type I PKA, whereas the inhibitory action of (+)-gossypol for type I PKA was less potent."( [Comparison between the effects of (-)- and (+)-gossypol on protein kinase C and protein kinase A].
Chen, HC; Wang, XL; Xiao, DM; Yang, GD; Zhang, JB; Zhang, YH; Zhou, WH; Zhu, B, 1993
)
1.02
"Gossypol promotes binding of PLA2 to the interface, and the binding of PLA2 to the interface promotes only the noncovalent binding of gossypol, but not the covalent modification."( Gossypol modification of Ala-1 of secreted phospholipase A2: a probe for the kinetic effects of sulfate glycoconjugates.
Apitz-Castro, R; Baker, S; Jain, MK; Ranadive, G; Rogers, J; Wilton, DC; Yu, BZ, 1997
)
2.46
"Gossypol was found to increase the G0/G1 fraction of the T-47D cells."( Effects of gossypol on the cell cycle phases in T-47D human breast cancer cells.
Monet, JD; Montmasson, MP; Moustafa, Y; Thomas, M; von Hagen, V,
)
1.24
"Gossypol did not increase mutational frequency as examined by the hypoxanthine guanine phosphoribosyl transferase and Na+,K(+)-ATPase loci in V79 cells."( The modulation of gap junctional communication by gossypol in various mammalian cell lines in vitro.
Akera, T; Bombick, D; Chang, CC; Hirst, K; Trosko, JE; Ye, YX; Zhang, GX, 1990
)
1.25
"Gossypol did not inhibit ATPase in erythrocytes from any of 5 volunteers, including 2 subjects of Chinese ancestry and 3 of European stock."( Gossypol and Na+, K+ ATPase from human erythrocytes.
Drayer, DE; Reidenberg, MM, 1988
)
2.34
"Gossypol is known to produce reactive oxygen species in vitro."( Effects of gossypol on the antioxidant defense system of the rat testis.
Bender, HS; Derolf, SZ; Misra, HP, 1988
)
1.39

Treatment

Gossypol treatment reduced the length of estrous with an increase in the duration of the diestrus phase. The treatment also markedly reduced the number of infiltrated lymphocytes in the auricles of DTH mice. In rats, sperm morphology was compromised severely but the epithelium in testis and epididymis appeared morphologically normal.

ExcerptReferenceRelevance
"The gossypol-treated mice also presented with complete, non-elongated spermatids, a large number of cells in the state of round spermatids, and negativity for acrosome PAS reaction; diffuse renal mesangial cell hyperplasia, increased mesangial matrix, and adhesion of the mesangium to the wall of the renal capsule were observed, with significantly shrinkage or even absence of the lumens of the renal capsules and reduced kidney mitochondrial ATPase activity."( [Short-term exposure to gossypol causes reversible reproductive toxicity and nephrotoxicity in mice].
Cao, L; Liu, J; Ma, H; Piao, Z; Wang, H; Wu, J, 2023
)
1.7
"Gossypol treatment resulted in an increase in TTP mRNA level by 6-20-fold and increased ZFP36L1, ZFP36L2 and ZFP36L3 mRNA levels by 26-69-fold."( Plant Polyphenol Gossypol Induced Cell Death and Its Association with Gene Expression in Mouse Macrophages.
Cao, H; Sethumadhavan, K, 2023
)
1.97
"Gossypol treatment up to 96 h resulted in a selective cytotoxicity of SCL-1 cells (IC"( Involvement of necroptosis in the selective toxicity of the natural compound (±) gossypol on squamous skin cancer cells in vitro.
Brenneisen, P; Ebbert, L; Golombek, M; Haasler, L; Kondadi, AK; Reichert, AS; Stahl, W; von Montfort, C; Wenzel, CK, 2023
)
1.86
"Gossypol treatment resulted in cell death through oxidative stress."( Gossypol induces apoptosis in ovarian cancer cells through oxidative stress.
Chen, Y; Deng, H; Ge, R; Jin, L; Li, X; Lian, Q; Wang, J, 2013
)
2.55
"Upon gossypol treatment, changes in phosphorylation of twenty-nine proteins including YAP1 and AKAP12 were characterized."( Phosphoproteomic analysis of gossypol-induced apoptosis in ovarian cancer cell line, HOC1a.
Chen, Y; Deng, H; Ge, R; Jin, L; Lian, Q; Mu, X, 2014
)
1.15
"Gossypol treatment reduced the length of estrous with an increase in the duration of the diestrus phase."( Gossypol promotes degeneration of ovarian follicles in rats.
de Macedo, MF; Gadelha, IC; Melo, MM; Oloris, SC; Soto-Blanco, B, 2014
)
2.57
"Gossypol-treated groups indicated significant increases in frequency of SCEs calculated for SCE/plate and SCE/chromosome. "( The genotoxic effects of anti-cancer drug gossypol on human lymphocytes and its mitigation by melatonin.
Narechania, MB; Rao, MV, 2016
)
2.14
"Gossypol treatment resulted in a decrease of c-Myc expression and binding activity."( Gossypol suppresses telomerase activity in human leukemia cells via regulating hTERT.
Choi, YH; Kim, GY; Kim, MO; Kim, ND; Lee, HG; Moon, DO, 2008
)
2.51
"Gossypol treatment affects angiogenic cytokine secretion from these two cell lines in a different manner."( Profiling of angiogenic cytokines produced by hormone- and drug-refractory prostate cancer cell lines, PC-3 and DU-145 before and after treatment with gossypol.
Atmaca, H; Cengiz, E; Erten, C; Gorumlu, G; Gul, MK; Karabulut, B; Karaca, B; Kucukzeybek, Y; Sanli, UA; Uslu, R; Uzunoglu, S, 2008
)
1.27
"Gossypol treatment also inhibited yeast phagocytosis by these cells."( Gossypol induced apoptosis of polymorphonuclear leukocytes and monocytes: involvement of mitochondrial pathway and reactive oxygen species.
Aguilar-Lemarroy, AC; Barba-Barajas, L; Barba-Barajas, M; Bravo-Cuellar, A; de Celis, R; Domínguez-Rodríguez, JR; Guevara-Barraza, MG; Hernández-Flores, G; Jave-Suarez, LF; Lerma-Díaz, JM; Ortiz-Lazareno, PC, 2009
)
2.52
"Gossypol treatment also markedly reduced the number of infiltrated lymphocytes in the auricles of DTH mice."( The immunosuppressive effect of gossypol in mice is mediated by inhibition of lymphocyte proliferation and by induction of cell apoptosis.
Di, JF; He, XH; Lu, HS; Ou-Yang, DY; Shi, HJ; Xu, LH; Xu, WB, 2009
)
1.36
"Gossypol treatment resulted in the decrease of anti-apoptotic genes such as Bcl-2 and Bcl-xl and an upregulation of the pro-apoptotic gene, Noxa."( Combination therapy with gossypol reveals synergism against gemcitabine resistance in cancer cells with high BCL-2 expression.
Liem, N; Wang, L; Wong, FY; Wong, WC; Xie, C; Yan, FL; Yong, WP, 2012
)
1.4
"In gossypol treated rats, sperm morphology was compromised severely, but the epithelium in testis and epididymis appeared morphologically normal."( Epididymis-specific pathologic disorders in rats exposed to gossypol from weaning through puberty.
de Andrade, SF; De Grava Kempinas, W; Klinefelter, GR; Oliva, SU, 2006
)
1.09
"In gossypol-treated animals 1C peak disappeared gradually and the arrest was seen predominantly at 2C stage and partially at 4C stage."( Rat testicular germ cell type(s) targeted by anti-spermatogenic agents in vivo and their recovery on withdrawal of treatment--a flow cytometric study.
Dhar, JD; Dwivedi, AK; Gupta, G; Ojha, P; Singh, RL, 2008
)
0.86
"Gossypol treatment did not cause any effect on the plasma Na+ level."( Studies on the male antifertility agent--gossypol acetic acid. III. Effect of gossypol acetic acid on rat testis.
Arora, G; Kalla, NR; Vasudev, M,
)
1.12
"Gossypol treatment of endometriosis and uterine myomas in 15 cases was started with a daily dose of 20 mg of gossypol-acetic acid twice a day for 20 days as a loading dose, followed by 40 mg (20 mg twice weekly). "( Electron microscopic observations of the effects of gossypol on the human endometrium.
Cheng, J; Dang, MY; Han, ML; Sun, YT; Tian, L; Zu, PD, 1984
)
1.96
"Gossypol treatment greatly decreased the number of spermatozoa seen in cervical mucus in 13 of 15 test subjects, and all spermatozoa seen were immobilized in 11 of the 15."( Vaginal contraception with gossypol: a clinical study.
Haukkamaa, M; Luukkainen, T; Ratsula, K; Wichmann, K, 1983
)
1.18
"Gossypol treatment did not affect the body weight and the weights of the accessory sex organs."( Studies on the male antifertility agent--gossypol acetic acid. V. Effect of gossypol acetic acid on the fertility of male rats.
Foo, TW; Kalla, NR; Sheth, AR,
)
1.12
"Gossypol treatment and trypanosomal infection, either alone or in concert, caused an anaemia that was both macrocytic and hypochromic."( The effects of protein malnutrition and experimental infection with Trypanosoma brucei on gossypol treatment in the rat: haematological and serum biochemical changes.
Aire, TA; Akingbemi, BT; Ogwuegbu, SO; Oke, BO; Onwuka, SK, 1995
)
1.23
"Gossypol-treated rats exhibited weight reductions in developed MAT-LyLu prostate tumor mass and prostate of 24% (p < 0.05) and 31% (p < 0.05), respectively; whereas testicular and epididymal weights were not significantly affected."( Antiproliferative and antimetastatic effects of gossypol on Dunning prostate cell-bearing Copenhagen rats.
Brueggemeier, RW; Chang, CJ; Ghosh, PK; Hu, YF; Lin, YC, 1993
)
1.26
"Gossypol treatment or trypanosome infection, either alone or together, invariably caused significant reductions in the serum activity of creatine phosphokinase and amylase and in the serum concentration of cortisol."( Gossypol toxicosis in the rat associated with protein malnutrition and experimental infection with Trypanosoma brucei.
Aire, TA; Akingbemi, BT; Ogwuegbu, SO; Oke, BO; Onwuka, SK, 1996
)
2.46
"Gossypol (10 microM) treated also decreased cyclin D1-associated kinase activity on histone H1 used as a substrate in MCF-7 cells."( Gossypol inhibition of mitosis, cyclin D1 and Rb protein in human mammary cancer cells and cyclin-D1 transfected human fibrosarcoma cells.
Hochhauser, D; Jeoung, D; Ligueros, M; Reidenberg, MM; Sonenberg, M; Tang, B, 1997
)
2.46
"Gossypol treatment induced a series of histological changes in the seminiferous epithelium of the hamster testis."( Response of hamster to the antifertility effect of gossypol.
Bisnooduth, U; Kalla, NR; Ranga, A,
)
1.1
"Gossypol treatments inhibited cell multiplication at 10 and 20 micrograms/ml concentrations and this inhibitory effect increased with elevated dosage and prolonged treatment."( Genotoxic effects of gossypol acetic acid on cultured murine erythroleukemia cells.
Baker, MA; Daehler, CC; Daly, EP; Kleemeyer, KM; Majumdar, SK, 1991
)
1.32
"Gossypol treatment had no effect on hematological parameters (total erythrocyte count, total leucocyte count, hematocrit and hemoglobin) studied in the present investigations."( Effect of gossypol on domestic fowl, Gallus domesticus.
Chadha, VK; Foo, J; Kalla, NR,
)
1.26
"Gossypol treatment did not affect the body weight or testicular weight, but caused a significant depression in the weight of the seminal vesicle."( Histologic changes in the mouse testis after treatment with gossypol tetra-acetic acid.
Rath, SK; Singh, SK, 1990
)
1.24
"Gossypol treatment of rats (20 mg/kg) for 6, 10 and 16 weeks resulted in partial inhibition of macromolecular synthesis."( The in vivo effect of gossypol on macromolecular synthesis in rat testis.
Frick, J; Kainz, P; Nussbaumer-Kainz, V, 1985
)
1.31
"Gossypol treatment had no direct effect on systemic blood pressure or femoral arterial flow."( Endothelium-derived relaxing factor is likely to modulate the tone of resistance arteries in rabbit hindlimb in vivo.
Dudel, C; Förstermann, U; Frölich, JC, 1987
)
0.99
"Gossypol treatment for 1 day and 7 days continuously did bring about changes in serum lipoprotein profile."( The effect of gossypol on serum lipoproteins of adult rats.
Fities, IA; Obeidy, A; Sheriff, DS, 1989
)
1.36
"Gossypol-treated males failed to impregnate healthy females, presumably because their sperm were immotile."( Effect of gossypol on the concentration of sodium and potassium in the rat epididymis.
Kaur, S, 1989
)
1.4
"In gossypol-treated TM4 cells, Rhodamine 123 mitochondrial staining was reduced significantly 1 hour after the drug addition and reached a minimal level at 3 hour."( Gossypol-induced damage to mitochondria of transformed Sertoli cells.
Bellvé, AR; Robinson, JM; Tanphaichitr, N, 1986
)
2.23
"Gossypol treatment decreased the potential activity of the proenzyme by 97%, but failed to affect the active enzyme."( Gossypol prevents activation of purified proenzyme of human seminal plasma acidic proteinase.
Svasti, J; Vongsorasak, L, 1986
)
2.34
"In gossypol-treated animals testis catalase and glutathione peroxidase activities were decreased."( Effects of gossypol on the antioxidant defense system of the rat testis.
Bender, HS; Derolf, SZ; Misra, HP, 1988
)
1.18
"Gossypol treatment did not bring about marked changes in the key enzymes like HMG Co A reductase, glucose-6-phosphate dehydrogenase malic enzyme and cytosolic isocitrate dehydrogenase involved in sterol biosynthesis."( Gossypol and testicular lipids of adult rats.
Sheriff, DS, 1988
)
2.44
"Gossypol treatment of males had no effect on the outcome of pregnancy."( A developmental toxicity evaluation of gossypol.
Beaudoin, AR, 1988
)
1.27
"In gossypol-treated, reproductively immature guinea pigs, the number of spermatozoa in the epididymis was markedly reduced (P less than 0.01) compared to controls, whereas the presence of spermatids and spermatocytes increased in the epididymis with the duration of gossypol administration."( Effect of gossypol acetate on guinea pig epididymal spermatozoa in vivo and their susceptibility to capacitation in vitro.
Friend, DS; Shi, QX,
)
1.05
"Gossypol treatment of males had no effect on the outcome of pregnancy."( The embryotoxicity of gossypol.
Beaudoin, AR, 1985
)
1.31
"Treatment with gossypol was responsible for a significant reduction in the number of normal ovarian follicles and a significant increase in the number of atretic follicles, both in all stages of development."( Gossypol promotes degeneration of ovarian follicles in rats.
de Macedo, MF; Gadelha, IC; Melo, MM; Oloris, SC; Soto-Blanco, B, 2014
)
2.18
"Co-treatment with gossypol acetate and dexamethasone notably amplified the pro-apoptosis activity of the latter in Raji cells."( [Effects of gossypol acetate on apoptosis in primary cultured cells from patients with lymphoid leukemia and its synergy with dexamethasone].
Cheng, W; Li, YM; Yang, DJ; Zhao, YQ, 2012
)
1.08
"Treatment with gossypol also downregulated expression of NF-kappaB-regulated gene products, including inhibitor of apoptosis protein (IAP)-1, IAP-2, and X-linked IAP."( Gossypol suppresses NF-kappaB activity and NF-kappaB-related gene expression in human leukemia U937 cells.
Kim, GY; Kim, MO; Lee, JD; Moon, DO, 2008
)
2.13
"Treatment with gossypol also had an inhibitory effect on epididymal sperm count at the two highest doses."( Short term metabolic effects of the anti-fertility agent, gossypol, on various reproductive organs of male mice.
Coulson, PB; Parise, C; Snell, RL, 1980
)
0.85
"Treatment with gossypol alone as well as with the supplementation of potassium salt resulted in severe oligospermia and azoospermia."( Gossypol-induced hypokalemia and role of exogenous potassium salt supplementation when used as an antispermatogenic agent in male langur monkey.
Kumar, M; Lohiya, NK; Sharma, S, 1997
)
2.08
"Sham treatment (gossypol solute only), exposure to indomethacin (10 microM), and ganglionic blockade had no differential effect on the flow responses."( Selective inhibition of endothelium-dependent dilation in resistance-sized vessels in vivo.
Busse, R; Dézsi, L; Pohl, U; Simon, B, 1987
)
0.61

Toxicity

Shortterm treatment with gossypol can cause reproductive toxicity and nephrotoxicity in mice. These toxic effects can be reversed after drug withdrawal.

ExcerptReferenceRelevance
" Antinutritional or toxic factors associated with them are reviewed and means of detoxifying them for human and livestock feeding are enumerated."( A review of toxicity factors in some food and feedingstuffs in the nutrition of man and livestock in Nigeria.
Aregheore, EM, 1992
)
0.28
"4% bovine serum albumin(BSA) to the perfusate completely prevented the toxic effect of gossypol on hepatocytes, decreasing the absorption of gossypol by the liver."( Zone-specific hepatotoxicity of gossypol in perfused rat liver.
Lin, YC; Manabe, S; Nuber, DC, 1991
)
0.79
" Treatment of mice with gossypol produced significant adverse effects on the dam and offspring including decreased pregnancy weight gain of the dam and growth retardation of the offspring."( Evidence for embryotoxicity of gossypol in mice and chicks with no evidence of mutagenic activity in the Ames test.
Booth, GM; Li, YF; Seegmiller, RE, 1989
)
0.87
" This adverse effect exerted by SP562, however, was not as strong as that caused by (+/-) gossypol acetic acid of the same molarity."( Adverse effects of gossypol analogs on TM4 cell mitochondrial function.
Fitzgerald, LM; Tanphaichitr, N, 1989
)
0.83
" The equipotency between the two isomers in causing toxic effects to some of the somatic tissues and the stereo-selectivity of (-)-gossypol to induce antispermatogenic effects indicate that gossypol may actually exhibit two categories of cytotoxic effects to different organs and tissues."( Probing into the mechanism of action, metabolism and toxicity of gossypol by studying its (+)- and (-)-stereoisomers.
Yu, YW, 1987
)
0.72
"The present study assessed the urinary protein with SDS-PAGE technique and by using gentamicin as a positive control for a comparative study to evaluate the renal toxic effect of gossypol."( Evaluation of the renal tubulo-toxic effect of gossypol by urinary protein analysis with SDS-polyacrylamide gel electrophoresis.
Li, HZ; Luo, HZ; Xue, SP; Zhao, SY; Zhu, JB, 1988
)
0.72
" Under the conditions of this experiment, gossypol administered to either the breeding male rat or the pregnant female rat had no demonstrable adverse effect on development in utero."( A developmental toxicity evaluation of gossypol.
Beaudoin, AR, 1988
)
0.81
" Under the conditions of this experiment, gossypol administered to either the breeding male rat or the pregnant female rat had no demonstrable adverse effect on development in utero."( The embryotoxicity of gossypol.
Beaudoin, AR, 1985
)
0.85
" Neither the 10-mg/kg dose nor the 20-mg/kg dose had any adverse effect in the dams."( The embryotoxicity of gossypol.
Beaudoin, AR, 1985
)
0.58
" It is concluded that gossypol is a very toxic substance in rats, since only a 10-fold increase of a non-effective dose caused serious side effects in addition to its antifertility effects."( Toxic effects of the antifertility agent gossypol in male rats.
Bergh, A; Damber, JE; Gåfvels, M; Selstam, G; Wang, J, 1984
)
0.85
" As derived from the antifertility responses of the GAA treatment groups it was evident that the toxic activity of GAA was not related to its antifertility efficacy."( Toxicity of gossypol at antifertility dosages in male rats: statistical analysis of lethal rates and body weight responses.
Frick, J; Rovan, E; Weinbauer, GF,
)
0.51
" Before gossypol can be considered safe for widespread human use, particularly by healthy people of childbearing age, its effect on normal genetic processes should be understood."( Genetic toxicity studies of gossypol.
de Peyster, A; Wang, YY, 1993
)
1.01
" Experiments conducted on Sprague-Dawley rats and cynomolgous monkeys confirm that either (-) or (+) gossypol is too toxic to be developed for human contraception."( Gossypol: reasons for its failure to be accepted as a safe, reversible male antifertility drug.
Griffin, PD; Waites, GM; Wang, C, 1998
)
1.96
" The adverse effects of GAA on the production of ROS, cytoplasmic acidification, GSH content, and [Ca2+]i were also attenuated."( Attenuation of gossypol cytotoxicity by cyclic AMP in a rat liver cell line.
Barhoumi, R; Burghardt, RC; Hutchinson, RW; Miles, JM, 1998
)
0.65
" Nonoils known to be toxic that may be found in cottonseed oils include gossypol, aflatoxin, and cyclopropenoid fatty acids (CPFA)."( Final report on the safety assessment of Hydrogenated Cottonseed Oil, Cottonseed (Gossypium) Oil, Cottonseed Acid, Cottonseed Glyceride, and Hydrogenated Cottonseed Glyceride.
, 2001
)
0.54
" These results show that gossypol is toxic to broiler chicks at high levels."( Pathology and histopathology of gossypol toxicity in broiler chicks.
Brown, TP; Henry, MH; Pesti, GM,
)
0.72
" The (-)-enantiomer is toxic to nonruminant animals while the (+)-enantiomer exhibits little, if any, toxicity to these animals."( Toxicity of (+)- and (-)-gossypol to the plant pathogen, Rhizoctonia solani.
Dowd, MK; Howell, CR; Puckhaber, LS; Stipanovic, RD, 2002
)
0.62
" Results showed that the dosage regimen could damage the epididymal sperms and onset of antifertility within 6 weeks in male rats, and prevent the incidence of the side effect of irreversible azoospermia."( [A beam of dawn light of study on gossypol as a safe, effective, and reversible male antifertility contraceptive--evaluation of the studies by using low dose gossypol combined with steroid hormone for male contraception].
Xue, S, 2000
)
0.59
" The purpose of this study was to determine if the adverse effects of gossypol on spermatogenesis in peripubertal bulls were reversible."( Reversibility of the reproductive toxicity of gossypol in peripubertal bulls.
Ehrhart, EJ; Faulkner, DB; Firkins, LD; Hassan, ME; Ott, RS; Schaeffer, DJ; Smith, GW, 2004
)
0.82
" Gossypolone was also observed to be more toxic than gossypol against both cell lines."( Cytotoxicity of enantiomers of gossypol Schiff's bases and optical stability of gossypolone.
Dao, VT; Dowd, MK; Gaspard, C; Martin, MT; Mayer, M; Michelot, RJ, 2004
)
1.52
" Our results indicated that both gossypol enantiomers were toxic to broilers but that (-)-gossypol was more harmful to efficient broiler production than (+)-gossypol."( Relative toxicity of gossypol enantiomers in broilers.
Calhoun, MC; Dale, NM; Davis, AJ; Dowd, MK; Lordelo, MM, 2005
)
0.93
" Hepatotoxicity and gastrointestinal toxicity represented the major adverse activities of gossypol, with apogossypol far less toxic."( Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2-transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048).
Jia, L; Kitada, S; Krajewska, M; Kress, CL; Pellecchia, M; Reed, JC, 2008
)
0.89
" Only in the case of a nonsymmetrical gossypol derivative bearing a 4-aminoantipyrine residue did we observe a deviation from the above correlation: its symmetrical counterpart was even more toxic, but still less toxic than gossypol."( [Synthesis, structures, and acute toxicity of gossypol nonsymmetrical aldehyde derivatives].
Ibragimov, BT; Iuldashev, AM; Kamaev, FG; Talipov, SA; Tiliabaev, KZ; Vypova, NL,
)
0.66
" In conclusion, free gossypol in diet induced adverse effects on semen quality in rams, but selenium supplementation successfully counteracts most of the hazardous effects of gossypol on semen characteristics."( Alleviation of reproductive toxicity of gossypol using selenium supplementation in rams.
El-Mokadem, MY; Samak, MA; Taha, TA; Yassen, AM, 2012
)
0.97
" However, the most common toxic effects is the impairment of male and female reproduction."( Gossypol toxicity from cottonseed products.
Fonseca, NB; Gadelha, IC; Melo, MM; Oloris, SC; Soto-Blanco, B, 2014
)
1.85
"Gossypol, an anti-cancer drug, induces genotoxicity on lymphocyte cells and co-supplementation of melatonin antioxidant ameliorates these toxic effects of gossypol."( The genotoxic effects of anti-cancer drug gossypol on human lymphocytes and its mitigation by melatonin.
Narechania, MB; Rao, MV, 2016
)
2.14
"Gossypol is a polyphenolic secondary metabolite produced by cotton plants, which is toxic to many organisms."( Gossypol toxicity and detoxification in Helicoverpa armigera and Heliothis virescens.
Boland, W; Heckel, DG; Heidel-Fischer, HM; Jiménez-Alemán, GH; Joußen, N; Krempl, C; Menezes, RC; Reichelt, M; Vogel, H, 2016
)
3.32
" It is noted that evaluation of the total toxic properties of Kagocel has revealed no signs of intoxication."( [Safety of the Russian antiviral drug Kagocel].
Borovskaya, TG,
)
0.13
" We previously identified gossypol as an effective inhibitor against ZIKV and DENV infections, but this compound is toxic and not suitable for in vivo treatment."( A gossypol derivative effectively protects against Zika and dengue virus infection without toxicity.
Chen, S; Debnath, AK; Du, L; Gao, Y; Jiang, S; Tai, W; Wang, X, 2022
)
1.74
"Overall, our data indicate the potential for further development of this gossypol derivative as an effective and safe broad-spectrum therapeutic agent to treat ZIKV and DENV diseases."( A gossypol derivative effectively protects against Zika and dengue virus infection without toxicity.
Chen, S; Debnath, AK; Du, L; Gao, Y; Jiang, S; Tai, W; Wang, X, 2022
)
1.67
"To study the toxic effects of short-term exposure to gossypol on the testis and kidney in mice and whether these effects are reversible."( [Short-term exposure to gossypol causes reversible reproductive toxicity and nephrotoxicity in mice].
Cao, L; Liu, J; Ma, H; Piao, Z; Wang, H; Wu, J, 2023
)
1.47
"Shortterm treatment with gossypol can cause reproductive toxicity and nephrotoxicity in mice, but these toxic effects can be reversed after drug withdrawal."( [Short-term exposure to gossypol causes reversible reproductive toxicity and nephrotoxicity in mice].
Cao, L; Liu, J; Ma, H; Piao, Z; Wang, H; Wu, J, 2023
)
1.52

Pharmacokinetics

Gossypol, apogossypols and hexaacetates were incubated in plasma or liver microsomes from various species, or administered to mice. The stability, metabolism and pharmacokinetic profiles of these analogs were determined using a liquid chromatography-mass spectrometry.

ExcerptReferenceRelevance
" Interspecies oral bioavailability and pharmacokinetic profile of (+/-)-gossypol were compared in male Fischer-344 rats and B6C3F mice after a 1) single intravenous dose, 2) single oral dose, and 3) 14 consecutive, daily, oral doses; all doses were 10 and 50 mg/kg rats and mice, respectively."( Interspecies comparison of pharmacokinetic profile and bioavailability of (+/-)-gossypol in male Fischer-344 rats and male B6C3F mice.
Abou-Donia, MB; Obih, P; Othman, MA, 1989
)
0.74
"The pharmacokinetic profile of (+/-)-gossypol was determined in male Sprague-Dawley rats following a single intravenous or oral 10 mg/kg dose and after receiving a daily oral 10 mg/kg dose for 14 days."( Pharmacokinetic profile of (+/-)-gossypol in male Sprague-Dawley rats following single intravenous and oral and subchronic oral administration.
Abou-Donia, MB; Othman, MA, 1988
)
0.83
"Gossypol, apogossypol and apogossypol hexaacetate were incubated in plasma or liver microsomes from various species, or administered to mice, respectively, from which the stability, metabolism and pharmacokinetic profiles of these analogs were quantitatively determined using a liquid chromatography-mass spectrometry (LC/MS/MS) method."( Comparison of pharmacokinetic and metabolic profiling among gossypol, apogossypol and apogossypol hexaacetate.
Cork, RL; Coward, LC; Gorman, GS; Jia, L; Kerstner-Wood, CD; Kitada, S; Noker, PE; Pellecchia, M; Reed, JC, 2008
)
2.03
" (+/-)-Gossypol and (-)-gossypol showed comparable pharmacokinetic profile and oral bioavailability (12."( Comparison of pharmacokinetic and metabolic profiling among gossypol, apogossypol and apogossypol hexaacetate.
Cork, RL; Coward, LC; Gorman, GS; Jia, L; Kerstner-Wood, CD; Kitada, S; Noker, PE; Pellecchia, M; Reed, JC, 2008
)
1.04
"Apogossypol and gossypol show similar oral and intravenous pharmacokinetic profiles and in vitro stability although apogossypol appears to have a slower clearance rate, larger AUC, and better microsomal stability."( Comparison of pharmacokinetic and metabolic profiling among gossypol, apogossypol and apogossypol hexaacetate.
Cork, RL; Coward, LC; Gorman, GS; Jia, L; Kerstner-Wood, CD; Kitada, S; Noker, PE; Pellecchia, M; Reed, JC, 2008
)
1.21
" We developed and validated a sensitive HPLC assay for pharmacokinetic evaluation of gossypol."( A validated HPLC assay for the determination of R-(-)-gossypol in human plasma and its application in clinical pharmacokinetic studies.
Bertino, JR; DiPaola, RS; Gounder, MK; Kong, AN; Lin, H; Stein, MN, 2012
)
0.85
" Neutropenia in cycle 1 may be a pharmacodynamic marker for docetaxel, which may enable tailored dosing in metastatic castration-resistant prostate cancer (mCRPC)."( Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer.
Berry, WR; Galsky, MD; Leopold, L; Pond, GR; Sonpavde, G; Wood, BA, 2012
)
0.38
"For patients with mCRPC who received docetaxel, ≥grade 3 neutropenia on day 8 was prognostic for improved OS, which suggests its utility as a pharmacodynamic marker, in this hypothesis-generating analysis."( Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer.
Berry, WR; Galsky, MD; Leopold, L; Pond, GR; Sonpavde, G; Wood, BA, 2012
)
0.38
" For the pharmacokinetic analysis, plasma AT-101 levels were measured by HPLC in blood samples collected from patients enrolled in our clinical phase I/II study."( Targeting anti-apoptotic Bcl-2 by AT-101 to increase radiation efficacy: data from in vitro and clinical pharmacokinetic studies in head and neck cancer.
Dubbelman, R; Hoebers, FJ; Kuipers, GK; Lafleur, MV; Slotman, BJ; Stoter, TR; van den Brekel, MW; Verheij, M; Zerp, SF, 2015
)
0.42

Compound-Compound Interactions

Irradiated PBMCs at low dose combined with (-)-gossypol can enhance the anti-tumor effects obviously. AT-101 is a pan small molecule inhibitor of BCl-2, Bcl-x(L), and Mcl-1.

ExcerptReferenceRelevance
" The effectiveness of the inducers increased markedly when used in combination with the specific vaccine against HAEM virus."( [Comparative study of the effectiveness of the interferon inducers, poly(I) : poly(C) and GSS (gossypol-beta-aminoethylsodium sulfate), in combination with a specific vaccine in experimental infection with the human acute encephalomyelitis virus].
Barinskiĭ, IF; Dushanbieva, S; Vagabov, RM,
)
0.35
" However, when gosyypol was given in combination with misoprostol 400, 800 or 1600 micrograms."( [Effect of gossypol in combination with misoprostol on termination of early pregnancy in rats and mice].
Cao, L; Chen, Y; Gu, ZP, 1997
)
0.69
"d-1) combined with steroid hormones (methyltestosterone 20 mg."( [A beam of dawn light of study on gossypol as a safe, effective, and reversible male antifertility contraceptive--evaluation of the studies by using low dose gossypol combined with steroid hormone for male contraception].
Xue, S, 2000
)
0.59
" Here we examined the growth inhibitory effect of (-)gossypol and its combination with imatinib in K562 cells."( (-)Gossypol and its combination with imatinib induce apoptosis in human chronic myeloid leukemic cells.
Chen, X; Fu, J; Li, H; Li, J; Li, Y; Liu, H; Liu, Y; Meng, Y, 2007
)
1.21
" Here, we investigated the efficacy of AT-101 (R-(-)-gossypol acetic acid; a pan small molecule inhibitor of Bcl-2, Bcl-x(L), and Mcl-1) in combination with surgical castration to delay the onset of androgen-independent growth in vivo."( In vivo evaluation of AT-101 (R-(-)-gossypol acetic acid) in androgen-independent growth of VCaP prostate cancer cells in combination with surgical castration.
Loberg, RD; McGregor, N; Pienta, KJ; Sargent, E; Ying, C, 2007
)
0.86
") 5 days/week) in combination with surgical castration delayed the onset of androgen-independent prostate cancer growth in vivo."( In vivo evaluation of AT-101 (R-(-)-gossypol acetic acid) in androgen-independent growth of VCaP prostate cancer cells in combination with surgical castration.
Loberg, RD; McGregor, N; Pienta, KJ; Sargent, E; Ying, C, 2007
)
0.61
"We conclude that AT-101 in combination with surgical castration delays the onset of androgen-independent prostate cancer in vivo by disrupting the antiapoptotic activity of Bcl-2 upregulation during the transition to androgen independence."( In vivo evaluation of AT-101 (R-(-)-gossypol acetic acid) in androgen-independent growth of VCaP prostate cancer cells in combination with surgical castration.
Loberg, RD; McGregor, N; Pienta, KJ; Sargent, E; Ying, C, 2007
)
0.61
" The objective of this study was to evaluate the effect of various SPI, both alone and in combination with cisplatin, on three different non-small cell lung cancer (NSCLC) cell lines."( Efficacy of signal pathway inhibitors alone and in combination with Cisplatin varies between human non-small cell lung cancer lines.
El-Hefnawy, T; Kilic, A; Landreneau, RJ; Luketich, JD; Schuchert, MJ, 2009
)
0.35
" Louis, MO), Cox-2 (NS-398 [Sigma-Aldrich] or Celecoxib [Pfizer]), MAPK (U0126 [Sigma-Aldrich]), and EGFR (Iressa; AstraZeneca, Macclesfield, United Kingdom) both alone and in combination with 10 or 30 mum cisplatin (Sigma-Aldrich) (18 possible regimens for each cell line)."( Efficacy of signal pathway inhibitors alone and in combination with Cisplatin varies between human non-small cell lung cancer lines.
El-Hefnawy, T; Kilic, A; Landreneau, RJ; Luketich, JD; Schuchert, MJ, 2009
)
0.35
"There is a substantial degree of variability between NSCLC cell lines in response to SPI, both alone and in combination with cisplatin."( Efficacy of signal pathway inhibitors alone and in combination with Cisplatin varies between human non-small cell lung cancer lines.
El-Hefnawy, T; Kilic, A; Landreneau, RJ; Luketich, JD; Schuchert, MJ, 2009
)
0.35
"To observe the killing effect of irradiated peripheral blood mononuclear cells (PBMCs) at low dose combined with (-)-gossypol on cultured human prostate cancer LNCaP cells."( [Studies on the killing effect of gamma ray irradiated peripheral blood mononuclear cells combined with (-)-gossypol on human prostate cancer LNCaP cells].
Yan, G; Zhan, WH; Zhan, YX; Zhang, XQ, 2010
)
0.78
"Irradiated PBMCs at low dose combined with (-)-gossypol can enhance the anti-tumor effects obviously."( [Studies on the killing effect of gamma ray irradiated peripheral blood mononuclear cells combined with (-)-gossypol on human prostate cancer LNCaP cells].
Yan, G; Zhan, WH; Zhan, YX; Zhang, XQ, 2010
)
0.83
"5/3-mda-7 alone or in combination with BI-97C1 would be predicted to exert significantly improved therapeutic efficacy in colorectal cancer patients."( Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) in combination with the Apogossypol derivative BI-97C1 (Sabutoclax) improves therapeutic efficacy in low CAR colorectal cancer cells.
Azab, B; Bhutia, SK; Curiel, DT; Das, SK; Dash, R; Dent, P; Dmitriev, IP; Fisher, PB; Grant, S; Hedvat, M; Pellecchia, M; Quinn, BA; Reed, JC; Sarkar, D; Sarkar, S; Shen, XN; Wang, XY, 2012
)
0.59
"AT-101 (A), a small molecule oral inhibitor of the Bcl-2 family, has activity alone and in combination with docetaxel (Taxotere) and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC)."( Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer.
Berry, WR; Brookes, M; Burke, JM; Caton, JR; Fleming, MT; Galsky, MD; Holmlund, JT; Hutson, TE; Karlov, P; Leopold, L; Matveev, V; Sonpavde, G; Wood, BA, 2012
)
0.38
"AT-101 was tolerable but did not extend OS when combined with DP in mCRPC; a potential benefit was observed in high-risk patients."( Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer.
Berry, WR; Brookes, M; Burke, JM; Caton, JR; Fleming, MT; Galsky, MD; Holmlund, JT; Hutson, TE; Karlov, P; Leopold, L; Matveev, V; Sonpavde, G; Wood, BA, 2012
)
0.38
" Together, our data suggest the potential for proteasome inhibitor based therapy in CLL and the rationale design of drug combination strategies based on CLL biology."( The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugs.
Advani, P; Akhtar, D; Chanan-Khan, A; Chitta, K; Colon-Otero, G; Foran, J; Khan, AN; Masood, A; Miller, KC; Paulus, A; Rivera, C; Roy, V, 2014
)
0.4
" In this study, the possible synergistic cytotoxic and apoptotic effect of octreotide in combination with AT-101 was investigated in DU-145 hormone and drug refractory prostate cancer cell line."( Octreotide in combination with AT-101 induces cytotoxicity and apoptosis through up-regulation of somatostatin receptors 2 and 5 in DU-145 prostate cancer cells.
Atmaca, H; Bulut, G; Degirmenci, M; Erdogan, AP; Karabulut, B; Karaca, B; Uslu, R; Uzunoglu, S, 2016
)
0.43
" Given the evidence of activity in xenograft models, treatment with AT-101 in combination with docetaxel is a therapeutic doublet of interest in metastatic head and neck squamous cell carcinoma."( A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer.
Bellile, E; Bradford, C; Carey, TE; Chepeha, DB; Eisbruch, A; Jackson, TL; Malloy, K; McKean, E; McLean, S; Moyer, J; Nör, JE; Pearson, AT; Prince, M; Sacco, AG; Shuman, A; Spector, ME; Sukari, A; Swiecicki, PL; Taylor, JM; Wang, S; Wolf, GT; Worden, FP, 2016
)
0.43

Bioavailability

Gossypol modifies its antifertility activity. It induced oxidative stress and hepatotoxicity. It reduced peripheral lipid metabolism, and enhanced hepatic lipid accumulation.

ExcerptReferenceRelevance
" Interspecies oral bioavailability and pharmacokinetic profile of (+/-)-gossypol were compared in male Fischer-344 rats and B6C3F mice after a 1) single intravenous dose, 2) single oral dose, and 3) 14 consecutive, daily, oral doses; all doses were 10 and 50 mg/kg rats and mice, respectively."( Interspecies comparison of pharmacokinetic profile and bioavailability of (+/-)-gossypol in male Fischer-344 rats and male B6C3F mice.
Abou-Donia, MB; Obih, P; Othman, MA, 1989
)
0.74
" The bioavailability of a single oral dose of (+/-)-gossypol in rats was 60%."( Pharmacokinetic profile of (+/-)-gossypol in male Sprague-Dawley rats following single intravenous and oral and subchronic oral administration.
Abou-Donia, MB; Othman, MA, 1988
)
0.81
" Mean (+/- SD) oral bioavailability of (+/-)-gossypol in dogs was 30."( Pharmacokinetics of (+/-)-, (+)-, and (-)-gossypol in humans and dogs.
Tang, ZM; Wang, MZ; Wu, DF; Yu, YW, 1986
)
0.8
" This effect, presumably mediated through changes caused to the bioavailability of gossypol, modifies its antifertility activity."( Chronic ethanol intake may delay the onset of gossypol-induced infertility in the male rat.
Aire, TA; Akingbemi, BT; Rao, PV,
)
0.61
" (+/-)-Gossypol and (-)-gossypol showed comparable pharmacokinetic profile and oral bioavailability (12."( Comparison of pharmacokinetic and metabolic profiling among gossypol, apogossypol and apogossypol hexaacetate.
Cork, RL; Coward, LC; Gorman, GS; Jia, L; Kerstner-Wood, CD; Kitada, S; Noker, PE; Pellecchia, M; Reed, JC, 2008
)
1.04
"Dietary antinutritional factors have been reported to adversely affect the digestibility of protein, bioavailability of amino acids and protein quality of foods."( Impact of antinutritional factors in food proteins on the digestibility of protein and the bioavailability of amino acids and on protein quality.
Cockell, KA; Sarwar Gilani, G; Wu Xiao, C, 2012
)
0.38
" These results demonstrate that gossypol induced oxidative stress and hepatotoxicity; reduced peripheral lipid metabolism, and enhanced hepatic lipid accumulation; decreased amino acid bioavailability and milk protein synthesis; and decreased gluconeogenesis and milk lactose in dairy cows."( Metabolic Characterization of Dairy Cows Treated with Gossypol by Blood Biochemistry and Body Fluid Untargeted Metabolome Analyses.
Tang, C; Zhan, T; Zhang, J; Zhang, K; Zhao, Q, 2017
)
0.99
"Our data suggest that PEGylation improved the bioavailability of Gn as well as achieved tumor-targeted delivery and controlled release of Gn, which enhanced its overall biocompatibility and drug efficacy in vivo."( Natural product derivative Gossypolone inhibits Musashi family of RNA-binding proteins.
Appelman, C; Aubé, J; De Guzman, RN; Gao, P; Gowthaman, R; Karanicolas, J; Lan, L; Larsen, S; Liu, FY; Liu, H; Marquez, RT; Neufeld, KL; Rogers, S; Smith, AR; Wu, X; Xu, L; Yu, J, 2018
)
0.78
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" However, the clinical application of (-)-gossypol was often hindered by its evident side effects and the low bioavailability via oral administration, which necessitated the development of suitable (-)-gossypol preparations to settle the problems."( Cyclic RGD-Decorated Liposomal Gossypol AT-101 Targeting for Enhanced Antitumor Effect.
Chen, S; Fu, X; Liu, H; Luo, Y; Qu, K; Shi, H; Wang, S; Wu, A; Zeng, W; Zhang, C; Zhang, D; Zhang, H; Zhang, R; Zhang, Z, 2022
)
1.27

Dosage Studied

Gossypol is more toxic in vitro for amoebae than other drugs widely used clinically. GHQ had a synergistic effect on survival and days-to-pupation when combined with gossypOL at the highest dosage tested.

ExcerptRelevanceReference
" With the increase in dosage and duration of treatment the spermatocytes are also damaged."( Gossypol--a new antifertility agent for males.
, 1979
)
1.7
" Besides, inhibition effect on the proliferation of prostatic epithelial cells was dosage dependent and related to the duration of treatment."( [Effect of gossypol on the proliferation of rat prostate cells studies in vivo and in vitro].
Chang, SM; Lei, LF; Tian, L, 1992
)
0.67
" Tolerance to this effect of ethanol is expressed by a rightward shift of the dose-response curve in aorta from animals intoxicated with ethanol for 2 days."( Endothelium-dependent tolerance to ethanol-induced contraction of rat aorta: effect of inhibition of EDRF action and nitric oxide synthesis.
Knych, ET, 1992
)
0.28
" Gossypol treatments inhibited cell multiplication at 10 and 20 micrograms/ml concentrations and this inhibitory effect increased with elevated dosage and prolonged treatment."( Genotoxic effects of gossypol acetic acid on cultured murine erythroleukemia cells.
Baker, MA; Daehler, CC; Daly, EP; Kleemeyer, KM; Majumdar, SK, 1991
)
1.51
" Our data suggest that both the route of drug administration and dosing regimen employed affect the antiinflammatory potency and/or efficacy of compounds on colitis induced by acetic acid in the rat."( Antiinflammatory effects of various drugs on acetic acid induced colitis in the rat.
Bostwick, JS; Decktor, DL; Fitzpatrick, LR; Pendleton, RG; Renzetti, M, 1990
)
0.28
" Results showed that the expected dose-response reduction in gamete quantity and quality was accompanied by reductions in reproductive organ weights and copulatory performance, but the reductions were modest and principally with the higher dosages."( Search for a male contraceptive: the effect of gossypol on sexual motivation and epididymal sperm.
Bardgett, M; Griffin, MG; Taylor, GT, 1991
)
0.54
" Sexual motivation fell as the dosage of gossypol increased."( Search for a male contraceptive: the effect of gossypol on sexual motivation and epididymal sperm.
Bardgett, M; Griffin, MG; Taylor, GT, 1991
)
0.8
" The dose-response curve of SNP was shifted to the right, and the relaxation to verapamil was slightly reduced."( Endothelium-derived relaxing factor influences renal vascular resistance.
Förstermann, U; Frölich, JC; Radermacher, J, 1990
)
0.28
" A dose-response relation was not observed, and a small increase in the frequency of SCE was obtained."( [Frequency of sister chromatid exchange in mice treated with gossypol].
González-Garza, MT; Leal-Garza, CH; Valenciano-Cedillo, G,
)
0.37
" Gossypol is more toxic in vitro for amoebae than other drugs widely used clinically, its pharmacological effects and safe dosage in humans are well known because of its antifertilizing effect, and it is accumulated mainly in the liver and colon."( High susceptibility of five axenic Entamoeba histolytica strains to gossypol.
Gonzalez-Garza, MT; Mata-Cárdenas, BD; Said-Fernández, S,
)
1.28
" While other attempts at gossypol detoxification using divalent ions have been, mainly, in the form of calcium hydroxide and/or ferrous sulphate, this paper describes the dose-response relationships between dietary oyster shell (a much cheaper source of calcium than Ca(OH)2) and some serum constituents and erythrocyte indices in the chicken fed gossypol-containing cottonseed cake (CSC) diets."( Effect of varying levels of oyster shell on serum constituents and erythrocyte indices in growing chicken fed gossypol-containing Nigerian cottonseed cake.
Aletor, VA, 1989
)
0.79
" In mice a single, dose of (+/-)-gossypol showed a biexponential plasma concentration pattern; daily dosing was monoexponential and was eliminated twice as fast as the single dose."( Interspecies comparison of pharmacokinetic profile and bioavailability of (+/-)-gossypol in male Fischer-344 rats and male B6C3F mice.
Abou-Donia, MB; Obih, P; Othman, MA, 1989
)
0.79
" Although no conspicuous loss in sperm motility and breeding performance occurred with this dosing regimen, even after prolonged treatment, a statistically significant reduction in serum testosterone (T) and decreases in accessory organ weights were observed after only 3 weeks."( Reproductive endocrine function in gossypol-treated male rats.
de Peyster, A; Srebnik, HH,
)
0.41
" The results indicate that multiple oral dosing of (+/-)-gossypol resulted in its longer retention in body tissue than a single oral dose."( Pharmacokinetic profile of (+/-)-gossypol in male Sprague-Dawley rats following single intravenous and oral and subchronic oral administration.
Abou-Donia, MB; Othman, MA, 1988
)
0.8
" This study further confirmed the genotoxic effects of gossypol acetic acid by investigating the dose-response relationships of gossypol acetic acid-induced SCEs in spermatogonial cells and bone marrow cells of mice."( Gossypol acetate-induced SCEs in spermatogonia and bone marrow cells of mice: dose-response relationships.
Tan, YB; Wang, RL; Zhang, ZS, 1988
)
1.96
" When administered at a dosage of 8 mg/kg/day, (-)-gossypol produced the same antifertility effects as twice that dose of racemic gossypol-acetic acid."( Large-scale resolution of gossypol enantiomers for biological evaluation.
Belenguer, A; Brookes, AN; Matlin, SA; Tyson, RG; Zhou, RH, 1988
)
0.83
" The lambs were allotted to 4 groups (A, B, C, D) and given (orally for 30 days) a daily dosage of gossypol (0, 45, 136, or 409 mg, respectively)."( Clinical, clinicopathologic, pathologic, and toxicologic alterations associated with gossypol toxicosis in feeder lambs.
Edwards, WC; Martin, T; Morgan, GL; Morgan, S; Stair, EL, 1988
)
0.72
"(+)-Gossypol has neither antifertility effect nor toxicity at the dosage of 30 mg/kg orally for 14 days in male rats, but slight damage was found in the germinal epithelium of the testis in animals dosed for 4 weeks."( Effect of (-)- and (+)-gossypol on fertility in male rats.
Guan, MH; Lei, HP; Wang, NG; Zhou, LF, 1987
)
1.14
"Gossypol acetic acid (GAA) at the dosage of 30 mg/kg daily for 2 weeks could prolong the sleeping time of pentobarbital, increase the SGPT level, decrease the liver concentration of cytochrome P-450 and GSH content, inhibit the activity of cytochrome C reductase and aminopyrine-N-demethylase, but was without effect on cytochrome b5 and aniline hydroxylase."( Hepatotoxicity of gossypol in rats.
Lei, HP; Wang, Y, 1987
)
2.05
"Ultrastructural changes were observed in the oocytes and granulosa cells of the ovarian follicles of sexually mature female rats treated daily for 60 days with gossypol acetic acid at a dosage known to induce sterility in male rats (20 mg/kg body weight, orally)."( Effects of ingested gossypol on the ultrastructure of rat ovarian follicles.
Jensen, DR; Nadakavukaren, MJ; Pan, LC, 1987
)
0.79
" Minor biochemical changes were noted at this dosage level."( The toxicity of gossypol to the male rat.
Gopinath, C; Heywood, R; Lloyd, GK; Majeed, SK, 1986
)
0.62
" Overall, based on the limited dosing schedule employed, the minus isomer appears about twice as potent as the racemic mixture."( (-)-Gossypol: an active male antifertility agent.
Bialy, G; Blye, RP; Lindberg, MC; Matlin, SA; Naqvi, RH; Zhou, R, 1985
)
0.83
" Splenectomized rats dosed with GAA exhibited a significant decrease in hemoglobin concentration, hematocrit and erythrocyte count."( Radioiron utilization and gossypol acetic acid in male rats.
Jensen, DR; Tone, JN, 1985
)
0.57
" In vitro dose-response curves showed a half-maximal inhibitory concentration (IC50) for inhibition of soluble testicular adenylate cyclase by gossypol of 400 microM in each treatment group."( Gossypol modulation of nucleotide metabolizing enzymes in the reproductive tract of male rats.
Hoffer, AP; Olgiati, KL; Toscano, WA, 1984
)
1.91
" In addition, the in vitro spermicidal activity on human semen, antifertility effect on male rats, and the toxic reaction of male mice by taking large dosage were preliminarily studied."( Studies on fertility control-the formation and antifertility effect of polyvinyl-pyrolidone-gossypol complex.
Feng, XD; Gu, ZW; Jiang, Y, 1984
)
0.49
" The dosage in the 2nd stage, the maintenance period, was reduced to 1/3 of the original dose to maintain infertility."( Clinical study of gossypol as a male contraceptive.
Liu, GZ,
)
0.47
" No appreciable differences were observed in plasma levels of TPC and LDL + VLDL-chol among 5 mg/kg/day gossypol-treated animals when compared to controls until the gossypol dosage was increased to 10 mg/kg/day, thus suggesting that hypolipidemic effect of gossypol is dose-dependent."( Hypolipidemic effects of gossypol in cynomolgus monkeys (Macaca fascicularis).
Clarkson, TB; Shandilya, LN, 1982
)
0.78
"01); dosage below 15 mg had no antifertility effect even after 20 weeks."( Antifertility efficacy of gossypol acetic acid in male rats.
Frick, J; Rovan, E; Weinbauer, GF,
)
0.43
" Infertility was exhibited at the end of the 4-week dosing period."( Deposition pattern of the antifertility agent, gossypol, in selected organs of male rats.
Bozek, SA; Jensen, DR; Sorensen, RH; Tone, JN, 1982
)
0.52
" However, (+) gossypol at the dosage of 40 mg."( [Effect of (+), (-) and (+/-) gossypol on early pregnancy in rats].
Guan, MZ; Wang, NG, 1996
)
0.94
" The present study sought to confirm the persistence of hypokalemia at two higher dosage levels (7."( Gossypol-induced hypokalemia and role of exogenous potassium salt supplementation when used as an antispermatogenic agent in male langur monkey.
Kumar, M; Lohiya, NK; Sharma, S, 1997
)
1.74
" Long-term daily dosing with gossypol is associated with minimal side effects and no myelosuppression."( Stereo-specific cytotoxic effects of gossypol enantiomers and gossypolone in tumour cell lines.
Evans, A; Fish, RG; Groundwater, P; Hartley, L; Mason, M; Morgan, JJ; Mort, D; Shelley, MD, 1999
)
0.87
" The optimal oral dosage of gossypol has been found to be 20 mg/day."( [The clinical study of gossypol in 8,806 men].
, 1985
)
0.87
" The fathers of test group members had been previously given oral doses of 20 mg/day gossypol acetate until sperm counts of less than 4 million/ml were achieved (generally 60-90 days after 1st medication), after which dosage was shifted to 40 mg/week."( [Gossypol acetate users].
Tan, FQ, 1986
)
1.4
" Besides the contraceptive dosage of gossypol has produced harmful effects on the liver."( [Gossypol and its related compounds as contraceptive drugs and drugs for gynecological diseases].
Wu, GP, 1988
)
1.46
" When the contraceptive effects were shown, a weekly maintenance dosage was administered."( [A possible mechanism of gossypol-induced hypokalemia and its relation to gossypol dose].
Chen, ZX; Wang, YX, 1991
)
0.58
" When his sperm count dropped below 4 million per ml semen, each participant's dosage was reduced to 200 to 300 mg per month."( [Sister chromatid exchanges in gossypol formic acid users after its discontinuation].
Wang, R, 1986
)
0.56
" Results showed that the dosage regimen could damage the epididymal sperms and onset of antifertility within 6 weeks in male rats, and prevent the incidence of the side effect of irreversible azoospermia."( [A beam of dawn light of study on gossypol as a safe, effective, and reversible male antifertility contraceptive--evaluation of the studies by using low dose gossypol combined with steroid hormone for male contraception].
Xue, S, 2000
)
0.59
" However, there was no significant difference in the mean seminal plasma zinc levels throughout the period of observation irrespective of the dosage regimen of gossypol used by the subjects."( Seminal plasma zinc level in users of gossypol.
Adejuwon, CA; Adekunle, AO; Arowojolu, AO; Ladipo, OA; Okpara, NC,
)
0.6
" In this paper novel tissue-dependent response to differential dosing regimen of gossypol and gossypol in association with Sn-protoporphyrin (SnPP) is described."( Modulatory influence of tin-protoporphyrin on gossypol-induced alterations of heme oxygenase activity in male Wistar rats.
Aneja, R; Chandra, R; Dass, SK,
)
0.62
" Results demonstrated that the combined dosage regimen could damage epididymal sperm motility and density, and induce infertility within 8 weeks in rats; the infertility could be consistently sustained by giving single GA (12."( Combined administration of low-dose gossypol acetic acid with desogestrel/mini-dose ethinylestradiol/testosterone undecanoate as an oral contraceptive for men.
Cui, GH; Guo, Y; Xue, SP; Yang, ZJ; Ye, WS, 2004
)
0.6
" Each molecule was screened in at least seven concentrations, such that dose-response curves were obtained for all molecules in the library."( A high-throughput screen for aggregation-based inhibition in a large compound library.
Austin, CP; Babaoglu, K; Feng, BY; Inglese, J; Jadhav, A; Shoichet, BK; Simeonov, A, 2007
)
0.34
" Daily oral dosing studies showed that mice tolerate doses of apogossypol 2- to 4-times higher than gossypol."( Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2-transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048).
Jia, L; Kitada, S; Krajewska, M; Kress, CL; Pellecchia, M; Reed, JC, 2008
)
0.91
"5 mg/kg d); Group H: the same dosage of DSG/EE/TU as in Group GH; Group C: rats were treated with vehicle (1% methyl cellulose) as control."( Effects of combined administration of low-dose gossypol with steroid hormones on the mitotic phase of spermatogenesis of rat.
Chang, Q; Qian, X; Xu, Z; Zhang, C, 2010
)
0.62
" Unlike trials with continuous daily dosing of AT-101, no cases of small bowel obstruction were reported."( Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer.
Holmlund, JT; Karaseva, NA; Leopold, L; Luft, AV; Orlov, SV; Popovych, O; Ready, N; Wood, BA, 2011
)
0.37
" Notably, the growth of human prostate tumor PC-3 xenografts in mice was significantly suppressed by (-)-gossypol at a dosage of 15 mg/kg/d."( (-)-Gossypol suppresses the growth of human prostate cancer xenografts via modulating VEGF signaling-mediated angiogenesis.
Chen, J; Liu, M; Lu, B; Pang, X; Qu, W; Wang, J; Wu, Y; Yi, Z, 2011
)
1.14
"5 mg×kg(-1)×d(-1)) was given; group H, the same dosage of DSG/EE/TU as in group GH were administered; group C, rats were treated with vehicle (1% methyl cellulose) as control."( Drug synergistic antifertility effect of combined administration of low-dose gossypol with steroid hormones in rats.
Chang, Q; Hei, CC; Liu, Z; Ma, WZ; Qian, XJ; Shen, XS; Xu, ZL, 2011
)
0.6
" Thus, we hypothesized that BH3-mimetic drugs that antagonize Bcl-2 family proteins may exert a greater efficacy when dosed metronomically."( Metronomic dosing of BH3 mimetic small molecule yields robust antiangiogenic and antitumor effects.
Dong, Z; Imai, A; Krishnamurthy, S; Light, E; Nör, JE; Visioli, F; Wang, S; Worden, F; Zeitlin, BD; Zhang, Z, 2012
)
0.38
" Neutropenia in cycle 1 may be a pharmacodynamic marker for docetaxel, which may enable tailored dosing in metastatic castration-resistant prostate cancer (mCRPC)."( Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer.
Berry, WR; Galsky, MD; Leopold, L; Pond, GR; Sonpavde, G; Wood, BA, 2012
)
0.38
" One-fifth normal dosage of the two drugs in MLDC NCs exhibited significantly higher anti-tumor efficiency in reducing tumor size compared with free drugs combination or single drug-loaded nanoparticles individually, indicating that the mulberry-like dual-drug nanoplatform has a great potential in tumor therapy."( Mulberry-like dual-drug complicated nanocarriers assembled with apogossypolone amphiphilic starch micelles and doxorubicin hyaluronic acid nanoparticles for tumor combination and targeted therapy.
Chen, M; Gao, W; Li, K; Liu, H; Liu, J; Wu, D; Xu, L; Zeng, Y, 2015
)
0.65
" Twenty-four female Wistar rats were assigned to two equal groups: one control group and the other dosed with gossypol (25 mg/kg/day, subcutaneously) for 15 days."( Gossypol promotes degeneration of ovarian follicles in rats.
de Macedo, MF; Gadelha, IC; Melo, MM; Oloris, SC; Soto-Blanco, B, 2014
)
2.06
" However, GHQ had a synergistic effect on survival and days-to-pupation when combined with gossypol at the highest dosage tested (0."( Gossypolhemiquinone, a dimeric sesquiterpenoid identified in cotton (Gossypium).
Bell, A; Dowd, M; Duke, S; Esquivel, J; Frelichowski, J; Hake, K; O'Neil, M; Puckhaber, L; Stipanovic, R; Westbrook, J, 2016
)
2.1
" No significant differences were noted between dosing strategies."( A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer.
Bellile, E; Bradford, C; Carey, TE; Chepeha, DB; Eisbruch, A; Jackson, TL; Malloy, K; McKean, E; McLean, S; Moyer, J; Nör, JE; Pearson, AT; Prince, M; Sacco, AG; Shuman, A; Spector, ME; Sukari, A; Swiecicki, PL; Taylor, JM; Wang, S; Wolf, GT; Worden, FP, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pathways (1)

PathwayProteinsCompounds
gossypol biosynthesis021

Protein Targets (187)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency30.48980.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency13.00010.004023.8416100.0000AID485290
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency19.35030.140911.194039.8107AID2451
Chain A, HADH2 proteinHomo sapiens (human)Potency6.99180.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency6.99180.025120.237639.8107AID886; AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency6.56480.177814.390939.8107AID2147
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency12.98680.125919.1169125.8920AID2549; AID2708
Chain A, CruzipainTrypanosoma cruziPotency21.82140.002014.677939.8107AID1476; AID1478
LuciferasePhotinus pyralis (common eastern firefly)Potency40.53340.007215.758889.3584AID624030
acetylcholinesteraseHomo sapiens (human)Potency38.90180.002541.796015,848.9004AID1347398
thioredoxin reductaseRattus norvegicus (Norway rat)Potency30.54610.100020.879379.4328AID488772; AID488773; AID588453; AID588456
15-lipoxygenase, partialHomo sapiens (human)Potency10.00000.012610.691788.5700AID887
pregnane X receptorRattus norvegicus (Norway rat)Potency31.62280.025127.9203501.1870AID651751
phosphopantetheinyl transferaseBacillus subtilisPotency50.11870.141337.9142100.0000AID1490
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency19.75363.189029.884159.4836AID1224846; AID1224894
RAR-related orphan receptor gammaMus musculus (house mouse)Potency9.19100.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency106.82200.173734.304761.8120AID1346924
ATAD5 protein, partialHomo sapiens (human)Potency18.64450.004110.890331.5287AID493107; AID504466
Fumarate hydrataseHomo sapiens (human)Potency36.06130.00308.794948.0869AID1347053
USP1 protein, partialHomo sapiens (human)Potency21.33670.031637.5844354.8130AID504865
GLS proteinHomo sapiens (human)Potency33.55210.35487.935539.8107AID624146; AID624170
PPM1D proteinHomo sapiens (human)Potency23.36170.00529.466132.9993AID1347411
SMAD family member 3Homo sapiens (human)Potency106.82200.173734.304761.8120AID1346924
TDP1 proteinHomo sapiens (human)Potency4.52490.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency25.13850.000714.592883.7951AID1259369; AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency28.12150.180013.557439.8107AID1460; AID1468
AR proteinHomo sapiens (human)Potency17.18850.000221.22318,912.5098AID1259243; AID1259247; AID588515; AID588516; AID743035; AID743042; AID743053; AID743054; AID743063
thioredoxin glutathione reductaseSchistosoma mansoniPotency50.11870.100022.9075100.0000AID485364
Smad3Homo sapiens (human)Potency1.12200.00527.809829.0929AID588855
DNA polymerase III, partialBacillus subtilisPotency10.62131.062114.152826.6795AID485295
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency33.49150.013326.981070.7614AID1346978
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency25.51540.011212.4002100.0000AID1030
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency10.00000.00137.762544.6684AID914; AID915
PINK1Homo sapiens (human)Potency2.51192.818418.895944.6684AID624263
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency6.82780.000657.913322,387.1992AID1259377; AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency28.81020.001022.650876.6163AID1224838; AID1224893
progesterone receptorHomo sapiens (human)Potency10.00780.000417.946075.1148AID1346784; AID1346795
regulator of G-protein signaling 4Homo sapiens (human)Potency4.22440.531815.435837.6858AID504845
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency13.80290.01237.983543.2770AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency13.53060.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency34.18410.000214.376460.0339AID588532; AID588533; AID720691; AID720692; AID720719
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency6.57170.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency17.67530.000817.505159.3239AID1159527; AID1159531; AID588546
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency6.99740.001530.607315,848.9004AID1224819; AID1224820; AID1224821; AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency23.74460.375827.485161.6524AID588526; AID588527; AID743217; AID743220
estrogen nuclear receptor alphaHomo sapiens (human)Potency15.23980.000229.305416,493.5996AID588513; AID743069; AID743075; AID743078; AID743079; AID743080; AID743091
GVesicular stomatitis virusPotency38.90180.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency34.67130.00108.379861.1304AID1645840
polyproteinZika virusPotency36.06130.00308.794948.0869AID1347053
67.9K proteinVaccinia virusPotency14.75470.00018.4406100.0000AID720579; AID720580
ParkinHomo sapiens (human)Potency12.81060.819914.830644.6684AID624263; AID720573
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency15.84890.707936.904389.1251AID504333
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency14.89370.001024.504861.6448AID588534; AID588535; AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency31.87900.001019.414170.9645AID588536; AID588537; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency12.61530.023723.228263.5986AID588541; AID588543; AID743222; AID743223; AID743241
arylsulfatase AHomo sapiens (human)Potency19.01151.069113.955137.9330AID720538
caspase-3Homo sapiens (human)Potency33.49150.013326.981070.7614AID1346978
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency18.72260.035520.977089.1251AID504332
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)Homo sapiens (human)Potency46.45150.016525.307841.3999AID602332
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency21.13170.001723.839378.1014AID743083
activating transcription factor 6Homo sapiens (human)Potency29.53980.143427.612159.8106AID1159516; AID1159519
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency13.448119.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency23.91450.057821.109761.2679AID1159526
Histone H2A.xCricetulus griseus (Chinese hamster)Potency52.19520.039147.5451146.8240AID1224845; AID1224896
Caspase-7Cricetulus griseus (Chinese hamster)Potency33.49150.006723.496068.5896AID1346980
Bloom syndrome protein isoform 1Homo sapiens (human)Potency28.25090.540617.639296.1227AID2528
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency31.62280.00207.533739.8107AID891
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency8.91250.036619.637650.1187AID2100
galactokinaseHomo sapiens (human)Potency23.69060.943115.289453.0367AID2015
hexokinase-4 isoform 1Homo sapiens (human)Potency37.61882.511913.800328.1838AID743206; AID743207
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency91.99970.01262.451825.0177AID485313
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency18.58470.316212.443531.6228AID902; AID924
polyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)Potency2.18281.000012.232631.6228AID1452
cytochrome P450 2C19 precursorHomo sapiens (human)Potency6.30960.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency23.73590.00636.904339.8107AID883
D(1A) dopamine receptorHomo sapiens (human)Potency17.48820.02245.944922.3872AID488981; AID488983
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency21.31800.001815.663839.8107AID894
atrial natriuretic peptide receptor 1 precursorHomo sapiens (human)Potency23.93410.134610.395030.1313AID1347049
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency8.81410.354828.065989.1251AID504847
chromobox protein homolog 1Homo sapiens (human)Potency10.00000.006026.168889.1251AID488953
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency35.42020.010039.53711,122.0200AID1469; AID1479; AID588547
caspase-3Cricetulus griseus (Chinese hamster)Potency33.49150.006723.496068.5896AID1346980
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency8.92590.000323.4451159.6830AID743065; AID743067
glucokinase regulatory proteinHomo sapiens (human)Potency37.61882.511913.800328.1838AID743206; AID743207
heat shock protein beta-1Homo sapiens (human)Potency22.83250.042027.378961.6448AID743210; AID743228
huntingtin isoform 2Homo sapiens (human)Potency12.58930.000618.41981,122.0200AID1688
DNA polymerase betaHomo sapiens (human)Potency0.56230.022421.010289.1251AID485314
mitogen-activated protein kinase 1Homo sapiens (human)Potency29.59470.039816.784239.8107AID1454; AID995
atrial natriuretic peptide receptor 2 precursorHomo sapiens (human)Potency26.12160.00669.809418.4927AID1347050
nuclear factor NF-kappa-B p105 subunit isoform 1Homo sapiens (human)Potency44.66844.466824.832944.6684AID651749
flap endonuclease 1Homo sapiens (human)Potency8.78220.133725.412989.1251AID488816; AID588795
ubiquitin carboxyl-terminal hydrolase 2 isoform aHomo sapiens (human)Potency13.06970.65619.452025.1189AID463106; AID463254; AID927
ras-related protein Rab-9AHomo sapiens (human)Potency58.04790.00022.621531.4954AID485297
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency14.52810.00378.618923.2809AID2660; AID2666; AID2667; AID2668
tyrosine-protein kinase YesHomo sapiens (human)Potency30.74750.00005.018279.2586AID686947
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency34.53350.000627.21521,122.0200AID651741; AID720636; AID743202; AID743219
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency4.30570.425612.059128.1838AID504536; AID624308; AID624312
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency2.51190.050127.073689.1251AID588590
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency19.19120.00798.23321,122.0200AID2546; AID2551
gemininHomo sapiens (human)Potency18.35640.004611.374133.4983AID624297
DNA polymerase kappa isoform 1Homo sapiens (human)Potency5.76770.031622.3146100.0000AID588579
survival motor neuron protein isoform dHomo sapiens (human)Potency35.48130.125912.234435.4813AID1458
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency31.62280.031610.279239.8107AID884; AID885
M-phase phosphoprotein 8Homo sapiens (human)Potency15.00300.177824.735279.4328AID488949
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency79.43280.00419.962528.1838AID2675
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency12.63200.251215.843239.8107AID504327
caspase-1 isoform alpha precursorHomo sapiens (human)Potency18.85410.000311.448431.6228AID896; AID900
4-(cytidine 5'-phospho)-2-C-methyl-D-erithritol kinaseArabidopsis thaliana (thale cress)Potency47.269047.269047.269047.2690AID2017
lethal factor (plasmid)Bacillus anthracis str. A2012Potency0.25120.020010.786931.6228AID912
lamin isoform A-delta10Homo sapiens (human)Potency2.23870.891312.067628.1838AID1487
neuropeptide S receptor isoform AHomo sapiens (human)Potency12.58930.015812.3113615.5000AID1461
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency6.18670.316212.765731.6228AID881
Interferon betaHomo sapiens (human)Potency27.24670.00339.158239.8107AID1347411; AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency38.90180.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency17.37220.002319.595674.0614AID651631; AID651743; AID720552
Integrin beta-3Homo sapiens (human)Potency19.95260.316211.415731.6228AID924
Integrin alpha-IIbHomo sapiens (human)Potency19.95260.316211.415731.6228AID924
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Caspase-1Homo sapiens (human)Potency17.85241.12209.584325.1189AID919; AID929; AID996
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Alpha-synucleinHomo sapiens (human)Potency6.79630.56239.398525.1189AID652106
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency14.96130.00638.235039.8107AID881; AID883
D(1A) dopamine receptorSus scrofa (pig)Potency14.68920.00378.108123.2809AID2667
Caspase-7Homo sapiens (human)Potency16.13033.981118.585631.6228AID889; AID897; AID908
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Disintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)Potency13.55711.584913.004325.1189AID927
Type 1 InsP3 receptor isoform S2 Sus scrofa (pig)Potency25.11892.511913.815425.1189AID929
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency12.58931.000010.475628.1838AID1457
Peroxisome proliferator-activated receptor alphaHomo sapiens (human)Potency15.84890.015823.527344.6684AID651778
GABA theta subunitRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency38.90180.01238.964839.8107AID1645842
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency36.87060.011917.942071.5630AID651632; AID720516
Ataxin-2Homo sapiens (human)Potency22.32870.011912.222168.7989AID588378; AID651632
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Histamine H3 receptorRattus norvegicus (Norway rat)Potency12.58933.981110.806415.8489AID897
cytochrome P450 2C9, partialHomo sapiens (human)Potency38.90180.01238.964839.8107AID1645842
phosphoglycerate kinaseTrypanosoma brucei brucei TREU927Potency23.93410.07578.474229.0628AID504547
2,3-bisphosphoglycerate-independent phosphoglycerate mutaseLeishmania major strain FriedlinPotency0.01517.568615.230621.3313AID504548
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency37.93300.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Mcl-1Homo sapiens (human)IC50 (µMol)1.19160.40007.134454.0000AID1417; AID1418
Estrogen receptor 1Homo sapiens (human)IC50 (µMol)2.55132.161613.689226.3472AID713
eukaryotic translation initiation factor 4 gamma 1 isoform 4Homo sapiens (human)IC50 (µMol)64.00001.150012.620025.6529AID855
eukaryotic translation initiation factor 4E isoform 1Mus musculus (house mouse)IC50 (µMol)64.00001.150012.620025.6529AID855
Prolyl endopeptidaseRattus norvegicus (Norway rat)IC50 (µMol)0.28000.00010.12430.3000AID481341
L-lactate dehydrogenase A chainHomo sapiens (human)Ki1.90000.05003.76508.5000AID1276043; AID1411566; AID1863552
Malate dehydrogenase, mitochondrialSus scrofa (pig)IC50 (µMol)4.26832.03004.26839.5400AID1798305; AID296880
Beta-lactamaseEscherichia coli K-12IC50 (µMol)64.00000.01502.46578.0000AID286782; AID286783
L-lactate dehydrogenase B chainHomo sapiens (human)Ki1.40000.05000.77001.4000AID1276044
Muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)IC50 (µMol)0.86000.00052.773925.1700AID1418
Muscarinic acetylcholine receptor M3Rattus norvegicus (Norway rat)IC50 (µMol)0.86000.00052.891925.1700AID1418
Muscarinic acetylcholine receptor M4Rattus norvegicus (Norway rat)IC50 (µMol)0.86000.00052.747825.1700AID1418
Muscarinic acetylcholine receptor M5Rattus norvegicus (Norway rat)IC50 (µMol)0.86000.00052.780225.1700AID1418
Apoptosis regulator Bcl-2Homo sapiens (human)IC50 (µMol)0.82680.00100.57634.3000AID1326250; AID1434724; AID273187; AID481341; AID743722
Apoptosis regulator Bcl-2Homo sapiens (human)Ki1.07520.00000.19012.9000AID1194539; AID1263150; AID1296598; AID1313652; AID1320544; AID1326250; AID1331912; AID1447200; AID1599454; AID273186; AID291311; AID293611; AID330776; AID526646; AID776626
Muscarinic acetylcholine receptor M2Rattus norvegicus (Norway rat)IC50 (µMol)0.86000.00053.314249.5000AID1418
Solute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)Ki20.00007.00007.00007.0000AID1425899
Malate dehydrogenase, cytoplasmicSus scrofa (pig)IC50 (µMol)4.76832.03004.76839.5400AID1798305; AID296881
Aldo-keto reductase family 1 member B1Homo sapiens (human)Ki0.50000.01903.41939.3000AID34665
L-lactate dehydrogenase B chainMus musculus (house mouse)Ki1.40001.40001.40001.4000AID1863553
DNA-3-methyladenine glycosylaseHomo sapiens (human)IC50 (µMol)3.00000.20002.07503.0000AID1191749
Caspase-1Homo sapiens (human)IC50 (µMol)1.23000.00201.70138.8000AID1801388
DNA repair protein RAD52 homologHomo sapiens (human)IC50 (µMol)5.00000.25502.63016.7000AID1743764
5-hydroxytryptamine receptor 7Cavia porcellus (domestic guinea pig)IC50 (µMol)2.27402.03005.53139.9000AID296877; AID296879
Kinesin-like protein KIF11Homo sapiens (human)IC50 (µMol)17.90000.00011.405710.0000AID310787; AID740552
BH3-interacting domain death agonistHomo sapiens (human)IC50 (µMol)2.39000.02501.08673.0300AID1858754; AID1858796
E3 ubiquitin-protein ligase Mdm2Homo sapiens (human)Ki25.00000.00090.19811.2400AID1296599
Bcl-2-like protein 1Homo sapiens (human)IC50 (µMol)2.78400.00031.04829.5400AID1798305; AID1858796; AID41595; AID462447; AID481340
Bcl-2-like protein 1Homo sapiens (human)Ki0.64800.00000.45819.0000AID1194221; AID1253031; AID1263149; AID1313654; AID1320545; AID1331911; AID1599455; AID1754975; AID273188; AID526645
Induced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)IC50 (µMol)1.81920.00442.923510.0000AID1326249; AID1701173; AID1858754; AID721800; AID721801
Induced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)Ki0.61580.00101.46539.5400AID1253032; AID1263148; AID1296597; AID1320546; AID1326249; AID1331909; AID1447201; AID1599457; AID1701173; AID1754973; AID273189; AID291313; AID431402; AID526650; AID721800; AID721801; AID776627
L-lactate dehydrogenasePlasmodium falciparum (malaria parasite P. falciparum)IC50 (µMol)2.64002.64002.64002.6400AID296877
Aspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)IC50 (µMol)0.27250.02002.66099.4300AID1677972; AID1677973; AID1677974; AID1677975
L-lactate dehydrogenasePlasmodium falciparum CDC/HondurasIC50 (µMol)4.56202.03004.56209.5400AID1798305
L-lactate dehydrogenase B chainBos taurus (cattle)IC50 (µMol)4.56202.03004.56209.5400AID1798305
L-lactate dehydrogenasePlasmodium falciparum (malaria parasite P. falciparum)IC50 (µMol)2.03002.03002.03002.0300AID296879
Bcl-2-like protein 2Homo sapiens (human)Ki17.70000.00101.25908.1900AID293613
Bcl2-associated agonist of cell death Homo sapiens (human)Ki0.46000.00050.15890.4900AID1754974
Inosine-5'-monophosphate dehydrogenase Pseudomonas aeruginosa PAO1IC50 (µMol)0.90000.90001.25001.6000AID1633130
Solute carrier organic anion transporter family member 1B3Homo sapiens (human)IC50 (µMol)4.57090.10472.71957.0795AID977603
Solute carrier organic anion transporter family member 1B3Homo sapiens (human)Ki3.47000.08002.46889.8000AID977604
Solute carrier organic anion transporter family member 1B1Homo sapiens (human)IC50 (µMol)3.23590.05002.37979.7000AID977600
Solute carrier organic anion transporter family member 1B1Homo sapiens (human)Ki1.78000.04401.36305.0000AID977601
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Apoptosis regulator Bcl-2Homo sapiens (human)Kd4.80000.00060.95874.8000AID721798
Bcl-2-like protein 1Homo sapiens (human)Kd169.85500.00010.90252.8000AID348914; AID348915
Induced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)Kd2.56362.32402.56362.6500AID721470; AID721799; AID734888
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (702)

Processvia Protein(s)Taxonomy
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lactate metabolic processL-lactate dehydrogenase A chainHomo sapiens (human)
pyruvate metabolic processL-lactate dehydrogenase A chainHomo sapiens (human)
glycolytic processL-lactate dehydrogenase A chainHomo sapiens (human)
antibiotic catabolic processBeta-lactamaseEscherichia coli K-12
response to antibioticBeta-lactamaseEscherichia coli K-12
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
lactate metabolic processL-lactate dehydrogenase B chainHomo sapiens (human)
pyruvate metabolic processL-lactate dehydrogenase B chainHomo sapiens (human)
NAD metabolic processL-lactate dehydrogenase B chainHomo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
protein polyubiquitinationApoptosis regulator Bcl-2Homo sapiens (human)
apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
extrinsic apoptotic signaling pathway via death domain receptorsApoptosis regulator Bcl-2Homo sapiens (human)
response to xenobiotic stimulusApoptosis regulator Bcl-2Homo sapiens (human)
response to toxic substanceApoptosis regulator Bcl-2Homo sapiens (human)
positive regulation of cell growthApoptosis regulator Bcl-2Homo sapiens (human)
response to cytokineApoptosis regulator Bcl-2Homo sapiens (human)
B cell proliferationApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of neuron apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
regulation of calcium ion transportApoptosis regulator Bcl-2Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligandApoptosis regulator Bcl-2Homo sapiens (human)
G1/S transition of mitotic cell cycleApoptosis regulator Bcl-2Homo sapiens (human)
ossificationApoptosis regulator Bcl-2Homo sapiens (human)
ovarian follicle developmentApoptosis regulator Bcl-2Homo sapiens (human)
metanephros developmentApoptosis regulator Bcl-2Homo sapiens (human)
branching involved in ureteric bud morphogenesisApoptosis regulator Bcl-2Homo sapiens (human)
behavioral fear responseApoptosis regulator Bcl-2Homo sapiens (human)
B cell homeostasisApoptosis regulator Bcl-2Homo sapiens (human)
B cell apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
release of cytochrome c from mitochondriaApoptosis regulator Bcl-2Homo sapiens (human)
regulation of cell-matrix adhesionApoptosis regulator Bcl-2Homo sapiens (human)
lymphoid progenitor cell differentiationApoptosis regulator Bcl-2Homo sapiens (human)
B cell lineage commitmentApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of B cell apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
response to ischemiaApoptosis regulator Bcl-2Homo sapiens (human)
renal system processApoptosis regulator Bcl-2Homo sapiens (human)
melanin metabolic processApoptosis regulator Bcl-2Homo sapiens (human)
regulation of nitrogen utilizationApoptosis regulator Bcl-2Homo sapiens (human)
autophagyApoptosis regulator Bcl-2Homo sapiens (human)
humoral immune responseApoptosis regulator Bcl-2Homo sapiens (human)
DNA damage responseApoptosis regulator Bcl-2Homo sapiens (human)
actin filament organizationApoptosis regulator Bcl-2Homo sapiens (human)
axonogenesisApoptosis regulator Bcl-2Homo sapiens (human)
female pregnancyApoptosis regulator Bcl-2Homo sapiens (human)
positive regulation of cell population proliferationApoptosis regulator Bcl-2Homo sapiens (human)
male gonad developmentApoptosis regulator Bcl-2Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stressApoptosis regulator Bcl-2Homo sapiens (human)
response to radiationApoptosis regulator Bcl-2Homo sapiens (human)
response to xenobiotic stimulusApoptosis regulator Bcl-2Homo sapiens (human)
response to toxic substanceApoptosis regulator Bcl-2Homo sapiens (human)
post-embryonic developmentApoptosis regulator Bcl-2Homo sapiens (human)
response to iron ionApoptosis regulator Bcl-2Homo sapiens (human)
response to UV-BApoptosis regulator Bcl-2Homo sapiens (human)
response to gamma radiationApoptosis regulator Bcl-2Homo sapiens (human)
regulation of gene expressionApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of autophagyApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of calcium ion transport into cytosolApoptosis regulator Bcl-2Homo sapiens (human)
regulation of glycoprotein biosynthetic processApoptosis regulator Bcl-2Homo sapiens (human)
mesenchymal cell developmentApoptosis regulator Bcl-2Homo sapiens (human)
positive regulation of neuron maturationApoptosis regulator Bcl-2Homo sapiens (human)
smooth muscle cell migrationApoptosis regulator Bcl-2Homo sapiens (human)
positive regulation of smooth muscle cell migrationApoptosis regulator Bcl-2Homo sapiens (human)
cochlear nucleus developmentApoptosis regulator Bcl-2Homo sapiens (human)
gland morphogenesisApoptosis regulator Bcl-2Homo sapiens (human)
regulation of transmembrane transporter activityApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of ossificationApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of cell growthApoptosis regulator Bcl-2Homo sapiens (human)
melanocyte differentiationApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of cell migrationApoptosis regulator Bcl-2Homo sapiens (human)
positive regulation of B cell proliferationApoptosis regulator Bcl-2Homo sapiens (human)
hair follicle morphogenesisApoptosis regulator Bcl-2Homo sapiens (human)
axon regenerationApoptosis regulator Bcl-2Homo sapiens (human)
regulation of protein stabilityApoptosis regulator Bcl-2Homo sapiens (human)
endoplasmic reticulum calcium ion homeostasisApoptosis regulator Bcl-2Homo sapiens (human)
glomerulus developmentApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of cellular pH reductionApoptosis regulator Bcl-2Homo sapiens (human)
regulation of protein localizationApoptosis regulator Bcl-2Homo sapiens (human)
myeloid cell apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of myeloid cell apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
T cell differentiation in thymusApoptosis regulator Bcl-2Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationApoptosis regulator Bcl-2Homo sapiens (human)
osteoblast proliferationApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of osteoblast proliferationApoptosis regulator Bcl-2Homo sapiens (human)
response to nicotineApoptosis regulator Bcl-2Homo sapiens (human)
organ growthApoptosis regulator Bcl-2Homo sapiens (human)
positive regulation of multicellular organism growthApoptosis regulator Bcl-2Homo sapiens (human)
cellular response to glucose starvationApoptosis regulator Bcl-2Homo sapiens (human)
response to hydrogen peroxideApoptosis regulator Bcl-2Homo sapiens (human)
neuron maturationApoptosis regulator Bcl-2Homo sapiens (human)
T cell homeostasisApoptosis regulator Bcl-2Homo sapiens (human)
positive regulation of apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
CD8-positive, alpha-beta T cell lineage commitmentApoptosis regulator Bcl-2Homo sapiens (human)
ear developmentApoptosis regulator Bcl-2Homo sapiens (human)
regulation of viral genome replicationApoptosis regulator Bcl-2Homo sapiens (human)
positive regulation of melanocyte differentiationApoptosis regulator Bcl-2Homo sapiens (human)
retinal cell programmed cell deathApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of retinal cell programmed cell deathApoptosis regulator Bcl-2Homo sapiens (human)
regulation of mitochondrial membrane permeabilityApoptosis regulator Bcl-2Homo sapiens (human)
focal adhesion assemblyApoptosis regulator Bcl-2Homo sapiens (human)
spleen developmentApoptosis regulator Bcl-2Homo sapiens (human)
thymus developmentApoptosis regulator Bcl-2Homo sapiens (human)
digestive tract morphogenesisApoptosis regulator Bcl-2Homo sapiens (human)
oocyte developmentApoptosis regulator Bcl-2Homo sapiens (human)
skeletal muscle fiber developmentApoptosis regulator Bcl-2Homo sapiens (human)
positive regulation of skeletal muscle fiber developmentApoptosis regulator Bcl-2Homo sapiens (human)
pigment granule organizationApoptosis regulator Bcl-2Homo sapiens (human)
stem cell developmentApoptosis regulator Bcl-2Homo sapiens (human)
homeostasis of number of cells within a tissueApoptosis regulator Bcl-2Homo sapiens (human)
B cell receptor signaling pathwayApoptosis regulator Bcl-2Homo sapiens (human)
response to glucocorticoidApoptosis regulator Bcl-2Homo sapiens (human)
neuron apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
defense response to virusApoptosis regulator Bcl-2Homo sapiens (human)
establishment of localization in cellApoptosis regulator Bcl-2Homo sapiens (human)
regulation of mitochondrial membrane potentialApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of mitochondrial depolarizationApoptosis regulator Bcl-2Homo sapiens (human)
hematopoietic stem cell differentiationApoptosis regulator Bcl-2Homo sapiens (human)
calcium ion transport into cytosolApoptosis regulator Bcl-2Homo sapiens (human)
T cell apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of T cell apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
cellular response to organic substanceApoptosis regulator Bcl-2Homo sapiens (human)
cellular response to hypoxiaApoptosis regulator Bcl-2Homo sapiens (human)
reactive oxygen species metabolic processApoptosis regulator Bcl-2Homo sapiens (human)
dendritic cell apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
motor neuron apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
cell-cell adhesionApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorApoptosis regulator Bcl-2Homo sapiens (human)
epithelial cell apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of epithelial cell apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of G1/S transition of mitotic cell cycleApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of dendritic cell apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of motor neuron apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of anoikisApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of apoptotic signaling pathwayApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathwayApoptosis regulator Bcl-2Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageApoptosis regulator Bcl-2Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandApoptosis regulator Bcl-2Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
central nervous system developmentSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
response to hypoxiaSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
female pregnancySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
long-chain fatty acid import across plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
L-ascorbic acid metabolic processSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cerebral cortex developmentSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cellular response to glucose starvationSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
xenobiotic transportSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
photoreceptor cell maintenanceSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
protein-containing complex assemblySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cellular response to mechanical stimulusSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cellular hyperosmotic responseSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose import across plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
response to Thyroglobulin triiodothyronineSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose transmembrane transportSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose importSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
response to insulinSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
dehydroascorbic acid transportSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
retinoid metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
epithelial cell maturationAldo-keto reductase family 1 member B1Homo sapiens (human)
renal water homeostasisAldo-keto reductase family 1 member B1Homo sapiens (human)
carbohydrate metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
prostaglandin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
C21-steroid hormone biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
L-ascorbic acid biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
regulation of urine volumeAldo-keto reductase family 1 member B1Homo sapiens (human)
retinol metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
negative regulation of apoptotic processAldo-keto reductase family 1 member B1Homo sapiens (human)
daunorubicin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
doxorubicin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
fructose biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
cellular hyperosmotic salinity responseAldo-keto reductase family 1 member B1Homo sapiens (human)
metanephric collecting duct developmentAldo-keto reductase family 1 member B1Homo sapiens (human)
DNA alkylation repairDNA-3-methyladenine glycosylaseHomo sapiens (human)
depurinationDNA-3-methyladenine glycosylaseHomo sapiens (human)
base-excision repairDNA-3-methyladenine glycosylaseHomo sapiens (human)
cellular response to organic substanceCaspase-1Homo sapiens (human)
pattern recognition receptor signaling pathwayCaspase-1Homo sapiens (human)
proteolysisCaspase-1Homo sapiens (human)
apoptotic processCaspase-1Homo sapiens (human)
signal transductionCaspase-1Homo sapiens (human)
osmosensory signaling pathwayCaspase-1Homo sapiens (human)
protein autoprocessingCaspase-1Homo sapiens (human)
positive regulation of interleukin-1 beta productionCaspase-1Homo sapiens (human)
positive regulation of interleukin-18 productionCaspase-1Homo sapiens (human)
defense response to bacteriumCaspase-1Homo sapiens (human)
regulation of apoptotic processCaspase-1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionCaspase-1Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processCaspase-1Homo sapiens (human)
icosanoid biosynthetic processCaspase-1Homo sapiens (human)
regulation of inflammatory responseCaspase-1Homo sapiens (human)
positive regulation of inflammatory responseCaspase-1Homo sapiens (human)
protein maturationCaspase-1Homo sapiens (human)
defense response to virusCaspase-1Homo sapiens (human)
pyroptosisCaspase-1Homo sapiens (human)
cellular response to lipopolysaccharideCaspase-1Homo sapiens (human)
cellular response to mechanical stimulusCaspase-1Homo sapiens (human)
cellular response to type II interferonCaspase-1Homo sapiens (human)
cytokine precursor processingCaspase-1Homo sapiens (human)
signaling receptor ligand precursor processingCaspase-1Homo sapiens (human)
AIM2 inflammasome complex assemblyCaspase-1Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayCaspase-1Homo sapiens (human)
calcium ion homeostasisAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAlpha-synucleinHomo sapiens (human)
microglial cell activationAlpha-synucleinHomo sapiens (human)
positive regulation of receptor recyclingAlpha-synucleinHomo sapiens (human)
positive regulation of neurotransmitter secretionAlpha-synucleinHomo sapiens (human)
negative regulation of protein kinase activityAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processAlpha-synucleinHomo sapiens (human)
neutral lipid metabolic processAlpha-synucleinHomo sapiens (human)
phospholipid metabolic processAlpha-synucleinHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
mitochondrial membrane organizationAlpha-synucleinHomo sapiens (human)
adult locomotory behaviorAlpha-synucleinHomo sapiens (human)
response to xenobiotic stimulusAlpha-synucleinHomo sapiens (human)
response to iron(II) ionAlpha-synucleinHomo sapiens (human)
regulation of phospholipase activityAlpha-synucleinHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
regulation of glutamate secretionAlpha-synucleinHomo sapiens (human)
regulation of dopamine secretionAlpha-synucleinHomo sapiens (human)
synaptic vesicle exocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle primingAlpha-synucleinHomo sapiens (human)
regulation of transmembrane transporter activityAlpha-synucleinHomo sapiens (human)
negative regulation of microtubule polymerizationAlpha-synucleinHomo sapiens (human)
receptor internalizationAlpha-synucleinHomo sapiens (human)
protein destabilizationAlpha-synucleinHomo sapiens (human)
response to magnesium ionAlpha-synucleinHomo sapiens (human)
negative regulation of transporter activityAlpha-synucleinHomo sapiens (human)
response to lipopolysaccharideAlpha-synucleinHomo sapiens (human)
negative regulation of monooxygenase activityAlpha-synucleinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAlpha-synucleinHomo sapiens (human)
response to type II interferonAlpha-synucleinHomo sapiens (human)
cellular response to oxidative stressAlpha-synucleinHomo sapiens (human)
SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
positive regulation of SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
regulation of locomotionAlpha-synucleinHomo sapiens (human)
dopamine biosynthetic processAlpha-synucleinHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportAlpha-synucleinHomo sapiens (human)
regulation of macrophage activationAlpha-synucleinHomo sapiens (human)
positive regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of neuron apoptotic processAlpha-synucleinHomo sapiens (human)
positive regulation of endocytosisAlpha-synucleinHomo sapiens (human)
negative regulation of exocytosisAlpha-synucleinHomo sapiens (human)
positive regulation of exocytosisAlpha-synucleinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAlpha-synucleinHomo sapiens (human)
synaptic vesicle endocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle transportAlpha-synucleinHomo sapiens (human)
positive regulation of inflammatory responseAlpha-synucleinHomo sapiens (human)
regulation of acyl-CoA biosynthetic processAlpha-synucleinHomo sapiens (human)
protein tetramerizationAlpha-synucleinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolAlpha-synucleinHomo sapiens (human)
neuron apoptotic processAlpha-synucleinHomo sapiens (human)
dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of serotonin uptakeAlpha-synucleinHomo sapiens (human)
regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
negative regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
excitatory postsynaptic potentialAlpha-synucleinHomo sapiens (human)
long-term synaptic potentiationAlpha-synucleinHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processAlpha-synucleinHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
response to interleukin-1Alpha-synucleinHomo sapiens (human)
cellular response to copper ionAlpha-synucleinHomo sapiens (human)
cellular response to epinephrine stimulusAlpha-synucleinHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityAlpha-synucleinHomo sapiens (human)
supramolecular fiber organizationAlpha-synucleinHomo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinoneAlpha-synucleinHomo sapiens (human)
positive regulation of glutathione peroxidase activityAlpha-synucleinHomo sapiens (human)
positive regulation of hydrogen peroxide catabolic processAlpha-synucleinHomo sapiens (human)
regulation of synaptic vesicle recyclingAlpha-synucleinHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processAlpha-synucleinHomo sapiens (human)
positive regulation of protein localization to cell peripheryAlpha-synucleinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyAlpha-synucleinHomo sapiens (human)
regulation of presynapse assemblyAlpha-synucleinHomo sapiens (human)
amyloid fibril formationAlpha-synucleinHomo sapiens (human)
synapse organizationAlpha-synucleinHomo sapiens (human)
chemical synaptic transmissionAlpha-synucleinHomo sapiens (human)
DNA double-strand break processing involved in repair via single-strand annealingDNA repair protein RAD52 homologHomo sapiens (human)
cellular response to oxidative stressDNA repair protein RAD52 homologHomo sapiens (human)
regulation of nucleotide-excision repairDNA repair protein RAD52 homologHomo sapiens (human)
DNA recombinase assemblyDNA repair protein RAD52 homologHomo sapiens (human)
double-strand break repairDNA repair protein RAD52 homologHomo sapiens (human)
DNA recombinationDNA repair protein RAD52 homologHomo sapiens (human)
double-strand break repair via homologous recombinationDNA repair protein RAD52 homologHomo sapiens (human)
mitotic recombinationDNA repair protein RAD52 homologHomo sapiens (human)
double-strand break repair via single-strand annealingDNA repair protein RAD52 homologHomo sapiens (human)
mitotic cell cycleKinesin-like protein KIF11Homo sapiens (human)
microtubule-based movementKinesin-like protein KIF11Homo sapiens (human)
spindle organizationKinesin-like protein KIF11Homo sapiens (human)
mitotic spindle organizationKinesin-like protein KIF11Homo sapiens (human)
mitotic centrosome separationKinesin-like protein KIF11Homo sapiens (human)
regulation of mitotic centrosome separationKinesin-like protein KIF11Homo sapiens (human)
cell divisionKinesin-like protein KIF11Homo sapiens (human)
mitotic spindle assemblyKinesin-like protein KIF11Homo sapiens (human)
spindle elongationKinesin-like protein KIF11Homo sapiens (human)
proteolysisCaspase-7Homo sapiens (human)
apoptotic processCaspase-7Homo sapiens (human)
heart developmentCaspase-7Homo sapiens (human)
response to UVCaspase-7Homo sapiens (human)
protein processingCaspase-7Homo sapiens (human)
protein catabolic processCaspase-7Homo sapiens (human)
defense response to bacteriumCaspase-7Homo sapiens (human)
fibroblast apoptotic processCaspase-7Homo sapiens (human)
striated muscle cell differentiationCaspase-7Homo sapiens (human)
neuron apoptotic processCaspase-7Homo sapiens (human)
protein maturationCaspase-7Homo sapiens (human)
lymphocyte apoptotic processCaspase-7Homo sapiens (human)
cellular response to lipopolysaccharideCaspase-7Homo sapiens (human)
cellular response to staurosporineCaspase-7Homo sapiens (human)
execution phase of apoptosisCaspase-7Homo sapiens (human)
positive regulation of plasma membrane repairCaspase-7Homo sapiens (human)
positive regulation of neuron apoptotic processCaspase-7Homo sapiens (human)
release of cytochrome c from mitochondriaBH3-interacting domain death agonistHomo sapiens (human)
protein targeting to mitochondrionBH3-interacting domain death agonistHomo sapiens (human)
extrinsic apoptotic signaling pathway via death domain receptorsBH3-interacting domain death agonistHomo sapiens (human)
positive regulation of mitochondrial membrane potentialBH3-interacting domain death agonistHomo sapiens (human)
positive regulation of protein-containing complex assemblyBH3-interacting domain death agonistHomo sapiens (human)
regulation of T cell proliferationBH3-interacting domain death agonistHomo sapiens (human)
signal transduction in response to DNA damageBH3-interacting domain death agonistHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportBH3-interacting domain death agonistHomo sapiens (human)
positive regulation of apoptotic processBH3-interacting domain death agonistHomo sapiens (human)
regulation of epithelial cell proliferationBH3-interacting domain death agonistHomo sapiens (human)
neuron apoptotic processBH3-interacting domain death agonistHomo sapiens (human)
protein-containing complex assemblyBH3-interacting domain death agonistHomo sapiens (human)
establishment of protein localization to membraneBH3-interacting domain death agonistHomo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaBH3-interacting domain death agonistHomo sapiens (human)
hepatocyte apoptotic processBH3-interacting domain death agonistHomo sapiens (human)
mitochondrial outer membrane permeabilizationBH3-interacting domain death agonistHomo sapiens (human)
supramolecular fiber organizationBH3-interacting domain death agonistHomo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damageBH3-interacting domain death agonistHomo sapiens (human)
regulation of G1/S transition of mitotic cell cycleBH3-interacting domain death agonistHomo sapiens (human)
positive regulation of fibroblast apoptotic processBH3-interacting domain death agonistHomo sapiens (human)
positive regulation of extrinsic apoptotic signaling pathwayBH3-interacting domain death agonistHomo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayBH3-interacting domain death agonistHomo sapiens (human)
apoptotic mitochondrial changesBH3-interacting domain death agonistHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processBH3-interacting domain death agonistHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to hypoxiaDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
neutrophil mediated immunityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
germinal center formationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of leukocyte chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane protein ectodomain proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch receptor processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell population proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to xenobiotic stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of T cell chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
signal releaseDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
B cell differentiationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell growthDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to lipopolysaccharideDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of chemokine productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
regulation of mast cell apoptotic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
T cell differentiation in thymusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesion mediated by integrinDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
wound healing, spreading of epidermal cellsDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor-activated receptor activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
spleen developmentDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell motilityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
defense response to Gram-positive bacteriumDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cellular response to high density lipoprotein particle stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
commissural neuron axon guidanceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of cold-induced thermogenesisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of vascular endothelial cell proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
regulation of cell cycleE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
ubiquitin-dependent protein catabolic processE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
protein polyubiquitinationE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
blood vessel developmentE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
blood vessel remodelingE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
regulation of heart rateE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
atrioventricular valve morphogenesisE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
endocardial cushion morphogenesisE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
ventricular septum developmentE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
atrial septum developmentE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
ubiquitin-dependent protein catabolic processE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
apoptotic processE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
traversing start control point of mitotic cell cycleE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
positive regulation of cell population proliferationE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
response to xenobiotic stimulusE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
response to toxic substanceE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
response to iron ionE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
positive regulation of gene expressionE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
negative regulation of protein processingE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
negative regulation of neuron projection developmentE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
protein ubiquitinationE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
protein sumoylationE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
protein destabilizationE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
response to magnesium ionE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
protein localization to nucleusE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
regulation of protein catabolic processE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
response to cocaineE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
negative regulation of DNA damage response, signal transduction by p53 class mediatorE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
establishment of protein localizationE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
response to etherE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
negative regulation of DNA-templated transcriptionE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
positive regulation of mitotic cell cycleE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
response to antibioticE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
positive regulation of protein export from nucleusE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
response to steroid hormoneE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
positive regulation of muscle cell differentiationE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
proteolysis involved in protein catabolic processE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
protein autoubiquitinationE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
cardiac septum morphogenesisE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
protein-containing complex assemblyE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
cellular response to hydrogen peroxideE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
cellular response to vitamin B1E3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
cellular response to alkaloidE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
cellular response to growth factor stimulusE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
cellular response to peptide hormone stimulusE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
cellular response to estrogen stimulusE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
cellular response to hypoxiaE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
cellular response to gamma radiationE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
cellular response to UV-CE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
fibroblast activationE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
cellular response to actinomycin DE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
negative regulation of signal transduction by p53 class mediatorE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway by p53 class mediatorE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
response to formaldehydeE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell migrationE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
amyloid fibril formationE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
response to water-immersion restraint stressE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
negative regulation of apoptotic processE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
cell cycleE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
regulation of gene expressionE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
response to cytokineBcl-2-like protein 1Homo sapiens (human)
negative regulation of apoptotic processBcl-2-like protein 1Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway via death domain receptorsBcl-2-like protein 1Homo sapiens (human)
ovarian follicle developmentBcl-2-like protein 1Homo sapiens (human)
in utero embryonic developmentBcl-2-like protein 1Homo sapiens (human)
release of cytochrome c from mitochondriaBcl-2-like protein 1Homo sapiens (human)
endocytosisBcl-2-like protein 1Homo sapiens (human)
germ cell developmentBcl-2-like protein 1Homo sapiens (human)
spermatogenesisBcl-2-like protein 1Homo sapiens (human)
male gonad developmentBcl-2-like protein 1Homo sapiens (human)
apoptotic mitochondrial changesBcl-2-like protein 1Homo sapiens (human)
fertilizationBcl-2-like protein 1Homo sapiens (human)
regulation of cytokinesisBcl-2-like protein 1Homo sapiens (human)
positive regulation of mononuclear cell proliferationBcl-2-like protein 1Homo sapiens (human)
ectopic germ cell programmed cell deathBcl-2-like protein 1Homo sapiens (human)
regulation of growthBcl-2-like protein 1Homo sapiens (human)
negative regulation of apoptotic processBcl-2-like protein 1Homo sapiens (human)
negative regulation of neuron apoptotic processBcl-2-like protein 1Homo sapiens (human)
dendritic cell proliferationBcl-2-like protein 1Homo sapiens (human)
response to cycloheximideBcl-2-like protein 1Homo sapiens (human)
regulation of mitochondrial membrane permeabilityBcl-2-like protein 1Homo sapiens (human)
epithelial cell proliferationBcl-2-like protein 1Homo sapiens (human)
negative regulation of developmental processBcl-2-like protein 1Homo sapiens (human)
neuron apoptotic processBcl-2-like protein 1Homo sapiens (human)
defense response to virusBcl-2-like protein 1Homo sapiens (human)
regulation of mitochondrial membrane potentialBcl-2-like protein 1Homo sapiens (human)
cellular response to amino acid stimulusBcl-2-like protein 1Homo sapiens (human)
cellular response to alkaloidBcl-2-like protein 1Homo sapiens (human)
cellular response to gamma radiationBcl-2-like protein 1Homo sapiens (human)
apoptotic process in bone marrow cellBcl-2-like protein 1Homo sapiens (human)
negative regulation of release of cytochrome c from mitochondriaBcl-2-like protein 1Homo sapiens (human)
dendritic cell apoptotic processBcl-2-like protein 1Homo sapiens (human)
hepatocyte apoptotic processBcl-2-like protein 1Homo sapiens (human)
negative regulation of execution phase of apoptosisBcl-2-like protein 1Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damageBcl-2-like protein 1Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayBcl-2-like protein 1Homo sapiens (human)
negative regulation of protein localization to plasma membraneBcl-2-like protein 1Homo sapiens (human)
negative regulation of reproductive processBcl-2-like protein 1Homo sapiens (human)
negative regulation of dendritic cell apoptotic processBcl-2-like protein 1Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligandBcl-2-like protein 1Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathwayBcl-2-like protein 1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageBcl-2-like protein 1Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandBcl-2-like protein 1Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processBcl-2-like protein 1Homo sapiens (human)
DNA damage responseInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
response to cytokineInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
cell fate determinationInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
negative regulation of autophagyInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
cellular homeostasisInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
positive regulation of apoptotic processInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
negative regulation of apoptotic processInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
protein transmembrane transportInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
positive regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathwayInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
negative regulation of anoikisInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligandInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
mitochondrial fusionInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
release of cytochrome c from mitochondriaInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
negative regulation of cytokine production involved in inflammatory responsePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of reactive oxygen species biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of hepatocyte apoptotic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of signaling receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of ATP biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of transformation of host cell by virusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to hypoxiaPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
gluconeogenesisPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
heart developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to nutrientPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
epidermis developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cellular response to starvationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of cellular ketone metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of cholesterol storagePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of sequestering of triglyceridePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
intracellular receptor signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid beta-oxidationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of appetitePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to insulinPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
circadian regulation of gene expressionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
behavioral response to nicotinePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
wound healingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
lipoprotein metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of circadian rhythmPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
steroid hormone mediated signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to ethanolPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of gluconeogenesisPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of blood pressurePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of glycolytic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nitric oxide metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid oxidationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of lipid biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of inflammatory responsePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of cell growth involved in cardiac muscle cell developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
enamel mineralizationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cellular response to fructose stimulusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of leukocyte cell-cell adhesionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of fatty acid transportPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
hormone-mediated signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cell differentiationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
muscle contractionAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
pattern specification processAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
cell population proliferationAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
negative regulation of cell population proliferationAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
regulation of protein stabilityAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
limb morphogenesisAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
positive regulation of proteolysisAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
roof of mouth developmentAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
face morphogenesisAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
activation of cysteine-type endopeptidase activityAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
regulation of protein depolymerizationAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
peptidyl-aspartic acid hydroxylationAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
response to ischemiaBcl-2-like protein 2Homo sapiens (human)
spermatogenesisBcl-2-like protein 2Homo sapiens (human)
negative regulation of mitochondrial membrane permeabilityBcl-2-like protein 2Homo sapiens (human)
regulation of apoptotic processBcl-2-like protein 2Homo sapiens (human)
negative regulation of apoptotic processBcl-2-like protein 2Homo sapiens (human)
Sertoli cell proliferationBcl-2-like protein 2Homo sapiens (human)
cellular response to estradiol stimulusBcl-2-like protein 2Homo sapiens (human)
negative regulation of release of cytochrome c from mitochondriaBcl-2-like protein 2Homo sapiens (human)
cellular response to amyloid-betaBcl-2-like protein 2Homo sapiens (human)
cellular response to glycineBcl-2-like protein 2Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandBcl-2-like protein 2Homo sapiens (human)
release of cytochrome c from mitochondriaBcl-2-like protein 2Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageBcl-2-like protein 2Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processBcl-2-like protein 2Homo sapiens (human)
glucose catabolic processBcl2-associated agonist of cell death Homo sapiens (human)
apoptotic processBcl2-associated agonist of cell death Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processBcl2-associated agonist of cell death Homo sapiens (human)
extrinsic apoptotic signaling pathway via death domain receptorsBcl2-associated agonist of cell death Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageBcl2-associated agonist of cell death Homo sapiens (human)
positive regulation of autophagyBcl2-associated agonist of cell death Homo sapiens (human)
positive regulation of mitochondrial membrane potentialBcl2-associated agonist of cell death Homo sapiens (human)
cytokine-mediated signaling pathwayBcl2-associated agonist of cell death Homo sapiens (human)
positive regulation of insulin secretionBcl2-associated agonist of cell death Homo sapiens (human)
positive regulation of glucokinase activityBcl2-associated agonist of cell death Homo sapiens (human)
positive regulation of insulin secretion involved in cellular response to glucose stimulusBcl2-associated agonist of cell death Homo sapiens (human)
glucose homeostasisBcl2-associated agonist of cell death Homo sapiens (human)
positive regulation of apoptotic processBcl2-associated agonist of cell death Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processBcl2-associated agonist of cell death Homo sapiens (human)
type B pancreatic cell proliferationBcl2-associated agonist of cell death Homo sapiens (human)
positive regulation of B cell differentiationBcl2-associated agonist of cell death Homo sapiens (human)
positive regulation of T cell differentiationBcl2-associated agonist of cell death Homo sapiens (human)
positive regulation of proteolysisBcl2-associated agonist of cell death Homo sapiens (human)
ADP metabolic processBcl2-associated agonist of cell death Homo sapiens (human)
ATP metabolic processBcl2-associated agonist of cell death Homo sapiens (human)
regulation of mitochondrial membrane permeabilityBcl2-associated agonist of cell death Homo sapiens (human)
pore complex assemblyBcl2-associated agonist of cell death Homo sapiens (human)
positive regulation of epithelial cell proliferationBcl2-associated agonist of cell death Homo sapiens (human)
cellular response to mechanical stimulusBcl2-associated agonist of cell death Homo sapiens (human)
cellular response to nicotineBcl2-associated agonist of cell death Homo sapiens (human)
cellular response to lipidBcl2-associated agonist of cell death Homo sapiens (human)
cellular response to hypoxiaBcl2-associated agonist of cell death Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaBcl2-associated agonist of cell death Homo sapiens (human)
extrinsic apoptotic signaling pathwayBcl2-associated agonist of cell death Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandBcl2-associated agonist of cell death Homo sapiens (human)
intrinsic apoptotic signaling pathwayBcl2-associated agonist of cell death Homo sapiens (human)
activation of cysteine-type endopeptidase activityBcl2-associated agonist of cell death Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway in response to osmotic stressBcl2-associated agonist of cell death Homo sapiens (human)
positive regulation of type B pancreatic cell developmentBcl2-associated agonist of cell death Homo sapiens (human)
release of cytochrome c from mitochondriaBcl2-associated agonist of cell death Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
xenobiotic metabolic processSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
monoatomic ion transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
organic anion transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
bile acid and bile salt transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
heme catabolic processSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
sodium-independent organic anion transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
transmembrane transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
xenobiotic metabolic processSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
monoatomic ion transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
organic anion transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
bile acid and bile salt transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
prostaglandin transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
heme catabolic processSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
sodium-independent organic anion transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
transmembrane transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
thyroid hormone transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (186)

Processvia Protein(s)Taxonomy
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
L-lactate dehydrogenase activityL-lactate dehydrogenase A chainHomo sapiens (human)
protein bindingL-lactate dehydrogenase A chainHomo sapiens (human)
identical protein bindingL-lactate dehydrogenase A chainHomo sapiens (human)
cadherin bindingL-lactate dehydrogenase A chainHomo sapiens (human)
beta-lactamase activityBeta-lactamaseEscherichia coli K-12
hydrolase activityBeta-lactamaseEscherichia coli K-12
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
L-lactate dehydrogenase activityL-lactate dehydrogenase B chainHomo sapiens (human)
protein bindingL-lactate dehydrogenase B chainHomo sapiens (human)
kinase bindingL-lactate dehydrogenase B chainHomo sapiens (human)
identical protein bindingL-lactate dehydrogenase B chainHomo sapiens (human)
NAD bindingL-lactate dehydrogenase B chainHomo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
protease bindingApoptosis regulator Bcl-2Homo sapiens (human)
protein bindingApoptosis regulator Bcl-2Homo sapiens (human)
channel activityApoptosis regulator Bcl-2Homo sapiens (human)
channel inhibitor activityApoptosis regulator Bcl-2Homo sapiens (human)
ubiquitin protein ligase bindingApoptosis regulator Bcl-2Homo sapiens (human)
identical protein bindingApoptosis regulator Bcl-2Homo sapiens (human)
sequence-specific DNA bindingApoptosis regulator Bcl-2Homo sapiens (human)
protein heterodimerization activityApoptosis regulator Bcl-2Homo sapiens (human)
BH3 domain bindingApoptosis regulator Bcl-2Homo sapiens (human)
protein phosphatase 2A bindingApoptosis regulator Bcl-2Homo sapiens (human)
molecular adaptor activityApoptosis regulator Bcl-2Homo sapiens (human)
DNA-binding transcription factor bindingApoptosis regulator Bcl-2Homo sapiens (human)
BH domain bindingApoptosis regulator Bcl-2Homo sapiens (human)
long-chain fatty acid transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
protein bindingSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
kinase bindingSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
dehydroascorbic acid transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
identical protein bindingSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
D-glucose transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
retinal dehydrogenase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
aldose reductase (NADPH) activityAldo-keto reductase family 1 member B1Homo sapiens (human)
protein bindingAldo-keto reductase family 1 member B1Homo sapiens (human)
electron transfer activityAldo-keto reductase family 1 member B1Homo sapiens (human)
prostaglandin H2 endoperoxidase reductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
glyceraldehyde oxidoreductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
allyl-alcohol dehydrogenase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
L-glucuronate reductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
glycerol dehydrogenase [NADP+] activityAldo-keto reductase family 1 member B1Homo sapiens (human)
all-trans-retinol dehydrogenase (NADP+) activityAldo-keto reductase family 1 member B1Homo sapiens (human)
damaged DNA bindingDNA-3-methyladenine glycosylaseHomo sapiens (human)
protein bindingDNA-3-methyladenine glycosylaseHomo sapiens (human)
DNA-3-methyladenine glycosylase activityDNA-3-methyladenine glycosylaseHomo sapiens (human)
DNA N-glycosylase activityDNA-3-methyladenine glycosylaseHomo sapiens (human)
DNA-7-methylguanine glycosylase activityDNA-3-methyladenine glycosylaseHomo sapiens (human)
DNA-7-methyladenine glycosylase activityDNA-3-methyladenine glycosylaseHomo sapiens (human)
DNA-3-methylguanine glycosylase activityDNA-3-methyladenine glycosylaseHomo sapiens (human)
alkylbase DNA N-glycosylase activityDNA-3-methyladenine glycosylaseHomo sapiens (human)
endopeptidase activityCaspase-1Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-1Homo sapiens (human)
protein bindingCaspase-1Homo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic processCaspase-1Homo sapiens (human)
kinase bindingCaspase-1Homo sapiens (human)
cytokine bindingCaspase-1Homo sapiens (human)
identical protein bindingCaspase-1Homo sapiens (human)
CARD domain bindingCaspase-1Homo sapiens (human)
caspase bindingCaspase-1Homo sapiens (human)
fatty acid bindingAlpha-synucleinHomo sapiens (human)
phospholipase D inhibitor activityAlpha-synucleinHomo sapiens (human)
SNARE bindingAlpha-synucleinHomo sapiens (human)
magnesium ion bindingAlpha-synucleinHomo sapiens (human)
transcription cis-regulatory region bindingAlpha-synucleinHomo sapiens (human)
actin bindingAlpha-synucleinHomo sapiens (human)
protein kinase inhibitor activityAlpha-synucleinHomo sapiens (human)
copper ion bindingAlpha-synucleinHomo sapiens (human)
calcium ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingAlpha-synucleinHomo sapiens (human)
phospholipid bindingAlpha-synucleinHomo sapiens (human)
ferrous iron bindingAlpha-synucleinHomo sapiens (human)
zinc ion bindingAlpha-synucleinHomo sapiens (human)
lipid bindingAlpha-synucleinHomo sapiens (human)
oxidoreductase activityAlpha-synucleinHomo sapiens (human)
kinesin bindingAlpha-synucleinHomo sapiens (human)
Hsp70 protein bindingAlpha-synucleinHomo sapiens (human)
histone bindingAlpha-synucleinHomo sapiens (human)
identical protein bindingAlpha-synucleinHomo sapiens (human)
alpha-tubulin bindingAlpha-synucleinHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
tau protein bindingAlpha-synucleinHomo sapiens (human)
phosphoprotein bindingAlpha-synucleinHomo sapiens (human)
molecular adaptor activityAlpha-synucleinHomo sapiens (human)
dynein complex bindingAlpha-synucleinHomo sapiens (human)
cuprous ion bindingAlpha-synucleinHomo sapiens (human)
DNA bindingDNA repair protein RAD52 homologHomo sapiens (human)
single-stranded DNA bindingDNA repair protein RAD52 homologHomo sapiens (human)
protein bindingDNA repair protein RAD52 homologHomo sapiens (human)
identical protein bindingDNA repair protein RAD52 homologHomo sapiens (human)
microtubule motor activityKinesin-like protein KIF11Homo sapiens (human)
protein bindingKinesin-like protein KIF11Homo sapiens (human)
ATP bindingKinesin-like protein KIF11Homo sapiens (human)
microtubule bindingKinesin-like protein KIF11Homo sapiens (human)
protein kinase bindingKinesin-like protein KIF11Homo sapiens (human)
plus-end-directed microtubule motor activityKinesin-like protein KIF11Homo sapiens (human)
RNA bindingCaspase-7Homo sapiens (human)
aspartic-type endopeptidase activityCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-7Homo sapiens (human)
protein bindingCaspase-7Homo sapiens (human)
peptidase activityCaspase-7Homo sapiens (human)
cysteine-type peptidase activityCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic processCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activity involved in execution phase of apoptosisCaspase-7Homo sapiens (human)
death receptor bindingBH3-interacting domain death agonistHomo sapiens (human)
protein bindingBH3-interacting domain death agonistHomo sapiens (human)
ubiquitin protein ligase bindingBH3-interacting domain death agonistHomo sapiens (human)
endopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
interleukin-6 receptor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
integrin bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
peptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metallopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
SH3 domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytokine bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
PDZ domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
tumor necrosis factor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metal ion bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activity involved in amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
p53 bindingE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
ubiquitin-protein transferase activityE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
protein bindingE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
5S rRNA bindingE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
zinc ion bindingE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
ligase activityE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
SUMO transferase activityE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
enzyme bindingE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
protein domain specific bindingE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
ubiquitin protein ligase bindingE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
receptor serine/threonine kinase bindingE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
identical protein bindingE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
peroxisome proliferator activated receptor bindingE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
ribonucleoprotein complex bindingE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
ubiquitin bindingE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
ubiquitin protein ligase activityE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
NEDD8 ligase activityE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
disordered domain specific bindingE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
protein bindingBcl-2-like protein 1Homo sapiens (human)
protein kinase bindingBcl-2-like protein 1Homo sapiens (human)
identical protein bindingBcl-2-like protein 1Homo sapiens (human)
BH3 domain bindingBcl-2-like protein 1Homo sapiens (human)
BH domain bindingBcl-2-like protein 1Homo sapiens (human)
protein bindingInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
protein transmembrane transporter activityInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
protein heterodimerization activityInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
BH3 domain bindingInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
channel activityInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
BH domain bindingInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription activator activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
transcription coactivator bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nuclear steroid receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nuclear receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
zinc ion bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
lipid bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
phosphatase bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein domain specific bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
mitogen-activated protein kinase kinase kinase bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
ubiquitin conjugating enzyme bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
sequence-specific DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein-containing complex bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
NFAT protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
MDM2/MDM4 family protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
structural molecule activityAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
calcium ion bindingAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
protein bindingAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
structural constituent of muscleAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
electron transfer activityAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
peptidyl-aspartic acid 3-dioxygenase activityAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
L-lactate dehydrogenase activityL-lactate dehydrogenase B chainBos taurus (cattle)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingBcl-2-like protein 2Homo sapiens (human)
identical protein bindingBcl-2-like protein 2Homo sapiens (human)
protein-containing complex bindingBcl-2-like protein 2Homo sapiens (human)
disordered domain specific bindingBcl-2-like protein 2Homo sapiens (human)
BH domain bindingBcl-2-like protein 2Homo sapiens (human)
protein bindingBcl2-associated agonist of cell death Homo sapiens (human)
phospholipid bindingBcl2-associated agonist of cell death Homo sapiens (human)
lipid bindingBcl2-associated agonist of cell death Homo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic processBcl2-associated agonist of cell death Homo sapiens (human)
protein kinase bindingBcl2-associated agonist of cell death Homo sapiens (human)
protein phosphatase bindingBcl2-associated agonist of cell death Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
serine-type endopeptidase inhibitor activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
bile acid transmembrane transporter activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
bile acid transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
thyroid hormone transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (120)

Processvia Protein(s)Taxonomy
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
nucleusL-lactate dehydrogenase A chainHomo sapiens (human)
cytosolL-lactate dehydrogenase A chainHomo sapiens (human)
membraneL-lactate dehydrogenase A chainHomo sapiens (human)
extracellular exosomeL-lactate dehydrogenase A chainHomo sapiens (human)
oxidoreductase complexL-lactate dehydrogenase A chainHomo sapiens (human)
mitochondrionL-lactate dehydrogenase A chainHomo sapiens (human)
outer membrane-bounded periplasmic spaceBeta-lactamaseEscherichia coli K-12
periplasmic spaceBeta-lactamaseEscherichia coli K-12
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
cytoplasmL-lactate dehydrogenase B chainHomo sapiens (human)
mitochondrial inner membraneL-lactate dehydrogenase B chainHomo sapiens (human)
cytosolL-lactate dehydrogenase B chainHomo sapiens (human)
membraneL-lactate dehydrogenase B chainHomo sapiens (human)
membrane raftL-lactate dehydrogenase B chainHomo sapiens (human)
extracellular exosomeL-lactate dehydrogenase B chainHomo sapiens (human)
oxidoreductase complexL-lactate dehydrogenase B chainHomo sapiens (human)
mitochondrionL-lactate dehydrogenase B chainHomo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
mitochondrial outer membraneApoptosis regulator Bcl-2Homo sapiens (human)
endoplasmic reticulum membraneApoptosis regulator Bcl-2Homo sapiens (human)
nucleusApoptosis regulator Bcl-2Homo sapiens (human)
cytoplasmApoptosis regulator Bcl-2Homo sapiens (human)
mitochondrionApoptosis regulator Bcl-2Homo sapiens (human)
mitochondrial outer membraneApoptosis regulator Bcl-2Homo sapiens (human)
endoplasmic reticulumApoptosis regulator Bcl-2Homo sapiens (human)
cytosolApoptosis regulator Bcl-2Homo sapiens (human)
membraneApoptosis regulator Bcl-2Homo sapiens (human)
nuclear membraneApoptosis regulator Bcl-2Homo sapiens (human)
myelin sheathApoptosis regulator Bcl-2Homo sapiens (human)
BAD-BCL-2 complexApoptosis regulator Bcl-2Homo sapiens (human)
protein-containing complexApoptosis regulator Bcl-2Homo sapiens (human)
pore complexApoptosis regulator Bcl-2Homo sapiens (human)
plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
Golgi membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
female germ cell nucleusSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
photoreceptor inner segmentSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
female pronucleusSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cytosolSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
caveolaSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
intercalated discSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
basolateral plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
Z discSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
midbodySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cortical actin cytoskeletonSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
sarcolemmaSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
melanosomeSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
extracellular exosomeSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
blood microparticleSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
presynapseSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose transporter complexSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
basolateral plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
extracellular spaceAldo-keto reductase family 1 member B1Homo sapiens (human)
nucleoplasmAldo-keto reductase family 1 member B1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B1Homo sapiens (human)
extracellular exosomeAldo-keto reductase family 1 member B1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
nucleoplasmDNA-3-methyladenine glycosylaseHomo sapiens (human)
cytosolDNA-3-methyladenine glycosylaseHomo sapiens (human)
mitochondrial nucleoidDNA-3-methyladenine glycosylaseHomo sapiens (human)
cytoplasmCaspase-1Homo sapiens (human)
cytosolCaspase-1Homo sapiens (human)
nucleolusCaspase-1Homo sapiens (human)
cytoplasmCaspase-1Homo sapiens (human)
cytosolCaspase-1Homo sapiens (human)
microtubuleCaspase-1Homo sapiens (human)
plasma membraneCaspase-1Homo sapiens (human)
canonical inflammasome complexCaspase-1Homo sapiens (human)
NLRP1 inflammasome complexCaspase-1Homo sapiens (human)
NLRP3 inflammasome complexCaspase-1Homo sapiens (human)
AIM2 inflammasome complexCaspase-1Homo sapiens (human)
protein-containing complexCaspase-1Homo sapiens (human)
IPAF inflammasome complexCaspase-1Homo sapiens (human)
protease inhibitor complexCaspase-1Homo sapiens (human)
platelet alpha granule membraneAlpha-synucleinHomo sapiens (human)
extracellular regionAlpha-synucleinHomo sapiens (human)
extracellular spaceAlpha-synucleinHomo sapiens (human)
nucleusAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
mitochondrionAlpha-synucleinHomo sapiens (human)
lysosomeAlpha-synucleinHomo sapiens (human)
cytosolAlpha-synucleinHomo sapiens (human)
plasma membraneAlpha-synucleinHomo sapiens (human)
cell cortexAlpha-synucleinHomo sapiens (human)
actin cytoskeletonAlpha-synucleinHomo sapiens (human)
membraneAlpha-synucleinHomo sapiens (human)
inclusion bodyAlpha-synucleinHomo sapiens (human)
axonAlpha-synucleinHomo sapiens (human)
growth coneAlpha-synucleinHomo sapiens (human)
synaptic vesicle membraneAlpha-synucleinHomo sapiens (human)
perinuclear region of cytoplasmAlpha-synucleinHomo sapiens (human)
postsynapseAlpha-synucleinHomo sapiens (human)
supramolecular fiberAlpha-synucleinHomo sapiens (human)
protein-containing complexAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
axon terminusAlpha-synucleinHomo sapiens (human)
neuronal cell bodyAlpha-synucleinHomo sapiens (human)
nucleusDNA repair protein RAD52 homologHomo sapiens (human)
nucleoplasmDNA repair protein RAD52 homologHomo sapiens (human)
protein-containing complexDNA repair protein RAD52 homologHomo sapiens (human)
protein-DNA complexDNA repair protein RAD52 homologHomo sapiens (human)
nucleusDNA repair protein RAD52 homologHomo sapiens (human)
spindle poleKinesin-like protein KIF11Homo sapiens (human)
spindle microtubuleKinesin-like protein KIF11Homo sapiens (human)
spindleKinesin-like protein KIF11Homo sapiens (human)
cytosolKinesin-like protein KIF11Homo sapiens (human)
microtubuleKinesin-like protein KIF11Homo sapiens (human)
membraneKinesin-like protein KIF11Homo sapiens (human)
mitotic spindleKinesin-like protein KIF11Homo sapiens (human)
kinesin complexKinesin-like protein KIF11Homo sapiens (human)
protein-containing complexKinesin-like protein KIF11Homo sapiens (human)
nucleusKinesin-like protein KIF11Homo sapiens (human)
mitotic spindleKinesin-like protein KIF11Homo sapiens (human)
extracellular spaceCaspase-7Homo sapiens (human)
nucleusCaspase-7Homo sapiens (human)
cytoplasmCaspase-7Homo sapiens (human)
cytosolCaspase-7Homo sapiens (human)
nucleusCaspase-7Homo sapiens (human)
nucleoplasmCaspase-7Homo sapiens (human)
cytosolCaspase-7Homo sapiens (human)
mitochondrial outer membraneBH3-interacting domain death agonistHomo sapiens (human)
cytosolBH3-interacting domain death agonistHomo sapiens (human)
membraneBH3-interacting domain death agonistHomo sapiens (human)
mitochondrionBH3-interacting domain death agonistHomo sapiens (human)
cytosolBH3-interacting domain death agonistHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
cell-cell junctionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
focal adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
ruffle membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Golgi membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytoplasmDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
endoplasmic reticulum lumenDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytosolDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell surfaceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
actin cytoskeletonDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
apical plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane raftDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
nuclear bodyE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
nucleusE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
nucleoplasmE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
nucleolusE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
cytoplasmE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
cytosolE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
plasma membraneE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
transcription repressor complexE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
endocytic vesicle membraneE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
protein-containing complexE3 ubiquitin-protein ligase Mdm2Homo sapiens (human)
cytoplasmBcl-2-like protein 1Homo sapiens (human)
mitochondrionBcl-2-like protein 1Homo sapiens (human)
mitochondrial outer membraneBcl-2-like protein 1Homo sapiens (human)
mitochondrial inner membraneBcl-2-like protein 1Homo sapiens (human)
mitochondrial matrixBcl-2-like protein 1Homo sapiens (human)
endoplasmic reticulumBcl-2-like protein 1Homo sapiens (human)
centrosomeBcl-2-like protein 1Homo sapiens (human)
cytosolBcl-2-like protein 1Homo sapiens (human)
synaptic vesicle membraneBcl-2-like protein 1Homo sapiens (human)
nuclear membraneBcl-2-like protein 1Homo sapiens (human)
Bcl-2 family protein complexBcl-2-like protein 1Homo sapiens (human)
mitochondrial outer membraneBcl-2-like protein 1Homo sapiens (human)
nucleusInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
nucleoplasmInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
cytoplasmInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
mitochondrionInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
mitochondrial outer membraneInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
cytosolInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
membraneInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
Bcl-2 family protein complexInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
mitochondrial outer membraneInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
nucleusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
chromatinPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
endoplasmic reticulumAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
endoplasmic reticulum membraneAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
plasma membraneAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
cortical endoplasmic reticulumAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
sarcoplasmic reticulum membraneAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
endoplasmic reticulumAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
mitochondrial inner membraneL-lactate dehydrogenase B chainBos taurus (cattle)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolBcl-2-like protein 2Homo sapiens (human)
Bcl-2 family protein complexBcl-2-like protein 2Homo sapiens (human)
mitochondrial outer membraneBcl-2-like protein 2Homo sapiens (human)
mitochondrionBcl2-associated agonist of cell death Homo sapiens (human)
mitochondrial outer membraneBcl2-associated agonist of cell death Homo sapiens (human)
cytosolBcl2-associated agonist of cell death Homo sapiens (human)
BAD-BCL-2 complexBcl2-associated agonist of cell death Homo sapiens (human)
cytosolBcl2-associated agonist of cell death Homo sapiens (human)
mitochondrionBcl2-associated agonist of cell death Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
plasma membraneSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
basal plasma membraneSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
basolateral plasma membraneSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
plasma membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
basal plasma membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
basolateral plasma membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (427)

Assay IDTitleYearJournalArticle
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID291314Growth inhibition of human MDA-MB-231 cells after 4 days by WST-based assay2007Journal of medicinal chemistry, Jul-12, Volume: 50, Issue:14
Structure-based design of flavonoid compounds as a new class of small-molecule inhibitors of the anti-apoptotic Bcl-2 proteins.
AID1636825Antifungal activity against Fusarium acuminatum ATCC 46651 after 18 hrs by serial microdilution assay2016Bioorganic & medicinal chemistry letters, 09-01, Volume: 26, Issue:17
Synthesis, structure and antimicrobial evaluation of a new gossypol triazole conjugates functionalized with aliphatic chains and benzyloxy groups.
AID744861Antiviral activity against Influenza A virus (A/Vietnam/1194/2004(H5N1)) infected in MDCK cells assessed as inhibition of viral entry at 20 uM treated 2 hrs prior to infection2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
Synthesis and anti-H5N1 activity of chiral gossypol derivatives and its analogs implicated by a viral entry blocking mechanism.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID526646Binding affinity to BCl22010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.
AID1636831Antibacterial activity against methicillin-resistant Staphylococcus aureus 2 after 18 hrs by serial microdilution assay2016Bioorganic & medicinal chemistry letters, 09-01, Volume: 26, Issue:17
Synthesis, structure and antimicrobial evaluation of a new gossypol triazole conjugates functionalized with aliphatic chains and benzyloxy groups.
AID1384637Growth inhibition of Saccharomyces cerevisiae harboring PIB2 deletion mutant at 400 uM measured for 11 hrs by HIP assay2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
Yeast Chemogenomic Profiling Reveals Iron Chelation To Be the Principle Cell Inhibitory Mode of Action of Gossypol.
AID1677971Inhibition of N-His6-tagged human AspH (315-755) expressed in Escherichia coli BL21 (DE3) at 20uM using 1 uM hFX-CP as substrate mixture with 3 uM 2OG, 100 uM L-ascorbic acid and 2 uM FAS incubated for 35 mins by MS analysis2020Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20
Small-molecule active pharmaceutical ingredients of approved cancer therapeutics inhibit human aspartate/asparagine-β-hydroxylase.
AID419225Antifungal activity against Fusarium oxysporum f. sp. lupini at 0.5 ug/ml after 48 hrs2009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
Antifungal activity of alkyl and heterocyclic aza-derivatives of gossypol as well as their complexes with NaClO4 against Fusarium oxysporum f. sp. lupini.
AID1705065Inhibition of biotinylated 5-(4-((Z)-3-Carboxy-3-hydroxyacryloyl)-4-(4-chlorobenzyl)piperidine-1-carbonyl)-2-((13,35-dioxo-39-((3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazole-4-yl)-3,6,9,16,19,22,25,28,31-nonaoxa-12,34-diazanonatriacontyl)oxy)benzoi2020European journal of medicinal chemistry, Dec-15, Volume: 208Unraveling the anti-influenza effect of flavonoids: Experimental validation of luteolin and its congeners as potent influenza endonuclease inhibitors.
AID1636829Antibacterial activity against Staphylococcus aureus ATCC 6538 after 18 hrs by serial microdilution assay2016Bioorganic & medicinal chemistry letters, 09-01, Volume: 26, Issue:17
Synthesis, structure and antimicrobial evaluation of a new gossypol triazole conjugates functionalized with aliphatic chains and benzyloxy groups.
AID1331912Inhibition of 5-FAM-QEDIIRNIARHLAQVGDSMDRSIPPG binding to Bcl-2 (unknown origin) preincubated for 30 mins followed by FAM-labeled peptide addition measured after 20 mins by fluorescence polarization assay2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Improved binding affinities of pyrrolidine derivatives as Mcl-1 inhibitors by modifying amino acid side chains.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID481341Displacement of FITC-labeled Bak BH3 peptide from Bcl-2 after 30 mins by fluorescence polarization assay2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins.
AID437160Ratio of compound IC50 to cisplatin IC50 for human HeLa cells2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
Chiral gossypol derivatives: evaluation of their anticancer activity and molecular modeling.
AID310787Inhibition of KSP2007Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3
Pharmacophore identification of KSP inhibitors.
AID421429Cytotoxicity against wild type mouse fibroblast assessed as induction of cell death at 10 uM by FITC-annexin V and propidium iodide assay2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Apogossypol derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins.
AID499177Toxicity in BALB/c mouse assessed as mortality at 120 umol/kg, po administered daily once for 12 days2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
A novel water-soluble gossypol derivative increases chemotherapeutic sensitivity and promotes growth inhibition in colon cancer.
AID526645Binding affinity to Bcl-xl2010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.
AID1755513AUC (0 to infinity) in human at 20 mg/kg, po measured up to 30 hrs by HPLC method2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients.
AID448476Antimicrobial activity against methicillin-resistant Staphylococcus aureus 218/7 by twofold dilution technique2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, crystal structures and antibacterial activity studies of aza-derivatives of phytoalexin from cotton plant--gossypol.
AID1636821Antifungal activity against Aspergillus brasiliensis ATCC 16404 after 18 hrs by serial microdilution assay2016Bioorganic & medicinal chemistry letters, 09-01, Volume: 26, Issue:17
Synthesis, structure and antimicrobial evaluation of a new gossypol triazole conjugates functionalized with aliphatic chains and benzyloxy groups.
AID1636826Antifungal activity against Fusarium oxysporum f. sp. lycopersici after 18 hrs by serial microdilution assay2016Bioorganic & medicinal chemistry letters, 09-01, Volume: 26, Issue:17
Synthesis, structure and antimicrobial evaluation of a new gossypol triazole conjugates functionalized with aliphatic chains and benzyloxy groups.
AID296880Inhibition of pig heart mitochondrial MDH2007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
Design, synthesis, and biological evaluation of Plasmodium falciparum lactate dehydrogenase inhibitors.
AID1754973Binding affinity to Mc1-1 (unknown origin) by fluorescence polarization competition assay2021Bioorganic & medicinal chemistry letters, 09-01, Volume: 47Design, synthesis and biological evaluation of dual Bcl-2/Mcl-1 inhibitors bearing 2-(1H-indol-4-yl)benzoic acid scaffold.
AID1636836Antibacterial activity against Bacillus subtilis ATCC 6635 after 18 hrs by serial microdilution assay2016Bioorganic & medicinal chemistry letters, 09-01, Volume: 26, Issue:17
Synthesis, structure and antimicrobial evaluation of a new gossypol triazole conjugates functionalized with aliphatic chains and benzyloxy groups.
AID34665The compound was tested for inhibitory activity against Aldose reductase from human placenta1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Gossypol and derivatives: a new class of aldose reductase inhibitors.
AID647175Antiviral activity against Influenza A virus (A/Vietnam/1194/2004(H5N1)) infected in MDCK cells assessed as inhibition of viral replication by plaque reduction assay2012Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3
Synthesis and antiviral activities of novel gossypol derivatives.
AID647166Cytotoxicity in human TZM-bl cells by MTT assay2012Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3
Synthesis and antiviral activities of novel gossypol derivatives.
AID437157Ratio of compound IC50 to (-)-gossypol IC50 for human HeLa cells2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
Chiral gossypol derivatives: evaluation of their anticancer activity and molecular modeling.
AID462447Inhibition of Bcl-xL2010Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
Fragment-based deconstruction of Bcl-xL inhibitors.
AID1743763Inhibition of FAM-conjugated ssDNA binding to His-tagged wild type RAD52 (unknown origin) expressed in Rosetta2(DE3)/pLysS cells measured after 30 mins by high-throughput fluorescence polarization assay relative to control2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Synthetic Lethality through the Lens of Medicinal Chemistry.
AID744867Antiviral activity against Influenza A virus (A/Vietnam/1194/2004(H5N1)) infected in MDCK cells by plaque reduction assay2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
Synthesis and anti-H5N1 activity of chiral gossypol derivatives and its analogs implicated by a viral entry blocking mechanism.
AID1633130Inhibition of Pseudomonas aeruginosa IMPDH using IMP as substrate in the presence of NAD+ incubated for 70 secs2019European journal of medicinal chemistry, Apr-01, Volume: 167First-in-class allosteric inhibitors of bacterial IMPDHs.
AID1755510Protein binding in human plasma2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients.
AID286783Inhibition of Escherichia coli AmpC beta lactamase using relaxed assay conditions in presence of 0.00001% Triton X-100 detergent2007Journal of medicinal chemistry, May-17, Volume: 50, Issue:10
A high-throughput screen for aggregation-based inhibition in a large compound library.
AID273189Displacement of FAM-Bid from human Mcl1 by FP assay2006Journal of medicinal chemistry, Oct-19, Volume: 49, Issue:21
Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins.
AID1636827Antifungal activity against Fusarium oxysporum f. sp. betae after 18 hrs by serial microdilution assay2016Bioorganic & medicinal chemistry letters, 09-01, Volume: 26, Issue:17
Synthesis, structure and antimicrobial evaluation of a new gossypol triazole conjugates functionalized with aliphatic chains and benzyloxy groups.
AID448467Antimicrobial activity against Methicillin susceptible Staphylococcus aureus 242/7 by twofold dilution technique2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, crystal structures and antibacterial activity studies of aza-derivatives of phytoalexin from cotton plant--gossypol.
AID1599457Inhibition of MCl-1 (unknown origin)2019European journal of medicinal chemistry, Sep-01, Volume: 177The chemical biology of apoptosis: Revisited after 17 years.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1384631Growth inhibition of Saccharomyces cerevisiae harboring FET3 deletion mutant at 400 uM measured for 11 hrs by HOP assay2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
Yeast Chemogenomic Profiling Reveals Iron Chelation To Be the Principle Cell Inhibitory Mode of Action of Gossypol.
AID448307Antimicrobial activity against Methicillin susceptible Staphylococcus aureus 208/7 by twofold dilution technique2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, crystal structures and antibacterial activity studies of aza-derivatives of phytoalexin from cotton plant--gossypol.
AID500191Cytotoxicity against mouse CT26 cells after 72 hrs by MTT assay2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
A novel water-soluble gossypol derivative increases chemotherapeutic sensitivity and promotes growth inhibition in colon cancer.
AID1425899Mixed type non-competitive inhibition of glucose displaceable binding of [4-3H]cytochalasin B to GLUT1 in human erythrocyte membranes after 10 mins2016MedChemComm, Sep-01, Volume: 7, Issue:9
Anticancer agents interacting with membrane glucose transporters.
AID1331914Antiproliferative activity against human PC3 cells measured after 48 hrs by MTT assay2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Improved binding affinities of pyrrolidine derivatives as Mcl-1 inhibitors by modifying amino acid side chains.
AID1320545Inhibition of 5-FAM-Bid peptide binding to Bcl-XL (unknown origin) by fluorescence polarization assay2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Design, synthesis, and activity evaluation of selective inhibitors of anti-apoptotic Bcl-2 proteins: The effects on the selectivity of the P1 pockets in the active sites.
AID500183Cytotoxicity against human A549 cells after 72 hrs by MTT assay2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
A novel water-soluble gossypol derivative increases chemotherapeutic sensitivity and promotes growth inhibition in colon cancer.
AID448463Antimicrobial activity against Methicillin susceptible Staphylococcus aureus 213/7 by twofold dilution technique2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, crystal structures and antibacterial activity studies of aza-derivatives of phytoalexin from cotton plant--gossypol.
AID500185Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
A novel water-soluble gossypol derivative increases chemotherapeutic sensitivity and promotes growth inhibition in colon cancer.
AID743722Inhibition of Bcl-2 (unknown origin) after 15 hrs by FRET method2013Bioorganic & medicinal chemistry letters, Apr-15, Volume: 23, Issue:8
Synthesis and evaluation of 3-(benzylthio)-5-(1H-indol-3-yl)-1,2,4-triazol-4-amines as Bcl-2 inhibitory anticancer agents.
AID448275Antimicrobial activity against Staphylococcus epidermidis ATCC 12228 at 400 ug after 18 hrs by disk diffusion method2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, crystal structures and antibacterial activity studies of aza-derivatives of phytoalexin from cotton plant--gossypol.
AID421419Inhibition of Bcl-xL at 200 uM by 1D 1H NMR binding assay2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Apogossypol derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins.
AID448280Antimicrobial activity against Micrococcus luteus ATCC 10240 at 400 ug after 18 hrs by disk diffusion method2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, crystal structures and antibacterial activity studies of aza-derivatives of phytoalexin from cotton plant--gossypol.
AID419232Antifungal activity against Fusarium oxysporum f. sp. lupini at 0.1 ug/ml after 144 hrs2009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
Antifungal activity of alkyl and heterocyclic aza-derivatives of gossypol as well as their complexes with NaClO4 against Fusarium oxysporum f. sp. lupini.
AID1253032Inhibition of Mcl-1 (unknown origin) by fluorescence polarization assay2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Design, synthesis and biological evaluation of 3-aryl-rhodanine benzoic acids as anti-apoptotic protein Bcl-2 inhibitors.
AID1594145Inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured rhodanese refolding by measuring rhodanese enzyme activity 2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID437162Ratio of compound IC50 to cisplatin IC50 for human M85 cells2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
Chiral gossypol derivatives: evaluation of their anticancer activity and molecular modeling.
AID1263154Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24
Design, synthesis and preliminary biological studies of pyrrolidine derivatives as Mcl-1 inhibitors.
AID1326268Cytotoxicity against human NCI60 cells assessed as cell growth inhibition after 48 hrs by SRB assay2016ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12
Gossypol with Hydrophobic Linear Esters Exhibits Enhanced Antitumor Activity as an Inhibitor of Antiapoptotic Proteins.
AID41595Inhibitory concentration against Bcl-xl2003Journal of medicinal chemistry, Sep-25, Volume: 46, Issue:20
Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins.
AID421423Induction of apoptosis in human RS11846 cells after 1 to 2 days by FITC-annexin V and propidium iodide assay2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Apogossypol derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins.
AID1313654Inhibition of Bcl-XL (unknown origin) using FAM-Bid peptide as substrate by fluorescence polarization-based assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Structural modification of luteolin from Flos Chrysanthemi leads to increased tumor cell growth inhibitory activity.
AID333843In vivo cytotoxicity against mouse P388 cells relative to control
AID1677973Inhibition of N-His6-tagged human AspH (315-755) expressed in Escherichia coli BL21 (DE3) using 1 uM hFX-CP as substrate mixture with high 200 uM 2OG, 100 uM L-ascorbic acid and 2 uM FAS incubated for 35 mins by MS analysis2020Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20
Small-molecule active pharmaceutical ingredients of approved cancer therapeutics inhibit human aspartate/asparagine-β-hydroxylase.
AID500184Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
A novel water-soluble gossypol derivative increases chemotherapeutic sensitivity and promotes growth inhibition in colon cancer.
AID1447200Inhibition of 6-carboxyfluorescein succinimidyl ester fluorescence tagged-Bid BH3 peptide (79 to 99 residues) binding to Bcl-2 (unknown origin) after 30 mins by fluorescence polarization assay2017Bioorganic & medicinal chemistry letters, 05-01, Volume: 27, Issue:9
Discovery and structure-activity relationship studies of N-substituted indole derivatives as novel Mcl-1 inhibitors.
AID448464Antimicrobial activity against Methicillin susceptible Staphylococcus aureus 237/7 by twofold dilution technique2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, crystal structures and antibacterial activity studies of aza-derivatives of phytoalexin from cotton plant--gossypol.
AID1755504Cmax in human at 20 mg, po measured up to 240 hrs by HPLC method2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients.
AID1808022Inhibition of porcine heart malate dehydrogenase assessed as critical aggregation concentration preincubated for 5 min followed by nicotinamide adenine dinucleotide addition and monitered for 90 sec by spectrophotometric method2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID273186Displacement of FAM-Bid from human Bcl2 by FP assay2006Journal of medicinal chemistry, Oct-19, Volume: 49, Issue:21
Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins.
AID293612Displacement of Flu-Bak peptide from recombinant antiapoptotic Bcl-XL protein by fluorescence polarization assay2007Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5
Development of selective inhibitors for anti-apoptotic Bcl-2 proteins from BHI-1.
AID500190Cytotoxicity against mouse 4T1 cells after 72 hrs by MTT assay2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
A novel water-soluble gossypol derivative increases chemotherapeutic sensitivity and promotes growth inhibition in colon cancer.
AID1755517Clearance in human at 40 mg, po BID cotreated with paclitaxel by HPLC method2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients.
AID419219Antifungal activity against Fusarium oxysporum f. sp. lupini at 20 ug/ml after 192 hrs relative to control2009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
Antifungal activity of alkyl and heterocyclic aza-derivatives of gossypol as well as their complexes with NaClO4 against Fusarium oxysporum f. sp. lupini.
AID647171Inhibition of HIV1 reverse transcriptase activity at 0.8 ug/ml2012Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3
Synthesis and antiviral activities of novel gossypol derivatives.
AID1755519Half life in human plasma at 5 ug/ml incubated for 1 to 24 hrs by LC/MS/MS method2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients.
AID647169Inhibition of HIV1 reverse transcriptase activity at 20 ug/ml2012Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3
Synthesis and antiviral activities of novel gossypol derivatives.
AID744862Antiviral activity against Influenza A virus (A/Vietnam/1194/2004(H5N1)) infected in MDCK cells assessed as inhibition of viral entry at 20 uM treated 2 hrs post infection2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
Synthesis and anti-H5N1 activity of chiral gossypol derivatives and its analogs implicated by a viral entry blocking mechanism.
AID1755509Half life in human at 20 mg/kg, po measured up to 240 hrs by HPLC method2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients.
AID1326245Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 72 hrs by MTT assay2016ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12
Gossypol with Hydrophobic Linear Esters Exhibits Enhanced Antitumor Activity as an Inhibitor of Antiapoptotic Proteins.
AID348915Inhibition of interaction between Bcl-xl and Bak by surface plasmon resonance assay2008Bioorganic & medicinal chemistry letters, Nov-01, Volume: 18, Issue:21
Interaction of kendomycin and semi-synthetic analogues with the anti-apoptotic protein Bcl-xl.
AID1326248Cytotoxicity against mouse CT26 cells assessed as reduction in cell viability after 72 hrs by MTT assay2016ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12
Gossypol with Hydrophobic Linear Esters Exhibits Enhanced Antitumor Activity as an Inhibitor of Antiapoptotic Proteins.
AID1636822Antifungal activity against Aspergillus fumigatus ATCC 204305 after 18 hrs by serial microdilution assay2016Bioorganic & medicinal chemistry letters, 09-01, Volume: 26, Issue:17
Synthesis, structure and antimicrobial evaluation of a new gossypol triazole conjugates functionalized with aliphatic chains and benzyloxy groups.
AID1599454Inhibition of Bcl2 (unknown origin)2019European journal of medicinal chemistry, Sep-01, Volume: 177The chemical biology of apoptosis: Revisited after 17 years.
AID448473Antimicrobial activity against methicillin-resistant Staphylococcus aureus 146/6 by twofold dilution technique2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, crystal structures and antibacterial activity studies of aza-derivatives of phytoalexin from cotton plant--gossypol.
AID744865Selectivity index, ratio of CC50 for MDCK cells to IC50 for Influenza A virus (A/Vietnam/1194/2004(H5N1))2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
Synthesis and anti-H5N1 activity of chiral gossypol derivatives and its analogs implicated by a viral entry blocking mechanism.
AID1755511Cmax in human at 20 mg/kg, po measured up to 30 hrs by HPLC method2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients.
AID721801Inhibition of FAM-Bid peptide binding to Mcl1 (unknown origin) expressed in Escherichia coli BL21 by fluorescence polarization-based binding assay2013European journal of medicinal chemistry, Feb, Volume: 60Fragment-based design, synthesis, and biological evaluation of N-substituted-5-(4-isopropylthiophenol)-2-hydroxynicotinamide derivatives as novel Mcl-1 inhibitors.
AID348914Inhibition of interaction between GST-tagged Bcl-xl and Bak by surface plasmon resonance assay2008Bioorganic & medicinal chemistry letters, Nov-01, Volume: 18, Issue:21
Interaction of kendomycin and semi-synthetic analogues with the anti-apoptotic protein Bcl-xl.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1326247Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay2016ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12
Gossypol with Hydrophobic Linear Esters Exhibits Enhanced Antitumor Activity as an Inhibitor of Antiapoptotic Proteins.
AID1326255Cytotoxicity against human colon cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay2016ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12
Gossypol with Hydrophobic Linear Esters Exhibits Enhanced Antitumor Activity as an Inhibitor of Antiapoptotic Proteins.
AID499178Toxicity in BALB/c mouse assessed as weight loss at 120 umol/kg, po administered daily once for 12 days2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
A novel water-soluble gossypol derivative increases chemotherapeutic sensitivity and promotes growth inhibition in colon cancer.
AID1434724Inhibition of biotinylated Bim peptide binding to His-tagged Bcl-2 (unknown origin) preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA2017Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4
Synthesis and evaluation of 5-(1H-indol-3-yl)-N-aryl-1,3,4-oxadiazol-2-amines as Bcl-2 inhibitory anticancer agents.
AID437158Ratio of compound IC50 to (-)-gossypol IC50 for human U87 cells2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
Chiral gossypol derivatives: evaluation of their anticancer activity and molecular modeling.
AID1194543Antiproliferative activity against human K562 cells after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9
Design, synthesis and preliminary bioactivity studies of 2-thioxo-4-thiazolidinone derivatives as Bcl-2 inhibitors.
AID1755507Clearance in dog at 0.5 mg/kg, iv by HPLC method2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients.
AID1755505Tmax in human at 20 mg, po measured up to 240 hrs by HPLC method2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients.
AID448282Antimicrobial activity against Staphylococcus aureus ATCC 6538 at 400 ug after 18 hrs by disk diffusion method2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, crystal structures and antibacterial activity studies of aza-derivatives of phytoalexin from cotton plant--gossypol.
AID293611Displacement of Flu-Bak peptide from recombinant antiapoptotic Bcl2 protein by fluorescence polarization assay2007Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5
Development of selective inhibitors for anti-apoptotic Bcl-2 proteins from BHI-1.
AID448474Antimicrobial activity against methicillin-resistant Staphylococcus aureus 200/7 by twofold dilution technique2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, crystal structures and antibacterial activity studies of aza-derivatives of phytoalexin from cotton plant--gossypol.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1101973Antifungal activity against Rhizoctonia solani J-1 after 72 hr by turbimetric assay2002Journal of agricultural and food chemistry, Nov-20, Volume: 50, Issue:24
Toxicity of (+)- and (-)-gossypol to the plant pathogen, Rhizoctonia solani.
AID419216Antifungal activity against Fusarium oxysporum f. sp. lupini at 20 ug/ml after 96 hrs2009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
Antifungal activity of alkyl and heterocyclic aza-derivatives of gossypol as well as their complexes with NaClO4 against Fusarium oxysporum f. sp. lupini.
AID1326246Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay2016ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12
Gossypol with Hydrophobic Linear Esters Exhibits Enhanced Antitumor Activity as an Inhibitor of Antiapoptotic Proteins.
AID448295Antimicrobial activity against Staphylococcus aureus ATCC 25923 after 18 hrs by twofold dilution technique2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, crystal structures and antibacterial activity studies of aza-derivatives of phytoalexin from cotton plant--gossypol.
AID1320544Inhibition of 5-FAM-Bid peptide binding to Bcl-2 (unknown origin) by fluorescence polarization assay2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Design, synthesis, and activity evaluation of selective inhibitors of anti-apoptotic Bcl-2 proteins: The effects on the selectivity of the P1 pockets in the active sites.
AID437155Anticancer activity against human U87 cells after 48 hrs by MTT assay2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
Chiral gossypol derivatives: evaluation of their anticancer activity and molecular modeling.
AID406997Inhibition of human recombinant 17beta-HSD2 expressed in HEK293 cell lysate assessed as conversion of radiolabeled estrone to estradiol2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries.
AID500188Cytotoxicity against mouse B16F10 cells after 72 hrs by MTT assay2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
A novel water-soluble gossypol derivative increases chemotherapeutic sensitivity and promotes growth inhibition in colon cancer.
AID344239Antibacterial activity against Bacillus subtilis2008Journal of natural products, Jul, Volume: 71, Issue:7
Cytotoxic and antibacterial sesquiterpenes from Thespesia populnea.
AID721039Induction of apoptosis in human MCF7 cells assessed as cytochrome c release at 5 uM incubated for 12 hrs in presence of Bax/Bak ShRNA by Western blotting method2013Bioorganic & medicinal chemistry, Jan-01, Volume: 21, Issue:1
3-Thiomorpholin-8-oxo-8H-acenaphtho [1,2-b] pyrrole-9-carbonitrile (S1) derivatives as pan-Bcl-2-inhibitors of Bcl-2, Bcl-xL and Mcl-1.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID448300Antimicrobial activity against Bacillus cereus ATCC 11778 after 18 hrs by twofold dilution technique2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, crystal structures and antibacterial activity studies of aza-derivatives of phytoalexin from cotton plant--gossypol.
AID421424Induction of apoptosis in human BP3 cells after 1 to 2 days by FITC-annexin V and propidium iodide assay2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Apogossypol derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins.
AID296879Inhibition of Plasmodium falciparum MDH2007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
Design, synthesis, and biological evaluation of Plasmodium falciparum lactate dehydrogenase inhibitors.
AID1384630Growth inhibition of Saccharomyces cerevisiae harboring FTR1 deletion mutant at 400 uM measured for 11 hrs by HOP assay2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
Yeast Chemogenomic Profiling Reveals Iron Chelation To Be the Principle Cell Inhibitory Mode of Action of Gossypol.
AID448283Antimicrobial activity against Staphylococcus aureus ATCC 29213 at 400 ug after 18 hrs by disk diffusion method2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, crystal structures and antibacterial activity studies of aza-derivatives of phytoalexin from cotton plant--gossypol.
AID1755516AUC (0 to 10 hrs) in human at 40 mg, po BID cotreated with paclitaxel by HPLC method2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients.
AID1101972Antifungal activity against Rhizoctonia solani J-1 after 4 to 5 days2002Journal of agricultural and food chemistry, Nov-20, Volume: 50, Issue:24
Toxicity of (+)- and (-)-gossypol to the plant pathogen, Rhizoctonia solani.
AID448304Antimicrobial activity against methicillin-resistant Staphylococcus aureus 136/6 by twofold dilution technique2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, crystal structures and antibacterial activity studies of aza-derivatives of phytoalexin from cotton plant--gossypol.
AID1384632Growth inhibition of Saccharomyces cerevisiae harboring CCC2 deletion mutant at 400 uM measured for 11 hrs by HOP assay2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
Yeast Chemogenomic Profiling Reveals Iron Chelation To Be the Principle Cell Inhibitory Mode of Action of Gossypol.
AID344240Antibacterial activity against Staphylococcus aureus TISTR5172008Journal of natural products, Jul, Volume: 71, Issue:7
Cytotoxic and antibacterial sesquiterpenes from Thespesia populnea.
AID448472Antimicrobial activity against methicillin-resistant Staphylococcus aureus 144/6 by twofold dilution technique2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, crystal structures and antibacterial activity studies of aza-derivatives of phytoalexin from cotton plant--gossypol.
AID721799Binding affinity to Mcl1 (unknown origin) expressed in Escherichia coli BL21 by ITC assay2013European journal of medicinal chemistry, Feb, Volume: 60Fragment-based design, synthesis, and biological evaluation of N-substituted-5-(4-isopropylthiophenol)-2-hydroxynicotinamide derivatives as novel Mcl-1 inhibitors.
AID448477Antimicrobial activity against methicillin-resistant Staphylococcus aureus 236/7 by twofold dilution technique2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, crystal structures and antibacterial activity studies of aza-derivatives of phytoalexin from cotton plant--gossypol.
AID296881Inhibition of pig cytosolic MDH2007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
Design, synthesis, and biological evaluation of Plasmodium falciparum lactate dehydrogenase inhibitors.
AID448276Antimicrobial activity against Bacillus subtilis ATCC 6633 at 400 ug after 18 hrs by disk diffusion method2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, crystal structures and antibacterial activity studies of aza-derivatives of phytoalexin from cotton plant--gossypol.
AID1755518Half life in human at 40 mg, po BID cotreated with paclitaxel by HPLC method2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients.
AID1263150Competitive binding affinity to Bcl-2 (unknown origin) using 5-FAM-Bid-BH3 peptide preincubated for 30 mins before 5-FAM-Bid-BH3 peptide addition and measured 20 mins after 5-FAM-Bid-BH3 peptide addition by fluorescence polarization assay2015Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24
Design, synthesis and preliminary biological studies of pyrrolidine derivatives as Mcl-1 inhibitors.
AID419218Antifungal activity against Fusarium oxysporum f. sp. lupini at 20 ug/ml after 192 hrs2009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
Antifungal activity of alkyl and heterocyclic aza-derivatives of gossypol as well as their complexes with NaClO4 against Fusarium oxysporum f. sp. lupini.
AID431402Inhibition of recombinant His6-tagged MCL1 (171-326) expressed in Escherichia coli BL21 (DE3) and Flu-Bak peptide interaction by fluorescence polarization assay2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4h-chromene-3-carboxylate (sha 14-1) and its analogues.
AID500186Cytotoxicity against human SW620 cells after 72 hrs by MTT assay2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
A novel water-soluble gossypol derivative increases chemotherapeutic sensitivity and promotes growth inhibition in colon cancer.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1755508Apparent volume of distribution at steady state in dog at 0.5 mg/kg, iv by HPLC method2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients.
AID671067Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay2012Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14
Structure-based design of rhodanine-based acylsulfonamide derivatives as antagonists of the anti-apoptotic Bcl-2 protein.
AID744864Inhibition of H5N1 subtype neuraminidase up to 20 uM2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
Synthesis and anti-H5N1 activity of chiral gossypol derivatives and its analogs implicated by a viral entry blocking mechanism.
AID1326249Inhibition of FAM-Bid binding to human MCL1 expressed in Escherichia coli BL21 after 30 mins by fluorescence polarization assay2016ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12
Gossypol with Hydrophobic Linear Esters Exhibits Enhanced Antitumor Activity as an Inhibitor of Antiapoptotic Proteins.
AID1777431Disruption of interaction between human recombinant GST-tagged MKK3/VF-tagged MYC expressed in HEK293T cells up to 100 uM measured after 2 hrs by TR-FRET assay2021Bioorganic & medicinal chemistry, 09-01, Volume: 45Discovery of the first chemical tools to regulate MKK3-mediated MYC activation in cancer.
AID1384633Growth inhibition of Saccharomyces cerevisiae harboring GEF1 deletion mutant at 400 uM measured for 11 hrs by HOP assay2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
Yeast Chemogenomic Profiling Reveals Iron Chelation To Be the Principle Cell Inhibitory Mode of Action of Gossypol.
AID1296598Displacement of FAM-Bid peptide from N-terminal 8x His-tagged Bcl-2 (unknown origin) expressed in Escherichia coli BL21 (DE3) after 30 mins by fluorescence polarization assay2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Bcl-2/MDM2 Dual Inhibitors Based on Universal Pyramid-Like α-Helical Mimetics.
AID1755520Half life in dog plasma at 5 ug/ml incubated for 1 to 24 hrs by LC/MS/MS method2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients.
AID159612Antimalarial activity against chloroquine-sensitive Plasmodium falciparum CDC/I/HB-31986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Biologically active derivatives of gossypol: synthesis and antimalarial activities of peri-acylated gossylic nitriles.
AID1253034Antiproliferative activity against human K562 cells by MTT assay2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Design, synthesis and biological evaluation of 3-aryl-rhodanine benzoic acids as anti-apoptotic protein Bcl-2 inhibitors.
AID437156Anticancer activity against human M85 cells after 48 hrs by MTT assay2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
Chiral gossypol derivatives: evaluation of their anticancer activity and molecular modeling.
AID437159Ratio of compound IC50 to (-)-gossypol IC50 for human M85 cells2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
Chiral gossypol derivatives: evaluation of their anticancer activity and molecular modeling.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID448466Antimicrobial activity against Methicillin susceptible Staphylococcus aureus 239/7 by twofold dilution technique2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, crystal structures and antibacterial activity studies of aza-derivatives of phytoalexin from cotton plant--gossypol.
AID1194539Inhibition of Bcl-2 (unknown origin) using 5-FAM-Bid-BH3 as substrate preincubated for 30 mins before substrate addition measured after 20 mins by fluorescence polarization technique2015Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9
Design, synthesis and preliminary bioactivity studies of 2-thioxo-4-thiazolidinone derivatives as Bcl-2 inhibitors.
AID419222Antifungal activity against Fusarium oxysporum f. sp. lupini at 1 ug/ml after 144 hrs2009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
Antifungal activity of alkyl and heterocyclic aza-derivatives of gossypol as well as their complexes with NaClO4 against Fusarium oxysporum f. sp. lupini.
AID421430Cytotoxicity against Bax/Bak double knockout mouse fibroblast assessed as induction of cell death at 10 uM by FITC-annexin V and propidium iodide assay2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Apogossypol derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins.
AID671070Inhibition of FAM-Bak-BH3 binding to human N-terminal His6-tagged Bcl2 isoform 2 after 4 hrs by fluorescence polarization assay2012Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14
Structure-based design of rhodanine-based acylsulfonamide derivatives as antagonists of the anti-apoptotic Bcl-2 protein.
AID1326260Cytotoxicity against human prostate cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay2016ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12
Gossypol with Hydrophobic Linear Esters Exhibits Enhanced Antitumor Activity as an Inhibitor of Antiapoptotic Proteins.
AID1326263Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability at 0.33 to 100 uM after 72 hrs by MTT assay2016ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12
Gossypol with Hydrophobic Linear Esters Exhibits Enhanced Antitumor Activity as an Inhibitor of Antiapoptotic Proteins.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1331909Inhibition of 5-FAM-QEDIIRNIARHLAQVGDSMDRSIPPG binding to Mcl-1 (unknown origin) preincubated for 30 mins followed by FAM-labeled peptide addition measured after 20 mins by fluorescence polarization assay2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Improved binding affinities of pyrrolidine derivatives as Mcl-1 inhibitors by modifying amino acid side chains.
AID103751Inhibitory concentration in MCF-7 cells2003Journal of medicinal chemistry, Sep-25, Volume: 46, Issue:20
Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins.
AID1677975Inhibition of N-His6-tagged human AspH (315-755) expressed in Escherichia coli BL21 (DE3) using high 10 uM hFX-CP as substrate mixture with 10 uM 2OG, 100 uM L-ascorbic acid and 2 uM FAS incubated for 35 mins by MS analysis2020Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20
Small-molecule active pharmaceutical ingredients of approved cancer therapeutics inhibit human aspartate/asparagine-β-hydroxylase.
AID647179Inhibition of HIV1 reverse transcriptase activity2012Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3
Synthesis and antiviral activities of novel gossypol derivatives.
AID385159Antiplasmodial activity against Plasmodium falciparum 3D72008Journal of natural products, Apr, Volume: 71, Issue:4
Combining HPLC-PDA-MS-SPE-NMR with circular dichroism for complete natural product characterization in crude extracts: levorotatory gossypol in Thespesia danis.
AID1808020Inhibition of porcine heart malate dehydrogenase preincubated for 5 min followed by nicotinamide adenine dinucleotide addition and monitered for 90 sec by spectrophotometric method2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID1636833Antibacterial activity against Staphylococcus epidermidis ATCC 49134 after 18 hrs by serial microdilution assay2016Bioorganic & medicinal chemistry letters, 09-01, Volume: 26, Issue:17
Synthesis, structure and antimicrobial evaluation of a new gossypol triazole conjugates functionalized with aliphatic chains and benzyloxy groups.
AID419224Antifungal activity against Fusarium oxysporum f. sp. lupini at 1 ug/ml after 192 hrs relative to control2009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
Antifungal activity of alkyl and heterocyclic aza-derivatives of gossypol as well as their complexes with NaClO4 against Fusarium oxysporum f. sp. lupini.
AID499179Toxicity in BALB/c mouse assessed as induction of small intestine damage at 120 umol/kg, po administered daily once for 12 days2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
A novel water-soluble gossypol derivative increases chemotherapeutic sensitivity and promotes growth inhibition in colon cancer.
AID1191750Binding affinity to ethenoadenine containing 5'-TCGAGGATCCTGAGCTCGAGTCGACGXTCGCGAATTCTGCGGATCCAAGC-3' duplex oligonucleotide DNA (unknown origin) at 15 uM by SPR assay2015Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5
Naturally occurring polyphenol, morin hydrate, inhibits enzymatic activity of N-methylpurine DNA glycosylase, a DNA repair enzyme with various roles in human disease.
AID776626Displacement of FAM-Bid BH3 peptide from recombinant Bcl-2 (unknown origin) expressed in Escherichia coli BL21 after 10 mins by fluorescence polarization assay2013European journal of medicinal chemistry, Nov, Volume: 69Design and application of a rigid quinazolone scaffold based on two-face Bim α-helix mimicking.
AID1384634Growth inhibition of wild type Saccharomyces cerevisiae BY4743 at 500 uM measured for 15 hrs in presence of Fe2+2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
Yeast Chemogenomic Profiling Reveals Iron Chelation To Be the Principle Cell Inhibitory Mode of Action of Gossypol.
AID344237Cytotoxicity against human HT29 cells by SRB assay2008Journal of natural products, Jul, Volume: 71, Issue:7
Cytotoxic and antibacterial sesquiterpenes from Thespesia populnea.
AID1636838Reduction in ergosterol content in Rhizopus stolonifer ATCC 56227 at 256 microg/ml by HPLC analysis2016Bioorganic & medicinal chemistry letters, 09-01, Volume: 26, Issue:17
Synthesis, structure and antimicrobial evaluation of a new gossypol triazole conjugates functionalized with aliphatic chains and benzyloxy groups.
AID273187Binding affinity to human Bcl2 by ELISA2006Journal of medicinal chemistry, Oct-19, Volume: 49, Issue:21
Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins.
AID1326257Cytotoxicity against human melanoma cells assessed as cell growth inhibition after 48 hrs by SRB assay2016ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12
Gossypol with Hydrophobic Linear Esters Exhibits Enhanced Antitumor Activity as an Inhibitor of Antiapoptotic Proteins.
AID1326250Inhibition of FAM-Bid binding to human BCL2 expressed in Escherichia coli BL21 after 30 mins by fluorescence polarization assay2016ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12
Gossypol with Hydrophobic Linear Esters Exhibits Enhanced Antitumor Activity as an Inhibitor of Antiapoptotic Proteins.
AID448301Antimicrobial activity against Enterococcus hirae ATCC 10541 after 18 hrs by twofold dilution technique2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, crystal structures and antibacterial activity studies of aza-derivatives of phytoalexin from cotton plant--gossypol.
AID1368352Spermicidal activity against mouse sperm assessed as motility of sperm at 100 uM after 1 hr by hemocytometric analysis2018Bioorganic & medicinal chemistry letters, 01-01, Volume: 28, Issue:1
Synthesis and biological evaluation of water-soluble derivatives of chiral gossypol as HIV fusion inhibitors targeting gp41.
AID1427422Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
AID1777430Disruption of interaction between human recombinant GST-tagged MKK3/VF-tagged MYC expressed in HEK293T cells at 20 uM measured after 2 hrs by TR-FRET assay2021Bioorganic & medicinal chemistry, 09-01, Volume: 45Discovery of the first chemical tools to regulate MKK3-mediated MYC activation in cancer.
AID1253035Antiproliferative activity against human PC3 cells by MTT assay2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Design, synthesis and biological evaluation of 3-aryl-rhodanine benzoic acids as anti-apoptotic protein Bcl-2 inhibitors.
AID344238Cytotoxicity against human KB cells by SRB assay2008Journal of natural products, Jul, Volume: 71, Issue:7
Cytotoxic and antibacterial sesquiterpenes from Thespesia populnea.
AID419228Antifungal activity against Fusarium oxysporum f. sp. lupini at 0.5 ug/ml after 192 hrs2009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
Antifungal activity of alkyl and heterocyclic aza-derivatives of gossypol as well as their complexes with NaClO4 against Fusarium oxysporum f. sp. lupini.
AID977600pIC50 values for sodium fluorescein (10 uM) uptake in OATP1B1-transfected CHO cells2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1754975Binding affinity to Bc1-xL (unknown origin) by fluorescence polarization competition assay2021Bioorganic & medicinal chemistry letters, 09-01, Volume: 47Design, synthesis and biological evaluation of dual Bcl-2/Mcl-1 inhibitors bearing 2-(1H-indol-4-yl)benzoic acid scaffold.
AID159610Antimalarial activity against chloroquine-resistant Plasmodium falciparum FCB/NC11986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Biologically active derivatives of gossypol: synthesis and antimalarial activities of peri-acylated gossylic nitriles.
AID526650Binding affinity to MCL12010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.
AID1326259Cytotoxicity against human renal cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay2016ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12
Gossypol with Hydrophobic Linear Esters Exhibits Enhanced Antitumor Activity as an Inhibitor of Antiapoptotic Proteins.
AID448299Antimicrobial activity against Bacillus subtilis ATCC 6633 after 18 hrs by twofold dilution technique2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, crystal structures and antibacterial activity studies of aza-derivatives of phytoalexin from cotton plant--gossypol.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1194542Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9
Design, synthesis and preliminary bioactivity studies of 2-thioxo-4-thiazolidinone derivatives as Bcl-2 inhibitors.
AID721800Inhibition of biotin-Bim peptide binding to Mcl1 (unknown origin) expressed in Escherichia coli BL21 by ELISA2013European journal of medicinal chemistry, Feb, Volume: 60Fragment-based design, synthesis, and biological evaluation of N-substituted-5-(4-isopropylthiophenol)-2-hydroxynicotinamide derivatives as novel Mcl-1 inhibitors.
AID1326256Cytotoxicity against human CNS cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay2016ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12
Gossypol with Hydrophobic Linear Esters Exhibits Enhanced Antitumor Activity as an Inhibitor of Antiapoptotic Proteins.
AID1263148Competitive binding affinity to Mcl-1 (unknown origin) using 5-FAM-Bid-BH3 peptide preincubated for 30 mins before 5-FAM-Bid-BH3 peptide addition and measured 20 mins after 5-FAM-Bid-BH3 peptide addition by fluorescence polarization assay2015Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24
Design, synthesis and preliminary biological studies of pyrrolidine derivatives as Mcl-1 inhibitors.
AID744868Antiviral activity against H5N1 subtype infected in MDCK cells2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
Synthesis and anti-H5N1 activity of chiral gossypol derivatives and its analogs implicated by a viral entry blocking mechanism.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1636834Antibacterial activity against Streptococcus pneumoniae ATCC 49619 after 18 hrs by serial microdilution assay2016Bioorganic & medicinal chemistry letters, 09-01, Volume: 26, Issue:17
Synthesis, structure and antimicrobial evaluation of a new gossypol triazole conjugates functionalized with aliphatic chains and benzyloxy groups.
AID740552Inhibition of human recombinant Eg5 ATPase activity expressed in Escherichia coli after 30 mins by malachite green-based spectrophotometric analysis2013European journal of medicinal chemistry, Apr, Volume: 62Advances in the discovery of kinesin spindle protein (Eg5) inhibitors as antitumor agents.
AID296877Inhibition of Plasmodium falciparum LDH2007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
Design, synthesis, and biological evaluation of Plasmodium falciparum lactate dehydrogenase inhibitors.
AID1633136Competitive inhibition of Pseudomonas aeruginosa IMPDH using IMP as substrate at varying levels and NAD+ in presence of ATP incubated for 70 secs2019European journal of medicinal chemistry, Apr-01, Volume: 167First-in-class allosteric inhibitors of bacterial IMPDHs.
AID1296597Displacement of FAM-Bid peptide from N-terminal 8x His-tagged MCl-1 (unknown origin) expressed in Escherichia coli BL21 (DE3) after 30 mins by fluorescence polarization assay2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Bcl-2/MDM2 Dual Inhibitors Based on Universal Pyramid-Like α-Helical Mimetics.
AID437161Ratio of compound IC50 to cisplatin IC50 for human U87 cells2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
Chiral gossypol derivatives: evaluation of their anticancer activity and molecular modeling.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID286782Aggregate based-inhibition of Escherichia coli AmpC beta lactamase using stringent assay conditions in presence of 0.01% Triton X-100 detergent2007Journal of medicinal chemistry, May-17, Volume: 50, Issue:10
A high-throughput screen for aggregation-based inhibition in a large compound library.
AID448303Antimicrobial activity against Micrococcus luteus ATCC 10240 by twofold dilution technique2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, crystal structures and antibacterial activity studies of aza-derivatives of phytoalexin from cotton plant--gossypol.
AID419234Antifungal activity against Fusarium oxysporum f. sp. lupini at 0.1 ug/ml after 192 hrs relative to control2009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
Antifungal activity of alkyl and heterocyclic aza-derivatives of gossypol as well as their complexes with NaClO4 against Fusarium oxysporum f. sp. lupini.
AID1863553Inhibition of mouse LDHB using sodium pyruvate as substrate2022European journal of medicinal chemistry, Oct-05, Volume: 240Discovery of novel human lactate dehydrogenase inhibitors: Structure-based virtual screening studies and biological assessment.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1636828Antibacterial activity against Staphylococcus aureus ATCC 25923 after 18 hrs by serial microdilution assay2016Bioorganic & medicinal chemistry letters, 09-01, Volume: 26, Issue:17
Synthesis, structure and antimicrobial evaluation of a new gossypol triazole conjugates functionalized with aliphatic chains and benzyloxy groups.
AID1755512Tmax in human at 20 mg/kg, po measured up to 30 hrs by HPLC method2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients.
AID1313649Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 72 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Structural modification of luteolin from Flos Chrysanthemi leads to increased tumor cell growth inhibitory activity.
AID448294Antimicrobial activity against Staphylococcus aureus NCTC 4163 after 18 hrs by twofold dilution technique2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, crystal structures and antibacterial activity studies of aza-derivatives of phytoalexin from cotton plant--gossypol.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1253031Inhibition of Bcl-xL (unknown origin) by fluorescence polarization assay2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Design, synthesis and biological evaluation of 3-aryl-rhodanine benzoic acids as anti-apoptotic protein Bcl-2 inhibitors.
AID1384636Growth inhibition of Saccharomyces cerevisiae harboring GRX6 deletion mutant at 400 uM measured for 11 hrs by HOP assay2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
Yeast Chemogenomic Profiling Reveals Iron Chelation To Be the Principle Cell Inhibitory Mode of Action of Gossypol.
AID1594144Inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured soluble pig heart MDH refolding by measuring MDH enzyme acti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID421421Cytotoxicity against human H460 cells assessed as cell viability after 72 hrs by ATP-LITE assay2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Apogossypol derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins.
AID1858754Inhibition of Mcl-1/Bid (unknown origin) by fluorescence polarization assay2021European journal of medicinal chemistry, Jan-15, Volume: 210Development of Mcl-1 inhibitors for cancer therapy.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID481345Cytotoxicity against human PC3 cells after 3 days by ATP-LITE assay2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID437154Anticancer activity against human HeLa cells after 48 hrs by MTT assay2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
Chiral gossypol derivatives: evaluation of their anticancer activity and molecular modeling.
AID1701173Displacement of FAM-Bid peptide from recombinant N-terminal His6x-tagged human Mcl-1 expressed in Escherichia coli BL21 (DE3) incubated for 30 mins by fluorescence polarization assay2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Synthesis and structure-activity relationship of coumarins as potent Mcl-1 inhibitors for cancer treatment.
AID421422Cytotoxicity against human PC3-ML cells assessed as cell viability after 72 hrs by ATP-LITE assay2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Apogossypol derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins.
AID500189Cytotoxicity against human PC3 cells after 72 hrs by MTT assay2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
A novel water-soluble gossypol derivative increases chemotherapeutic sensitivity and promotes growth inhibition in colon cancer.
AID296878Inhibition of bovine heart LDH2007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
Design, synthesis, and biological evaluation of Plasmodium falciparum lactate dehydrogenase inhibitors.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID448308Antimicrobial activity against Methicillin susceptible Staphylococcus aureus 212/7 by twofold dilution technique2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, crystal structures and antibacterial activity studies of aza-derivatives of phytoalexin from cotton plant--gossypol.
AID419233Antifungal activity against Fusarium oxysporum f. sp. lupini at 0.1 ug/ml after 192 hrs2009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
Antifungal activity of alkyl and heterocyclic aza-derivatives of gossypol as well as their complexes with NaClO4 against Fusarium oxysporum f. sp. lupini.
AID1313650Cytotoxicity against human HEK293 cells assessed as reduction in cell viability after 72 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Structural modification of luteolin from Flos Chrysanthemi leads to increased tumor cell growth inhibitory activity.
AID647168Binding affinity to human serum albumin by fluorescence quenching assay2012Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3
Synthesis and antiviral activities of novel gossypol derivatives.
AID1755521Half life in mouse plasma at 5 ug/ml incubated for 1 to 24 hrs by LC/MS/MS method2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients.
AID448305Antimicrobial activity against Methicillin susceptible Staphylococcus aureus 206/7 by twofold dilution technique2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, crystal structures and antibacterial activity studies of aza-derivatives of phytoalexin from cotton plant--gossypol.
AID448475Antimicrobial activity against methicillin-resistant Staphylococcus aureus 217/7 by twofold dilution technique2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, crystal structures and antibacterial activity studies of aza-derivatives of phytoalexin from cotton plant--gossypol.
AID1263153Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24
Design, synthesis and preliminary biological studies of pyrrolidine derivatives as Mcl-1 inhibitors.
AID977603pIC50 values for sodium fluorescein (10 uM) uptake in OATP1B3-transfected CHO cells2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID721470Binding affinity to cMcl-1 (residues 171 to 327) (unknown origin) by ITC assay2013Bioorganic & medicinal chemistry, Jan-01, Volume: 21, Issue:1
3-Thiomorpholin-8-oxo-8H-acenaphtho [1,2-b] pyrrole-9-carbonitrile (S1) derivatives as pan-Bcl-2-inhibitors of Bcl-2, Bcl-xL and Mcl-1.
AID344235Cytotoxicity against human MCF7 cells by SRB assay2008Journal of natural products, Jul, Volume: 71, Issue:7
Cytotoxic and antibacterial sesquiterpenes from Thespesia populnea.
AID419215Antifungal activity against Fusarium oxysporum f. sp. lupini at 20 ug/ml after 48 hrs2009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
Antifungal activity of alkyl and heterocyclic aza-derivatives of gossypol as well as their complexes with NaClO4 against Fusarium oxysporum f. sp. lupini.
AID419231Antifungal activity against Fusarium oxysporum f. sp. lupini at 0.1 ug/ml after 96 hrs2009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
Antifungal activity of alkyl and heterocyclic aza-derivatives of gossypol as well as their complexes with NaClO4 against Fusarium oxysporum f. sp. lupini.
AID1296599Displacement of FAM-p53TAD peptide from N-terminal 8x His-tagged human MDM2 (25 to 108 residues) expressed in Escherichia coli BL21 (DE3) after 30 mins by fluorescence polarization assay2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Bcl-2/MDM2 Dual Inhibitors Based on Universal Pyramid-Like α-Helical Mimetics.
AID1636830Antibacterial activity against methicillin-resistant Staphylococcus aureus 1 after 18 hrs by serial microdilution assay2016Bioorganic & medicinal chemistry letters, 09-01, Volume: 26, Issue:17
Synthesis, structure and antimicrobial evaluation of a new gossypol triazole conjugates functionalized with aliphatic chains and benzyloxy groups.
AID1754974Binding affinity to Bcl-2 (unknown origin) by fluorescence polarization competition assay2021Bioorganic & medicinal chemistry letters, 09-01, Volume: 47Design, synthesis and biological evaluation of dual Bcl-2/Mcl-1 inhibitors bearing 2-(1H-indol-4-yl)benzoic acid scaffold.
AID1304505Binding affinity to PEST and transmembrane regions lacking N-terminal His6/MBP-tagged human MCl1 (172 to 327 residues) expressed in Escherichia coli Rosetta2(2DE3) pLysS cells assesed as inhibition of protein interaction with carboxyfluorescein-labeled 262016Journal of medicinal chemistry, 05-12, Volume: 59, Issue:9
DARC: Mapping Surface Topography by Ray-Casting for Effective Virtual Screening at Protein Interaction Sites.
AID734888Binding affinity to his-tagged Mcl-1 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells by ITC analysis2013European journal of medicinal chemistry, Jan, Volume: 59Novel soluble myeloid cell leukemia sequence 1 (Mcl-1) inhibitor (E,E)-2-(benzylaminocarbonyl)-3-styrylacrylonitrile (4g) developed using a fragment-based approach.
AID406994Inhibition of human recombinant 17beta-HSD1 expressed in HEK293 cell lysate assessed as conversion of radiolabeled estrone to estradiol at 20 uM2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries.
AID448469Antimicrobial activity against methicillin-resistant Staphylococcus aureus 140/6 by twofold dilution technique2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, crystal structures and antibacterial activity studies of aza-derivatives of phytoalexin from cotton plant--gossypol.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID500187Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
A novel water-soluble gossypol derivative increases chemotherapeutic sensitivity and promotes growth inhibition in colon cancer.
AID1808021Inhibition of porcine heart malate dehydrogenase assessed as reduction in enzyme inhibition at 3 times IC50 preincubated for 5 min followed by nicotinamide adenine dinucleotide addition and monitered for 90 sec in presence of 0.01% Triton-X100 by spectrop2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID419220Antifungal activity against Fusarium oxysporum f. sp. lupini at 1 ug/ml after 48 hrs2009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
Antifungal activity of alkyl and heterocyclic aza-derivatives of gossypol as well as their complexes with NaClO4 against Fusarium oxysporum f. sp. lupini.
AID1863552Inhibition of human LDHA using sodium pyruvate as substrate2022European journal of medicinal chemistry, Oct-05, Volume: 240Discovery of novel human lactate dehydrogenase inhibitors: Structure-based virtual screening studies and biological assessment.
AID1411566Inhibition of LDHA (unknown origin)2017MedChemComm, Aug-01, Volume: 8, Issue:8
Discovery of human lactate dehydrogenase A (LDHA) inhibitors as anticancer agents to inhibit the proliferation of MG-63 osteosarcoma cells.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID419227Antifungal activity against Fusarium oxysporum f. sp. lupini at 0.5 ug/ml after 144 hrs2009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
Antifungal activity of alkyl and heterocyclic aza-derivatives of gossypol as well as their complexes with NaClO4 against Fusarium oxysporum f. sp. lupini.
AID1326258Cytotoxicity against human ovarian cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay2016ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12
Gossypol with Hydrophobic Linear Esters Exhibits Enhanced Antitumor Activity as an Inhibitor of Antiapoptotic Proteins.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID419230Antifungal activity against Fusarium oxysporum f. sp. lupini at 0.1 ug/ml after 48 hrs2009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
Antifungal activity of alkyl and heterocyclic aza-derivatives of gossypol as well as their complexes with NaClO4 against Fusarium oxysporum f. sp. lupini.
AID1313652Inhibition of Bcl-2 (unknown origin) using FAM-Bid peptide as substrate by fluorescence polarization-based assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Structural modification of luteolin from Flos Chrysanthemi leads to increased tumor cell growth inhibitory activity.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID977601Ki values for sodium fluorescein (10 uM) uptake in OATP1B1-transfected CHO cells2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1276043Competitive inhibition of human LDH5 in presence of NADH2016Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2
Recent Update on Human Lactate Dehydrogenase Enzyme 5 (hLDH5) Inhibitors: A Promising Approach for Cancer Chemotherapy.
AID1447201Inhibition of 6-carboxyfluorescein succinimidyl ester fluorescence tagged-Bid BH3 peptide (79 to 99 residues) binding to Mcl-1 (unknown origin) after 30 mins by fluorescence polarization assay2017Bioorganic & medicinal chemistry letters, 05-01, Volume: 27, Issue:9
Discovery and structure-activity relationship studies of N-substituted indole derivatives as novel Mcl-1 inhibitors.
AID481340Displacement of FITC-labeled Bak BH3 peptide from Bcl-XL after 30 mins by fluorescence polarization assay2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins.
AID647170Inhibition of HIV1 reverse transcriptase activity at 4 ug/ml2012Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3
Synthesis and antiviral activities of novel gossypol derivatives.
AID1320546Inhibition of 5-FAM-Bid peptide binding to MCL-1 (unknown origin) by fluorescence polarization assay2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Design, synthesis, and activity evaluation of selective inhibitors of anti-apoptotic Bcl-2 proteins: The effects on the selectivity of the P1 pockets in the active sites.
AID1368347Cytotoxicity against human TZM-bl cells after 72 hrs by MTT assay2018Bioorganic & medicinal chemistry letters, 01-01, Volume: 28, Issue:1
Synthesis and biological evaluation of water-soluble derivatives of chiral gossypol as HIV fusion inhibitors targeting gp41.
AID220417Inhibitory concentration in ZR-75-1 cells2003Journal of medicinal chemistry, Sep-25, Volume: 46, Issue:20
Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins.
AID448465Antimicrobial activity against Methicillin susceptible Staphylococcus aureus 238/7 by twofold dilution technique2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, crystal structures and antibacterial activity studies of aza-derivatives of phytoalexin from cotton plant--gossypol.
AID291313Displacement of FAM-Bim peptide from human Mcl1 by fluorescence polarization assay2007Journal of medicinal chemistry, Jul-12, Volume: 50, Issue:14
Structure-based design of flavonoid compounds as a new class of small-molecule inhibitors of the anti-apoptotic Bcl-2 proteins.
AID721798Binding affinity to Bcl2 (unknown origin) expressed in Escherichia coli BL21 by ITC assay2013European journal of medicinal chemistry, Feb, Volume: 60Fragment-based design, synthesis, and biological evaluation of N-substituted-5-(4-isopropylthiophenol)-2-hydroxynicotinamide derivatives as novel Mcl-1 inhibitors.
AID1194221Inhibition of GST-tagged Bcl-xL (unknown origin) measured after 1 hr incubation by fluorescence polarization assay2015Bioorganic & medicinal chemistry, Apr-15, Volume: 23, Issue:8
A combination of in silico and SAR studies to identify binding hot spots of Bcl-xL inhibitors.
AID291311Displacement of FAM-Bim peptide from human Bcl2 by fluorescence polarization assay2007Journal of medicinal chemistry, Jul-12, Volume: 50, Issue:14
Structure-based design of flavonoid compounds as a new class of small-molecule inhibitors of the anti-apoptotic Bcl-2 proteins.
AID1677972Inhibition of N-His6-tagged human AspH (315-755) expressed in Escherichia coli BL21 (DE3) using 1 uM hFX-CP as substrate mixture with 3 uM 2OG, 100 uM L-ascorbic acid and 2 uM FAS incubated for 35 mins by MS analysis2020Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20
Small-molecule active pharmaceutical ingredients of approved cancer therapeutics inhibit human aspartate/asparagine-β-hydroxylase.
AID1313651Inhibition of Bcl-2 (unknown origin) using FAM-Bid peptide as substrate at 50 uM by fluorescence polarization-based assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Structural modification of luteolin from Flos Chrysanthemi leads to increased tumor cell growth inhibitory activity.
AID1331915Antiproliferative activity against human K562 cells measured after 48 hrs by MTT assay2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Improved binding affinities of pyrrolidine derivatives as Mcl-1 inhibitors by modifying amino acid side chains.
AID1636835Antibacterial activity against Micrococcus luteus ATCC 10240 after 18 hrs by serial microdilution assay2016Bioorganic & medicinal chemistry letters, 09-01, Volume: 26, Issue:17
Synthesis, structure and antimicrobial evaluation of a new gossypol triazole conjugates functionalized with aliphatic chains and benzyloxy groups.
AID1755514Half life in human at 20 mg/kg, po measured up to 30 hrs by HPLC method2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients.
AID421437Induction of spleen weight shrinkage in human Bcl2 expressing B6 transgenic mouse at 72 umol/kg, ip administered as single dose after 24 hrs2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Apogossypol derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins.
AID1191749Inhibition of human purified MPG pre-incubated with compound for 10 mins followed by addition of 1,N6 ethenoadenine containing 32P-labeled duplex oligonucleotide substrates by gel-based excision activity assay2015Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5
Naturally occurring polyphenol, morin hydrate, inhibits enzymatic activity of N-methylpurine DNA glycosylase, a DNA repair enzyme with various roles in human disease.
AID1313653Inhibition of Bcl-XL (unknown origin) using FAM-Bid peptide as substrate at 50 uM by fluorescence polarization-based assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Structural modification of luteolin from Flos Chrysanthemi leads to increased tumor cell growth inhibitory activity.
AID1755506AUC (0 to infinity) in human at 20 mg, po measured up to 240 hrs by HPLC method2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients.
AID406995Inhibition of human recombinant 17beta-HSD1 expressed in HEK293 cell lysate assessed as conversion of radiolabeled estrone to estradiol2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries.
AID1677974Inhibition of N-His6-tagged human AspH (315-755) expressed in Escherichia coli BL21 (DE3) using 1 uM hFX-CP as substrate mixture with 3 uM 2OG, 100 uM L-ascorbic acid and high 20 uM FAS incubated for 35 mins by MS analysis2020Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20
Small-molecule active pharmaceutical ingredients of approved cancer therapeutics inhibit human aspartate/asparagine-β-hydroxylase.
AID448297Antimicrobial activity against Staphylococcus aureus ATCC 29213 after 18 hrs by twofold dilution technique2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, crystal structures and antibacterial activity studies of aza-derivatives of phytoalexin from cotton plant--gossypol.
AID1858796Inhibition of Bcl-xL/Bid (unknown origin) by fluorescence polarization assay2021European journal of medicinal chemistry, Jan-15, Volume: 210Development of Mcl-1 inhibitors for cancer therapy.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID448281Antimicrobial activity against Staphylococcus aureus ATCC 25923 at 400 ug after 18 hrs by disk diffusion method2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, crystal structures and antibacterial activity studies of aza-derivatives of phytoalexin from cotton plant--gossypol.
AID419229Antifungal activity against Fusarium oxysporum f. sp. lupini at 0.5 ug/ml after 192 hrs relative to control2009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
Antifungal activity of alkyl and heterocyclic aza-derivatives of gossypol as well as their complexes with NaClO4 against Fusarium oxysporum f. sp. lupini.
AID1320548Selectivity index, ratio of Ki for Bcl-2 (unknown origin) to Ki for MCL-1 (unknown origin)2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Design, synthesis, and activity evaluation of selective inhibitors of anti-apoptotic Bcl-2 proteins: The effects on the selectivity of the P1 pockets in the active sites.
AID1636823Antifungal activity against Trichophyton mentagrophytes ATCC 9533 after 18 hrs by serial microdilution assay2016Bioorganic & medicinal chemistry letters, 09-01, Volume: 26, Issue:17
Synthesis, structure and antimicrobial evaluation of a new gossypol triazole conjugates functionalized with aliphatic chains and benzyloxy groups.
AID744869Selectivity index, ratio of cytotoxicity against MDCK cells to antiviral activity against H5N1 subtype2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
Synthesis and anti-H5N1 activity of chiral gossypol derivatives and its analogs implicated by a viral entry blocking mechanism.
AID1633127Inhibition of Pseudomonas aeruginosa IMPDH at 35.1 uM using IMP as substrate in the presence of NAD+ incubated for 70 secs relative to control2019European journal of medicinal chemistry, Apr-01, Volume: 167First-in-class allosteric inhibitors of bacterial IMPDHs.
AID1326254Cytotoxicity against human non-small cell lung cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay2016ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12
Gossypol with Hydrophobic Linear Esters Exhibits Enhanced Antitumor Activity as an Inhibitor of Antiapoptotic Proteins.
AID315772Growth inhibition of human PC3 cells after 4 days by WST-8 based assay2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Acylpyrogallols as inhibitors of antiapoptotic Bcl-2 proteins.
AID448278Antimicrobial activity against Enterococcus hirae ATCC 10541 at 400 ug after 18 hrs by disk diffusion method2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, crystal structures and antibacterial activity studies of aza-derivatives of phytoalexin from cotton plant--gossypol.
AID421436Reduction of spleen weight in human Bcl2 expressing B6 transgenic mouse at 72 umol/kg, ip administered as single dose after 24 hrs2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Apogossypol derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins.
AID744866Cytotoxicity against MDCK cells by MTT assay2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
Synthesis and anti-H5N1 activity of chiral gossypol derivatives and its analogs implicated by a viral entry blocking mechanism.
AID1326261Cytotoxicity against human breast cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay2016ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12
Gossypol with Hydrophobic Linear Esters Exhibits Enhanced Antitumor Activity as an Inhibitor of Antiapoptotic Proteins.
AID448470Antimicrobial activity against methicillin-resistant Staphylococcus aureus 141/6 by twofold dilution technique2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, crystal structures and antibacterial activity studies of aza-derivatives of phytoalexin from cotton plant--gossypol.
AID499176Toxicity in BALB/c mouse assessed as mortality at 120 umol/kg, po administered daily once for 12 days measured on day 82010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
A novel water-soluble gossypol derivative increases chemotherapeutic sensitivity and promotes growth inhibition in colon cancer.
AID448274Antimicrobial activity against Staphylococcus aureus NCTC 4163 at 400 ug after 18 hrs by disk diffusion method2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, crystal structures and antibacterial activity studies of aza-derivatives of phytoalexin from cotton plant--gossypol.
AID671069Antiproliferative activity against mouse B16/F10 cells after 48 hrs by MTT assay2012Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14
Structure-based design of rhodanine-based acylsulfonamide derivatives as antagonists of the anti-apoptotic Bcl-2 protein.
AID1326253Cytotoxicity against human leukemia cells assessed as cell growth inhibition after 48 hrs by SRB assay2016ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12
Gossypol with Hydrophobic Linear Esters Exhibits Enhanced Antitumor Activity as an Inhibitor of Antiapoptotic Proteins.
AID448277Antimicrobial activity against Bacillus cereus ATCC 11778 at 400 ug after 18 hrs by disk diffusion method2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, crystal structures and antibacterial activity studies of aza-derivatives of phytoalexin from cotton plant--gossypol.
AID344236Cytotoxicity against human HeLa cells by SRB assay2008Journal of natural products, Jul, Volume: 71, Issue:7
Cytotoxic and antibacterial sesquiterpenes from Thespesia populnea.
AID647165Antiviral activity against HIV1 3B infected human TZM-bl cells assessed as inhibition of viral replication by luciferase reporter assay2012Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3
Synthesis and antiviral activities of novel gossypol derivatives.
AID1636824Antifungal activity against Rhizopus stolonifer ATCC 56227b after 18 hrs by serial microdilution assay2016Bioorganic & medicinal chemistry letters, 09-01, Volume: 26, Issue:17
Synthesis, structure and antimicrobial evaluation of a new gossypol triazole conjugates functionalized with aliphatic chains and benzyloxy groups.
AID419223Antifungal activity against Fusarium oxysporum f. sp. lupini at 1 ug/ml after 192 hrs2009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
Antifungal activity of alkyl and heterocyclic aza-derivatives of gossypol as well as their complexes with NaClO4 against Fusarium oxysporum f. sp. lupini.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1427421Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
AID744860Inhibition of H5N1 subtype hemagglutinin adsorption into chicken RBC at 100 ug/mL2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
Synthesis and anti-H5N1 activity of chiral gossypol derivatives and its analogs implicated by a viral entry blocking mechanism.
AID1253033Antiproliferative activity against human MDA-MB-231 cells by MTT assay2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Design, synthesis and biological evaluation of 3-aryl-rhodanine benzoic acids as anti-apoptotic protein Bcl-2 inhibitors.
AID977604Ki values for sodium fluorescein (10 uM) uptake in OATP1B3-transfected CHO cells2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1313648Cytotoxicity against human HL60 cells assessed as inhibition of cell growth at 100 uM after 72 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Structural modification of luteolin from Flos Chrysanthemi leads to increased tumor cell growth inhibitory activity.
AID647176Cytotoxicity against MDCK cells by MTT assay2012Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3
Synthesis and antiviral activities of novel gossypol derivatives.
AID419226Antifungal activity against Fusarium oxysporum f. sp. lupini at 0.5 ug/ml after 96 hrs2009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
Antifungal activity of alkyl and heterocyclic aza-derivatives of gossypol as well as their complexes with NaClO4 against Fusarium oxysporum f. sp. lupini.
AID448471Antimicrobial activity against methicillin-resistant Staphylococcus aureus 143/6 by twofold dilution technique2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, crystal structures and antibacterial activity studies of aza-derivatives of phytoalexin from cotton plant--gossypol.
AID744863Antiviral activity against Influenza A virus (A/Vietnam/1194/2004(H5N1)) infected in MDCK cells assessed as inhibition of viral entry at 20 uM treated at the time of infection2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
Synthesis and anti-H5N1 activity of chiral gossypol derivatives and its analogs implicated by a viral entry blocking mechanism.
AID419221Antifungal activity against Fusarium oxysporum f. sp. lupini at 1 ug/ml after 96 hrs2009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
Antifungal activity of alkyl and heterocyclic aza-derivatives of gossypol as well as their complexes with NaClO4 against Fusarium oxysporum f. sp. lupini.
AID1808025Inhibition of SARS-Cov2 N-terminal full-length MBP-tagged 3CL protease expressed in Escherichia coli using DABCYL-KTSAVLQSGFRKME-EDANS as substrate preincubated for 30 mins followed by substrate addition and measured after 3 hrs by fluorescence assay2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID448468Antimicrobial activity against Methicillin susceptible Staphylococcus aureus 243/7 by twofold dilution technique2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, crystal structures and antibacterial activity studies of aza-derivatives of phytoalexin from cotton plant--gossypol.
AID1503774Cytotoxicity against human HL cells assessed as cell viability at 50 uM after 72 hrs by resazurin dye based fluorescence assay relative to control2017Journal of natural products, 10-27, Volume: 80, Issue:10
Identification of Privileged Antichlamydial Natural Products by a Ligand-Based Strategy.
AID1263149Competitive binding affinity to Bcl-XL (unknown origin) using 5-FAM-Bid-BH3 peptide preincubated for 30 mins before 5-FAM-Bid-BH3 peptide addition and measured 20 mins after 5-FAM-Bid-BH3 peptide addition by fluorescence polarization assayy2015Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24
Design, synthesis and preliminary biological studies of pyrrolidine derivatives as Mcl-1 inhibitors.
AID1599455Inhibition of Bcl-xL (unknown origin)2019European journal of medicinal chemistry, Sep-01, Volume: 177The chemical biology of apoptosis: Revisited after 17 years.
AID1326262Cytotoxicity against HEK293T cells assessed as reduction in cell viability at 0.33 to 100 uM after 72 hrs by MTT assay2016ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12
Gossypol with Hydrophobic Linear Esters Exhibits Enhanced Antitumor Activity as an Inhibitor of Antiapoptotic Proteins.
AID1808019Inhibition of SARS CoV2 C-terminal His6-tagged 3CL protease (3264 to 3569 residues) expressed in Escherichia coli BL21 DE3 using rr-K(MCA)-ATLQAIAS-K(DNP)-COOH preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 0.02021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID293613Displacement of Flu-Bak peptide from recombinant antiapoptotic Bcl-w protein by fluorescence polarization assay2007Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5
Development of selective inhibitors for anti-apoptotic Bcl-2 proteins from BHI-1.
AID421420Cytotoxicity against human H1299 cells assessed as cell viability after 72 hrs by ATP-LITE assay2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Apogossypol derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins.
AID315771Growth inhibition of human MDA-MB-231 2LMP cells after 4 days by WST-8 based assay2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Acylpyrogallols as inhibitors of antiapoptotic Bcl-2 proteins.
AID448302Antimicrobial activity against Micrococcus luteus ATCC 9341 after 18 hrs by twofold dilution technique2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, crystal structures and antibacterial activity studies of aza-derivatives of phytoalexin from cotton plant--gossypol.
AID1194541Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9
Design, synthesis and preliminary bioactivity studies of 2-thioxo-4-thiazolidinone derivatives as Bcl-2 inhibitors.
AID776627Displacement of FAM-Bid BH3 peptide from recombinant Mcl-1 (unknown origin) expressed in Escherichia coli BL21 after 10 mins by fluorescence polarization assay2013European journal of medicinal chemistry, Nov, Volume: 69Design and application of a rigid quinazolone scaffold based on two-face Bim α-helix mimicking.
AID448296Antimicrobial activity against Staphylococcus aureus ATCC 6538 after 18 hrs by twofold dilution technique2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, crystal structures and antibacterial activity studies of aza-derivatives of phytoalexin from cotton plant--gossypol.
AID1331913Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Improved binding affinities of pyrrolidine derivatives as Mcl-1 inhibitors by modifying amino acid side chains.
AID500192Solubility of the compound in 100 gram of water2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
A novel water-soluble gossypol derivative increases chemotherapeutic sensitivity and promotes growth inhibition in colon cancer.
AID1427420Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
AID1320547Selectivity index, ratio of Ki for Bcl-2 (unknown origin) to Ki for Bcl-XL (unknown origin)2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Design, synthesis, and activity evaluation of selective inhibitors of anti-apoptotic Bcl-2 proteins: The effects on the selectivity of the P1 pockets in the active sites.
AID1276044Competitive inhibition of human LDH1 in presence of NADH2016Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2
Recent Update on Human Lactate Dehydrogenase Enzyme 5 (hLDH5) Inhibitors: A Promising Approach for Cancer Chemotherapy.
AID273188Displacement of FAM-Bak from human Bcl-xL by FP assay2006Journal of medicinal chemistry, Oct-19, Volume: 49, Issue:21
Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins.
AID671068Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay2012Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14
Structure-based design of rhodanine-based acylsulfonamide derivatives as antagonists of the anti-apoptotic Bcl-2 protein.
AID406996Inhibition of human recombinant 17beta-HSD2 expressed in HEK293 cell lysate assessed as conversion of radiolabeled estrone to estradiol at 40 uM2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries.
AID1263155Antiproliferative activity against human K562 cells after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24
Design, synthesis and preliminary biological studies of pyrrolidine derivatives as Mcl-1 inhibitors.
AID448279Antimicrobial activity against Micrococcus luteus ATCC 9341 at 400 ug after 18 hrs by disk diffusion method2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, crystal structures and antibacterial activity studies of aza-derivatives of phytoalexin from cotton plant--gossypol.
AID448306Antimicrobial activity against Methicillin susceptible Staphylococcus aureus 207/7 by twofold dilution technique2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, crystal structures and antibacterial activity studies of aza-derivatives of phytoalexin from cotton plant--gossypol.
AID419217Antifungal activity against Fusarium oxysporum f. sp. lupini at 20 ug/ml after 144 hrs2009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
Antifungal activity of alkyl and heterocyclic aza-derivatives of gossypol as well as their complexes with NaClO4 against Fusarium oxysporum f. sp. lupini.
AID528416Toxicity in human PPC1 cells xenografted nude mouse assessed as mortality at 25 mg/kg, ip administered weekly 3 times2010Journal of medicinal chemistry, Nov-25, Volume: 53, Issue:22
Synthesis and biological evaluation of Apogossypolone derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins.
AID1755515Cmax in human at 40 mg, po BID cotreated with paclitaxel by HPLC method2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients.
AID1331911Inhibition of 5-FAM-DMRPEIWIAQELRRIGDEFNAYYARR binding to Bcl-XL (unknown origin) preincubated for 30 mins followed by FAM-labeled peptide addition measured after 20 mins by fluorescence polarization assay2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Improved binding affinities of pyrrolidine derivatives as Mcl-1 inhibitors by modifying amino acid side chains.
AID1743764Inhibition of FAM-conjugated ssDNA binding to His-tagged wild type RAD52 (unknown origin) expressed in Rosetta2(DE3)/pLysS cells measured after 30 mins by fluorescence polarization assay2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Synthetic Lethality through the Lens of Medicinal Chemistry.
AID448298Antimicrobial activity against Staphylococcus epidermidis ATCC 12228 by twofold dilution technique2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis, crystal structures and antibacterial activity studies of aza-derivatives of phytoalexin from cotton plant--gossypol.
AID1636832Antibacterial activity against Staphylococcus epidermidis ATCC 12228 after 18 hrs by serial microdilution assay2016Bioorganic & medicinal chemistry letters, 09-01, Volume: 26, Issue:17
Synthesis, structure and antimicrobial evaluation of a new gossypol triazole conjugates functionalized with aliphatic chains and benzyloxy groups.
AID330776Binding affinity to BCL22007Proceedings of the National Academy of Sciences of the United States of America, Dec-04, Volume: 104, Issue:49
Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1798305Lactate Dehydrogenase Inhibition Assay from Article 10.1021/jm070336k: \\Design, synthesis, and biological evaluation of Plasmodium falciparum lactate dehydrogenase inhibitors.\\2007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
Design, synthesis, and biological evaluation of Plasmodium falciparum lactate dehydrogenase inhibitors.
AID1801388Inhibition Assay from Article 10.1111/cbdd.12572: \\Lazaroids U83836E and U74389G are potent, time-dependent inhibitors of caspase-1.\\2015Chemical biology & drug design, Nov, Volume: 86, Issue:5
Lazaroids U83836E and U74389G are potent, time-dependent inhibitors of caspase-1.
AID1799904Enzyme Assay from Article 10.1021/cc060110n: \\Generation of oxamic acid libraries: antimalarials and inhibitors of Plasmodium falciparum lactate dehydrogenase.\\
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID686947qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347158ZIKV-mCherry secondary qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347081qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Confirmatory Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347087qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Confirmatory Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347084qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Confirmatory Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347088qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): Viability assay - Alamar blue signal for LCMV Confirmatory Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347157Confirmatory screen GU Rhodamine qHTS for Zika virus inhibitors qHTS2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347172Secondary qRT-PCR qHTS assay for selected Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347170Vero cells viability counterscreen for qRT-PCR qHTS assay of selected Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347171Orthogonal mCherry assay for qRT-PCR qHTS of selected Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347163384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347164384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,685)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990626 (37.15)18.7374
1990's266 (15.79)18.2507
2000's275 (16.32)29.6817
2010's402 (23.86)24.3611
2020's116 (6.88)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 60.00

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index60.00 (24.57)
Research Supply Index7.53 (2.92)
Research Growth Index4.57 (4.65)
Search Engine Demand Index103.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (60.00)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials47 (2.60%)5.53%
Reviews96 (5.30%)6.00%
Case Studies5 (0.28%)4.05%
Observational1 (0.06%)0.25%
Other1,661 (91.77%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (12)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase I, Open Label Study of AT-101 Plus Radiotherapy and Temozolomide and of AT-101 Plus Adjuvant Temozolomide for Patients With Newly-Diagnosed Glioblastoma Multiforme [NCT00390403]Phase 150 participants (Anticipated)Interventional2007-02-28Completed
A Phase 1 Study of R-(-)-Gossypol (Ascenta's AT-101) in Combination With Paclitaxel and Carboplatin in Solid Tumors [NCT00891072]Phase 136 participants (Actual)Interventional2009-07-31Completed
A Randomized, Double Blind, Placebo-controlled Multiple-center Phase III Trial of Gossypol Combined With Docetaxel and Cisplatin Scheme in Advanced Non Small-cell Lung Cancers With APE1 High Expression [NCT01977209]Phase 3204 participants (Anticipated)Interventional2013-09-30Recruiting
Phase I/II Trial of AT-101 in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed Symptomatic Multiple Myeloma [NCT02697344]Phase 110 participants (Actual)Interventional2016-04-14Completed
A Phase II Study of AT-101 in Recurrent Extensive Stage Small Cell Lung Cancer [NCT00773955]Phase 215 participants (Actual)Interventional2008-11-30Completed
A Phase 1 Study of R-(-)-Gossypol (AT-101) in Combination With Cisplatin and Etoposide in Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer [NCT00544596]Phase 127 participants (Actual)Interventional2007-09-30Completed
A Phase II Study of AT101, to Abrogate BCL-2 Mediated Resistance to Androgen Ablation Therapy in Patients With Newly Diagnosed Stage D2 Prostate Cancer [NCT00666666]Phase 255 participants (Actual)Interventional2009-07-31Completed
A Phase II Study of the Orally Administered Negative Enantiomer of Gossypol (AT-101) in Patients With Advanced Adrenocortical Carcinoma (ACC) [NCT00848016]Phase 229 participants (Actual)Interventional2009-02-28Completed
An Open-label, Single-arm, Multi-center, Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AT101 (Anti-CD19 Chimeric Antigen Receptor T Cell) in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma [NCT05338931]Phase 1/Phase 282 participants (Anticipated)Interventional2022-03-15Recruiting
A Phase I/II Clinical Trial of Lenalidomide in Combination With AT-101 for the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia (B-CLL) [NCT01003769]Phase 1/Phase 25 participants (Actual)Interventional2015-07-09Terminated(stopped due to Lack of funding)
Explore the Efficacy and Safety of Dalpiciclib Combined With Fluvestrant and Compound Gossypol Acetate Tablets in Advanced HR-positive and HER2-negative Breast Cancer After CDK4/6 Treatment Failed. [NCT06133088]Phase 253 participants (Anticipated)Interventional2023-08-01Recruiting
A Phase 2 Study of R-(-)-Gossypol (Ascenta's AT-101) in Recurrent Glioblastoma Multiforme [NCT00540722]Phase 256 participants (Actual)Interventional2008-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00540722 (3) [back to overview]Overall Survival
NCT00540722 (3) [back to overview]Progression-free Survival Rate, Defined as Patient Who is Alive and Disease Progression Free at the Time of 26-week (6 Months) From First Day of the Treatment
NCT00540722 (3) [back to overview]Percent of Patients With Grade 3 and 4 Adverse Events Related to Treatment
NCT00666666 (3) [back to overview]Percentage of Patients With Overall PSA < 4.0 ng/mL
NCT00666666 (3) [back to overview]Percentage of Patients With PSA ≥ 0.2 ng/mL But < 4.0 ng/mL
NCT00666666 (3) [back to overview]Percentage of Patients With Undetectable Prostate-specific Antigen (PSA) (< 0.2 ng/mL) at End of 7 Cycles
NCT00773955 (3) [back to overview]Survival Time
NCT00773955 (3) [back to overview]Time to Disease Progression
NCT00773955 (3) [back to overview]Number of Participants With Confirmed Tumor Response Defined to be Either a Complete Response (CR) or Partial Response (PR)
NCT00848016 (3) [back to overview]Overall Survival
NCT00848016 (3) [back to overview]Progression-free Survival
NCT00848016 (3) [back to overview]The Proportion of Patients Who Achieve a Confirmed Objective Response to Treatment, Either Partial Response (PR) or Complete Response (CR) as Defined by Response Evaluation Criteria In Solid Tumors (RECIST) Criteria

Overall Survival

The overall failure rate will be estimated along with 95% confidence intervals. A median time of survival will be estimated using standard methods. (NCT00540722)
Timeframe: 4.5 years

Interventionmonths (Median)
Treatment (R-(-)-Gossypol Acetic Acid)5.9

[back to top]

Progression-free Survival Rate, Defined as Patient Who is Alive and Disease Progression Free at the Time of 26-week (6 Months) From First Day of the Treatment

The probability of 6-month progression-free survival will be estimated using binomial distribution. (NCT00540722)
Timeframe: 6 months

Interventionmonths (Median)
Treatment (R-(-)-Gossypol Acetic Acid)1.87

[back to top] [back to top]

Percentage of Patients With Overall PSA < 4.0 ng/mL

(NCT00666666)
Timeframe: 3 years

Interventionpercentage of participants (Number)
AT101 (R-(-)-Gossypol Acetic Acid)60

[back to top]

Percentage of Patients With PSA ≥ 0.2 ng/mL But < 4.0 ng/mL

(NCT00666666)
Timeframe: 3 years

Interventionpercentage of participants (Number)
AT101 (R-(-)-Gossypol Acetic Acid)18

[back to top]

Percentage of Patients With Undetectable Prostate-specific Antigen (PSA) (< 0.2 ng/mL) at End of 7 Cycles

(NCT00666666)
Timeframe: 3 years

Interventionpercentage of participants (Number)
AT101 (R-(-)-Gossypol Acetic Acid)22

[back to top]

Survival Time

Estimated using the method of Kaplan-Meier. (NCT00773955)
Timeframe: From registration to death due to any cause, assessed up to 5 years

Interventionmonths (Median)
Treatment (R-(-)-Gossypol)8.5

[back to top]

Time to Disease Progression

"Time to disease progression is defined as the time from registration to the earliest date documentation of disease progression. Estimated using the method of Kaplan-Meier.~Per the RECIST criteria, progression is defined as at least a 20% increase in the sum of Longest Dimension (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions." (NCT00773955)
Timeframe: From registration to the earliest date documentation of disease progression, assessed up to 5 years

Interventionmonths (Median)
Treatment (R-(-)-Gossypol)1.7

[back to top]

Number of Participants With Confirmed Tumor Response Defined to be Either a Complete Response (CR) or Partial Response (PR)

"The number of successes will be estimated by counting the number of participants with confirmed responses. A confirmed tumor response is defined to be either a CR or PR noted as the objective status on 2 consecutive evaluations at least 4 weeks apart.~Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions:~A Complete Response (CR) requires the disappearance of all target lesions~A Partial Response (PR) requires a >=30% decrease in the sum of the longest diameter of target lesions from baseline measurements." (NCT00773955)
Timeframe: During the first 6 courses of treatment

Interventionparticipants (Number)
Confirmed Partial Response (PR)Confirmed Complete Response (CR)
Treatment (R-(-)-Gossypol)00

[back to top]

Overall Survival

The overall survival time is defined as the time from registration to date of last follow-up or death due to any cause. Estimated using the method of Kaplan-Meier. (NCT00848016)
Timeframe: From registration to date of last follow-up or death due to any cause, assessed up to 2 years

Interventionmonths (Median)
Treatment (R-(-)-Gossypol Acetic Acid)8.5

[back to top]

Progression-free Survival

The progression-free survival is defined as the time from registration to the date of progression or death, whichever comes first. The distributions of progression-free survival time will be estimated using the method of Kaplan-Meier. (NCT00848016)
Timeframe: From registration to progression or death, whichever occurs first, up to 2 years.

Interventionmonths (Number)
Treatment (R-(-)-Gossypol Acetic Acid)1.9

[back to top]

The Proportion of Patients Who Achieve a Confirmed Objective Response to Treatment, Either Partial Response (PR) or Complete Response (CR) as Defined by Response Evaluation Criteria In Solid Tumors (RECIST) Criteria

"In order for a patient to be a confirmed objective responder, they must achieve a PR or CR on consecutive evaluations, at least 4 weeks apart. The proportion of patients who achieve a confirmed objective response to treatment will be estimated by the standard binomial estimator, i.e., the number of successes divided by the total number of evaluable patients.~Complete Response (CR): Disappearance of all target lesions and normalization of tumor biomarkers.~Partial Response (PR): At least a 30% decrease in the sum of the longest dimension (LD) of target lesions taking as reference the baseline sum LD." (NCT00848016)
Timeframe: Up to 2 years

Interventionpercentage of participants (Number)
Treatment (R-(-)-Gossypol Acetic Acid)0

[back to top]